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DEVELOPMENT OF POLYMER PEPTIDE CONJUGATES FOR ENHANCED 
PANCREATIC CANCER IMAGING 
 
Wen Shi, Ph.D. 
University of Nebraska, 2015 
Supervisor: Jered Garrison, Ph.D. 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related 
deaths in the US with very poor prognosis. All clinically available biomarkers and 
diagnostic tools either fail to detect early stage PDAC or suffer from low specificity and 
sensitivity. There is an urgent need for diagnostic agents with greater efficacy for PDAC 
detection and staging. Nanomaterials such as N-(2-Hydroxypropyl) methacrylamide 
(HPMA) copolymers can effectively target tumors, and offer novel opportunities for the 
development of effective diagnostic agents for cancer. However, a major problem of 
many nanomaterials-based diagnostics is their opsonization and sequestration by the 
mononuclear phagocyte system (MPS), leading to substantial accumulation in MPS 
tissues such as the liver and spleen. This MPS accumulation in non-target tissues can 
hinder identification of resident or nearby metastatic malignant lesions thereby 
decreasing the diagnostic efficacy. 
 
In this thesis, we focused on developing new approaches in which radiolabeled 
HPMA copolymers can be synthetically modified to significantly reduce the MPS 
accumulation and/or to increase the tumor accumulation, thereby enhancing the 
diagnostic and/or radiotherapeutic efficacy of the agents. First, we evaluated the 
effectiveness of incorporating metabolic active linkers into HPMA copolymers to 
decrease the radioactivity retention in the liver and spleen in pancreatic tumor xenograft 
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mice. We demonstrated that 177Lu-labeled HPMA copolymers conjugated with cathepsin 
B/S cleavable peptide linkers exhibited significant long-term reduction in hepatic and 
splenic radioactivity accumulation as compared to the non-cleavable control. Next we 
conjugated a 109 kDa HPMA copolymer with three different cathepsin S cleavable 
linkers and evaluated the structure-activity relationship with regard to the lengths of the 
linking groups on the in vitro and in vivo efficacy of 177Lu-labeled cathepsin S cleavable 
HPMA copolymers. Biodistribution results showed that the 177Lu-labeled HPMA 
copolymer with the shortest length linker had a significant enhancement in the tumor-to-
non-target ratios, which was also confirmed by SPECT/CT imaging. Finally, the potential 
of active tumor targeting for PDAC was evaluated using a plectin-1 targeted peptide 
(PTP) conjugated HPMA copolymer on pancreatic cancer cells in vitro. Unfortunately, we 
found that incorporation of the PTP into the HPMA copolymer diminished the binding of 
the peptide, possibly due to steric hindrance.  
 
Overall, our 177Lu-labeled cathepsin cleavable HPMA copolymer showed decreased 
MPS tissue accumulation and significant improvement in tumor-to-non-target organ ratio, 
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Chapter 1  
Introduction 
 
1.1 PANCREATIC CANCER  
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-
related death in the US with a median survival of <6 months and a dismal 5-years 
survival rate of 3%–5% [1]. This severe prognosis is mainly due to the cancer’s 
aggressive clinical behavior with early invasion and metastasis as well as its resistance 
to conventional and targeted chemotherapeutics, leading to an initial diagnosis at an 
advanced and incurable stage in more than 80% patients [2].  
 
PDAC commonly arises in the head region of the pancreas and infiltrates into nearby 
tissues including lymphatics, spleen, and peritoneal cavity, and metastasizes to the liver 
and lungs [3]. The disease is characterized by the presence of a dense stroma 
consisting of abundant extracellular matrix and mainly fibroblasts and inflammatory cells, 
termed desmoplasia [3]. Clinical and histopathologic studies have identified three PDAC 
precursor lesions (Figure 1.1): pancreatic intraepithelial neoplasia (PanIN), mucinous 
cystic neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN) [4, 5]. The 
most common and best studied type is the PanIN, which can be graded from stages I to 
III, with the beginning stage characterized by the presence of columnar epithelial cells 
with increasing architectural disorganization and cytological changes through stages II 





Figure 1.1: Pancreatic precursor lesions and genetic mutations involved in pancreatic 
adenocarcinoma progression. Adapted from Ref[3]. Pictured are three known human 
PDAC precursor lesions: PanIN, MCN, and IPMN. The PanIN grading scheme is shown 
on the left; increasing grade (1–3) reflects increasing morphology change, eventually 
leading to invasive adenocarcinoma. The right side shows the potential progression of 
MCNs and IPMNs to PDAC. The genetic alterations existing in adenocarcinomas also 












PDAC are highly resistant to conventional chemotherapy due to the impairment of 
drug delivery pathways caused by the hypovasculature within the tumor sites [8]. 
Besides, the surrounded stroma has been shown to induce resistance to chemotherapy 
and radiation therapy [9]. Gemcitabine is the standard chemotherapy for all stages of 
pancreatic adenocarcinoma in the last decade with the median overall survival of 6.7 
months and a response rate as low as 7% [10]. Although there has been progress made 
in improving the various chemotherapeutic regimens and in the development of targeted 
therapies against pancreatic cancer, the overall survival has not been significantly 
improved.   
 
1.2 CURRENT DIAGNOSTIC METHODS FOR PANCREATIC CANCER 
Given the non-symptomatic nature of this disease, surgery is only a viable option for 
15- 20% of PDAC patients with localized diseases [11]. Like many cancers, the earlier 
pancreatic cancer is detected, the more likely surgery will be successful and lead to 
longer patient survival. It was found that the 5-year survival of resectable PDAC is about 
20%, increasing to 30% to 60% for node-negative tumors of less than 2 cm, and higher 
than 60% for small lesions less than 10 mm. More encouraging results come from 
patients who are diagnosed with high-grade dysplastic, but still noninvasive precursor 
lesions [12]. Large tumor size is directly related to poor prognosis. Early diagnosis of 
small or even pre-invasive cancers before the onset of metastasis offers the best hope 
for survival [13].  
 
Unfortunately, all clinical available biomarkers and diagnostic tools fail to detect early 
stage PDAC and suffer from low specificity and sensitivity [14]. Blood biomarker 
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carbohydrate CA 19-9 is an oligosaccharide sialylated Lewis A antigen attached to 
mucin core proteins, and is the only available test in routine clinical use for PDAC [15]. 
But it is only used for PDAC patients’ therapeutic management not diagnostic purposes, 
because only 50% of patients with small lesions (< 2 cm) presented with an increased 
CA19-9 value [16]. Also, this marker can be elevated in patients with other types of 
cancer [17] as well as in nonmalignant conditions including liver cirrhosis, cholangitis 
and chronic pancreatitis [18, 19]. Recent studies have identified some promising 
biomarkers from blood, saliva, stool and pancreatic juice [12]. But these biomarkers are 
still in the process of being validated in clinical trials.   
 
Diagnostic imaging tools are highly valuable because they not only provide early 
detection but also enable appropriate treatment stratification (and staging) and in vivo 
therapeutic response monitoring. Imaging techniques currently applied for diagnosis and 
preoperative staging of pancreatic cancer include abdominal ultrasound (US), contrast-
enhanced computed tomography(CT), magnetic resonance imaging (MRI), positron 
emission tomography (PET) and the minimal invasive endoscopic ultrasound (EUS) [20]. 
Below, we discuss the strengths and weakness of each imaging modality. 
 
EUS allows the identification of diminutive structures with sizes ranging from 1-5 mm, 
including lymph nodes, bile ducts, pancreatic ducts, blood vessels, solid masses and 
cystic masses, so it is able to locate lymph node metastases and vascular tumor 
infiltration with high sensitivity [21]. However, EUS is an operator highly dependent 
technique and suffers from poor specificity for pancreatic cancer imaging [22]. The 
presence of pancreatitis like features such as cysts and solid nodules can lead to great 
doubt with regard to the importance of any discovered small pancreatic lesions [12].   
5 
 
Abdominal US is often used first to find out the reason for abdominal pain or jaundice. 
The sensitivity of conventional US for diagnosing PDAC is only 50–70% [23]. There are 
no characteristic signs for different kinds of pancreatic lesions including PDAC, chronic 
pancreatitis and endocrine cell tumors [20]. US might be an initial screening examination 
as it is a cost-effective method, but CT or MRI are still needed for further, more accurate 
diagnosis of malignant lesions [20].  
 
CT is the most widely used imaging tool for the detection and staging of PDAC. Due 
to the abundance of fibrous stroma and hypovascularity in PDAC, non-contrast CT 
scans have very poor sensitivity and specificity [24]. Using contrast-enhanced CT, PDAC 
is poorly enhanced compared to the surrounding parenchyma in the early phase of 
dynamic CT but gradually enhanced with delayed images [20]. It’s usually seen as a 
hypoattenuating area but may occasionally be seen as isoattenuating, thus resulting in 
misdiagnosis [24]. Although the sensitivity and specificity in diagnosis of PDAC by CT 
has been greatly improved recently (such as the introduction of multi-detector-row CT, 
MDCT), this modality still has difficulty in diagnosing PDAC at an early stage [25]. The 
difficulties are thought to be due to the small tumor size (<2 cm), loss of biliary dilatation, 
vascular involvement and mass effect, and little attenuation difference compared with 
normal pancreatic parenchyma [26].  
 
MRI is commonly used to detect PDAC when a mass lesion is not detectable on CT 
scan as it provides better soft tissue contrast compared to non-contrast enhanced CT. 
However, there is no significant diagnostic advantage of MRI over contrast enhanced CT 
(sensitivity of 86% on CT vs. 84% on MRI) [27]. Combination of two modalities did not 
improve diagnostic efficacy relative to either one alone. Another problem with the use of 
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MRI for PDAC detection/staging is that chronic pancreatitis remained difficult to be 
differentiated from PDAC since both show enhanced contrast images on MRI and both 
may be associated with pancreatic ductal obstruction [28, 29]. The choice of MRI or CT 
may depend on the availability in hospitals and clinician’s comfort with either modality. 
 
PET imaging, using radiolabeled glucose analog 18F-fluorodeoxyglucose (18F-FDG), 
is a promising tool for noninvasive differentiation between benign and malignant lesions 
[30]. But the utility of PET in PDAC diagnosis and staging remains uncertain. Integrated 
PET/CT is considered superior to conventional imaging (MDCT, CT, EUS) used for 
tumor staging and identification of additional distant metastases (sensitivity and 
specificity rates were 81% versus 56% and 100% versus 95%, respectively, as reported 
in one study [31]). However, it has been argued that when compared to contrast 
enhanced MDCT, currently available data does not support that PET or PET/ CT provide 
any additional information for PDAC [24]. Additionally, chronic and acute pancreatitis 
and autoimmune pancreatitis can occasionally exhibit substantial FDG uptake and result 
in false positive results. Lastly, the sensitivity of 18F-FDG PET in hyperglycemic patients 
could be lower than that in euglycemic patients because the elevated serum glucose 
levels suppress 18F-FDG uptake in tumors by 50% due to the competitive inhibition [32].  
 
The application of the single-photon emission computed tomography (SPECT) 
modality in PDAC is hampered by the lack of an effective radiotracer. Many radiotracers 
were reported in the literature, but these studies were limited to pre-clinical evaluation 
[14, 33, 34]. The αvβ3-integrin is often over-expressed in pancreatic tumor cells, whereas 
it is rarely expressed in normal pancreatic cells [35]. In one study, Indium-111 (111In)- 
labeled DOTA-c(RGDfK) was evaluated in a hamster pancreatic carcinogenesis model 
7 
 
[33]. The c(RGDfK) is a  cyclic, stable arginine-glycine-aspartic acid peptide analogue 
that binds with αvβ3-integrin with high affinity [36]. Using the radiolabeled peptide 
111In-
DOTA-c(RGDfK),  malignant lesions as small as 3mm in diameter could be clearly 
visualized in using SPECT/CT and the uptake of the radiolabeled peptide was found to 
be well correlated with αvβ3-integrin expression. In another study, Technetium-99m 
(99mTc) labeled integrin αvβ6-targeted peptide was found to effectively detect primary and 
metastatic lesions of αvβ6-positive pancreatic tumors [34]. Lastly, plectin-1 is a protein 
that is ubiquitously expressed in cells, but is normally constrained to the intracellular 
compartment. However, in the case of PDAC, plectin-1 becomes aberrantly expressed 
on the extracellular surface [14]. The peptide sequence KTLLPTP, discovered by phage 
display, was found to have submicromolar affinity for plectin-1 [37]. An 111In-labeled-
tetrametric form of plectin-1 targeting peptide exhibited high tumor uptake and visualized 
the primary and metastatic pancreatic tumors by SPECT/CT [14].    
 
1.3 NANOMATERIALS FOR PANCREATIC CANCER IMAGING 
The advancement in nanomedicine has sparked the development of emerging tools 
in cancer diagnostics and treatment [38]. Nanoparticles (1-100 nm in size), with carefully 
controlled chemistry, size, surface charge and other properties can delivery diagnostic 
and/or therapeutic agents to targeted locations in the body [39]. These nanoparticle 
systems include paradigms such as gold/magnetic nanoparticles, quantum dots, 
liposomes, polymer micelles, dendrimers, and polymer conjugates. In the case of cancer 
diagnosis and therapy, these nanoparticles can passively accumulate in tumors due to 
enhanced permeability and retention (EPR) effect [40]. The presence of larger than 
normal fenestrations in the tumor vasculature endothelial walls with the impairment of 
tumor lymphatic drainage system results in the retained accumulation of nanoparticles 
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[41]. Recent developments have led to the transformation from passive to active tumor 
targeting, which is normally achieved by covalently conjugating nanoparticles with cell-
specific targeting ligands such as antibodies, small molecules or peptides [42]. Active 
targeting allows efficient intracellular accumulation of the anticancer therapeutic agents 
in specific tissues/cells which largely increase the efficacy [43]. PDAC expresses many 
different specific protein/receptors, making them potential biomarkers for targeted 
imaging and therapy [44].  
 
A variety of nanoparticles have been investigated for pancreatic cancer imaging over 
the years [43]. Magnetic nanoparticles are biocompatible and have been used as 
contrast agents for MRI imaging for pancreatic cancer. For example, Hedgire et al. 
proved that using superparamagnetic iron oxide nanoparticles (SPION) as a contrast 
agent for MRI offered better delineation of pancreatic cancer in patients receiving 
preoperative imaging, which might contribute a roadmap for the surgeons [45]. Yang’s 
group modified SPION with the urokinase amino-terminal fragment, which is a targeting 
ligand for the urokinase plasminogen activator receptor (uPAR) with high affinity [46]. 
uPAR is found to be highly expressed in pancreatic cancer cells and tumor stromal cells 
[47]. The modified nanoparticles produced significant MR signal changes in pancreatic 
tumor xenograft mice and allowed the distinction between malignant lesions and 
pancreatitis. Many pancreatic tumors highly express epidermal growth factor receptor 
(EGFR) [48]. Single chain anti-EGFR antibody (ScFvEGFR) has been conjugated to iron 
oxide (IO) magnetic nanoparticles, the resulting ScFvEGFR-IO nanoparticles selectively 
accumulated within the pancreatic tumors in an orthotopic pancreatic cancer xenograft 
model, as evidenced by an enhanced contrast in MRI signal in the area of the tumor [49]. 
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A 4.8 fold MRI signal change was observed when comparing the ScFvEGFR-IO 
nanoparticles with the non-targeted IO nanoparticles.  
  
Quantum dots (QD) are a class of semiconducting nanocrystals composed of 
inorganic cores and surrounding metal shells, with excellent optical properties [50]. They 
have been well studied for imaging pancreatic cancer [43]. Prasad’s group attached 
many different targeting ligands including folic acid, cyclic arginine-glycine-aspartic acid 
(cRGD) and anti-mesothelin antibody, to CdTe quantum dots and successfully applied 
them for in vivo pancreatic cancer imaging [51-53]. Those QDs showed minimal toxicity 
in vivo and could target tumors with high signal-to-noise ratio, which allowed near 
infrared optical imaging of pancreatic tumors.  ScFvEGFR conjugated quantum dots 
bound and internalized to EGFR positive pancreatic tumor cells and targeted efficiently 
to tumor in pancreatic tumor bearing mice while the non-targeted QD was almost 
undetectable in tumor [49]. These results suggest that QDs might be promising 
diagnostic agents for PDAC detection. 
 
Liposomes have been successfully used as carriers for chemotherapeutics in clinic 
[54]. The development of liposome formulations has led to clinical trials investigating 
liposomal drug delivery systems for pancreatic cancer. Some of them have shown 
improved efficacy as compared to gemcitabine alone [55]. Liposomes have also been 
evaluated as pancreatic cancer diagnostic agents but only in animal models. Kato’s 
group developed L-fucose-bound liposomes containing Cy 5.5 for effective near infrared 
optical imaging of CA19-9 expressing pancreatic tumors [56]. A multifunctional liposome 
platform conjugated with anti-mesothelin antibodies was loaded with SPION for MR 
imaging of pancreatic cancer. The in vivo imaging results showed that tumor signal 
10 
 
intensity dropped by 4 hour post injection (p.i.) and the decrease was much higher than 
free SPION without antibodies [57].         
 
Many different polymers and polymer conjugates have been evaluated for pancreatic 
cancer imaging. Eser et al. developed a cathepsin-activatable, near-infrared probe 
based on PEG modified poly-l-lysine for pancreatic cancer imaging in a genetically 
mutated Kras mouse model [58]. The 35.5 kDa poly-l-lysine backbone was attached with 
92 molecules of 5 kDa PEG and 11 molecules of Cy5.5. The fluorescence of the polymer 
conjugates was initially relatively low due to self-quenching, but could be substantially 
increased when cleaved by proteases. They identified increased expression of cathepsin 
proteases during pancreatic tumor progression. The elevated amount of cathepsins from 
PanIN lesions and early stage PDAC digested the accumulated conjugate in the tumor, 
thereby generating near-infrared fluorescence for pancreatic tumor imaging. They 
concluded that utilization of this technique enabled the detection and evaluation of early 
precursors of PDAC in vivo, holding great promise to improve early detection of PDAC. 
The Lammers’ group prepared near infrared fluorophore labeled N-(2-Hydroxypropyl) 
methacrylamide (HPMA) copolymers and compared the active targeting RGD peptide 
conjugated HPMA copolymer with passive targeting HPMA copolymer modified with 
scrambled peptide DRG or without peptides in a pancreatic tumor xenograft model [59]. 
Interestingly they found that vascular targeting only worked in early time point at 1~2 h 
p.i., but passive targeting was more efficient at the long-term points (24~72 h).  Work 
from Ghandehari’s group demonstrated that pancreatic tumor targeting efficacy could be 
increased by utilizing hyaluronidase to break down the hyaluronic acid present in the 




1.4 RADIOLABELED HPMA COPOLYMERS FOR CANCER IMAGING AND 
RADIOTHERAPY 
N-(2-Hydroxypropyl)methacrylamide or HPMA copolymers possess many distinct 
advantages including good biocompatibility and water solubility as well as prolonged in 
vivo circulation time. By means of EPR effect, these copolymers extravasate to tumor 
sites effectively and selectively [61]. The research on the use of HPMA copolymers as 
drug carriers started in the early 70s in Dr. Kopeček’s laboratory [62]. To date, six HPMA 
conjugates have entered different stages of clinical trials, including two of them applied 
as theranostic agents (Table 1.1) [63]. Clinical trials have proven that HPMA conjugates 
were non-immunogenic and can be safely administered parenterally and exhibited 
anticancer activity. Given the high sensitivity of imaging modalities like SPECT and PET, 
radiolabeled HPMA copolymers have been successfully used to quantify the in vivo 
biodistribution of the copolymers and to visualize the tumor size and location for 
diagnostic imaging [61]. These agents can also serve as a platform to selectively deliver 
therapeutic doses of ionizing radiation to the tumor [64]. The application of radiolabeled 










Table 1.1: HPMA-drug conjugates that have entered clinical trials. Modified from Ref[63]. 
Code Compounds Molecular Weight Status 
FCE 28068 HPMA-GFLG-doxorubicin 30,000 Phase I/II 
FCE 28069 HPMA-galactosamine-GFLG-doxorubicin 25,000 Phase I/II 
PNU 166945 HPMA-paclitaxel N.A. Phase I- stopped 
PCNU 166148 HPMA-camptothecin 18,000 Phase I - stopped 
AP5280 HPMA-carboplatinate analogue 25,000 Phase I/II 























1.4.1 Design and Structure of Radiolabeled HPMA Copolymer 
The radiolabeled HPMA copolymer typically comprises at least three parts: a 
synthetic HPMA copolymer for prolonged circulation and tumor targeting; a polymer 
conjugated radionuclide chelator system to stably chelate the radioisotope, and the 
corresponding radionuclide for imaging or radiotherapy purpose.  Different types of 
radionuclides utilized in HPMA copolymers, so far, with their respective characteristics 

















Table 1.2: Different radionuclides and their corresponding chelators applied in HPMA 
copolymers evaluated to date.  






Chelator Status Ref 
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There are two main approaches that can introduce the radionuclide chelators into 
HPMA copolymer: the co-polymerization method and the post-polymerization method. 
The co-polymerization method involves either free radical or controlled polymerization 
(e.g. the atom transfer radical polymerization (ATRP) and reversible addition-
fragmentation chain transfer polymerization (RAFT)) of HPMA monomer, monomers 
containing the chelation system and other desired monomers. The polymerization is 
carried out in homogeneous solution phase and in the presence of radical initiators. The 
reaction is mostly initiated through heating (40 ºC to 80 ºC). Chain transfer agents can 
be added to better control the polydispersity and molecular weight. For example, to 
prepare the human epidermal growth factor receptor 2 (HER2) targeted 111In-labeled 
HPMA copolymer, four monomers: HPMA monomer, a chelator containing monomer: N-
methacryloylaminopropul-2-amino-3-(isothiurea-phenyl)propylcyclohexane-1,2-diamine-
N,N-N’,N’,N’’,N’’-pentaacetic acid (APMA-CHX-A’’-DTPA), the drug containing monomer 
N-methacryloylglycylphenyl-ananylleucylglycyl-gemcitabine and a HER2 targeted 
peptide conjugated monomer: N-methacryloylglycylglycyllysylcystyl-
cystyltyrylserylleucine (MA-GG-KCCYSL) were dissolved together and RAFT 
polymerized for 24 hours using 2-cyano-2-propyl dodecyl trithiocarbonate as the chain 
transfer agent and 2,2’-azobis[2-(2-imidazolin-2-yl)propane] as the initiator (Figure 1.2) 
[65]. The copolymer was then radiolabeled with 111InCl3 after heating at 50 ºC for 45 min 
in sodium acetate buffer. The radiolabeled copolymer was finally purified using size 








Figure 1.2: Preparation of 111In-labeled HPMA copolymers by co-polymerization method. 

















The co-polymerization method is quite straightforward. Many different functional 
monomers, modified with either a targeting moiety or therapeutic drugs, can be 
introduced at the same time with the chelation system. The content of each component 
in the copolymer can be controlled by adjusting the feeding ratios of each monomer. The 
resulting copolymer can be easily purified and characterized using size exclusion 
chromatography. One problem is that the preparation of many modified monomers may 
require expensive and time-consuming synthesis development.  
 
The other method for the synthesis of a radiolabeled HPMA copolymer is the post-
polymerization method. In this case, a copolymer precursor, containing a certain reactive 
functional group, is prepared after the polymerization step and subsequently conjugated 
to the chelation system. For example, HPMA and N-(3-aminopropyl)methacrylamide 
(APMA) were RAFT polymerized using 4,4’-azobis(4-cyanovaleric acid) as the initiator 
and 4-cyanopentanoic acid dithiobenzoate as the chain transfer agent (Figure 1.3) [66]. 
Activated 2-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl) 
acetic acid (DOTA(tBu)3) was conjugated to the primary amine functional groups from 
APMA. The amount of conjugated DOTA(tBu)3 was determined by ninhydrin assay. The 
HPMA-DOTA conjugate was treated with TFA, to remove the t-butyl protecting groups 




Figure 1.3: Preparation of 177Lu-labeled HPMA copolymers by post-polymerization 















Post-polymerization is a relatively straightforward way to introduce the radionuclide 
chelator. However, the conjugation reaction efficiency can be adversely affected by the 
steric hindrance from randomly coiled polymer chains and the side chains of the other 
block components [61]. The degree of conjugation can be hard to control at times and 
additional characterizations are required to determine the conjugation efficiency. The 
characterization techniques may include colorimetric analysis, MS or NMR. The choice 
of co-polymerization or post-polymerization method depends on many factors, such as 
time, the availability of different functional monomers and the experimental purpose, and 
should be carefully selected in each case.  
 
A variety of radionuclide chelators have been incorporated into HPMA copolymers. 
For the radioactive iodine labeled HPMA copolymer, tyrosine analogues are most 
commonly introduced in the modified monomer form (N-methacryloyltyrosinamide (MA-
Tyr)) during the co-polymerization step [67-69]. The labeling is done under mild 
conditions by treatment of the copolymer with radioactive sodium iodine in the presence 
of an oxidizing reagent, to generate the electrophilic radio-iodine. The electrophilic 
species then react with the aromatic moiety of the compound to be labeled and form the 
radio-iodine-labeled copolymer.  
 
For the preparation of 99mTc-labeled polymer, a monomer called N-methacryloylglycyl 
glycyl-(N-ω-bis(2-pyridylmethyl)-l-lysine) (MA-GG-DPK) was synthesized and introduced 
in the co-polymerization step [70]. N-ω-bis(2-pyridylmethyl)-l-lysine (DPK) can provide a 
compact tridentate coordination with 99mTc-tricarbonyl core and form very stable 
complexes. For most radio-metals, DTPA or DOTA analogues have been utilized [60,65, 
66]. These macrocyclic chelators have good radiolabeling yield and can form stable 
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complexes with radio-metals. DTPA or DOTA moieties can be introduced in the co-
polymerization step or by post-polymerization conjugation. However, one concern is that 
those macrocyclics themselves are rather bulky and mostly charged and as a result may 
influence the copolymer structure and consequently in vivo biological behavior [71].  
 
For the most part, efforts in the pursuit of diagnostic HPMA copolymers have mainly 
focused on SPECT compatible radioisotopes. However, the last few years has seen an 
increase in the number of reports describing PET radionuclide incorporated into HPMA 
copolymers. Herth et al. prepared 18F- labeled HPMA copolymers for short-term blood 
pool imaging [71]. They reacted 2-[18F]fluoroethyl-1-toylate ([18F]FETos) with the phenol 
group of a tyramine moiety from an HPMA copolymer after deprotonation of phenolic 
tyramine with a smaller amount of NaOH (Figure 1.4A). They reported radiochemical 
fluoroalkylation yields of ∼80% for block copolymers and >50% for random polymers 
after a 10 min reaction at 120 °C. The synthesized 18F-labeled HPMA copolymer could 
be purified and collected within 90 min. The same group also tried to label HPMA 
copolymers with the longer-living positron emitter Arsenic-72/74 (72/74As) (Figure 1.4B) 
[72]. HPMA copolymers were prepared by RAFT polymerization, using the dithiobenzoic 
ester as the chain transfer agent. The end group in each copolymer, coming from the 
chain transfer agent was converted to -SH group after reduction with tris(2-carboxyethyl) 
phosphine treatment. 72/74As-labeling of HPMA was carried out in water at 70 ºC with 









Figure 1.4: Preparations of 18F-radiolabeled HPMA copolymers for PET imaging. 












1.4.2 Preclinical Evaluation of Radiolabeled HPMA Copolymers in Animal Models 
Various radiolabeled HPMA copolymers have been evaluated in different animal 
models and have shown great potential as tumor imaging agents. With respect to tumor 
targeting mechanism, those copolymers can be briefly categorized into two types: the 
passive tumor-targeting HPMA copolymers and the active tumor-targeting HPMA 
copolymers. The following part will mainly discuss about the design and in vivo 
performances of different kinds of radiolabeled HPMA copolymers in animal models:   
 
Passive tumor-targeting HPMA copolymers 
Early studies have assessed the in vivo pharmacokinetics and imaging characteristic 
of HPMA copolymer labeled with different radioiodines (123I, 125I and 131I) [67-69, 73]. The 
biodistribution of the radioactive conjugates in tumor xenograft mice were monitored 
using the gamma scintigraphy and also by ex vivo biodistribution measurements.[67] 
There was a clear relationship between the copolymer molecular weight and body 
clearance and tumor uptake of HPMA copolymers [73]. It was found that the urinary 
excretion of radioactivity was dependent on the molecular weight of the copolymer. 
HPMA copolymers with molecular weight below the renal threshold (~45 kDa) cleared 
mostly through the renal system, which lead to the kidney containing the highest 
radioactive content [68]. Contrastingly, high molecular weight (Mw) HPMA copolymers 
were predominately cleared by the mononuclear phagocyte system (MPS) and the 
hepatobiliary system, leading to retention in the liver and spleen. The tumor uptake 
displayed continuous increase with time even after 72 h and was much higher as 




The biodistribution of HPMA copolymers can be easily affected by the other 
components in the copolymer. Biotin-labeled HPMA copolymers were initially prepared 
to investigate the cellular localization of HPMA copolymers in normal and tumor tissues. 
However, it was found that biotinylation could significantly alter the biodistribution, which 
was assessed by 125I-labeled HPMA copolymers [74].The biotinylated HPMA copolymer 
cleared faster from the circulation than the unmodified HPMA copolymer of comparable 
molecular weight and had lower accumulation in the liver, spleen and tumor. The kidney 
uptake was 33 times higher for the biotinylated HPMA copolymer possibly due to the 
presence of biotin transporters in the brush border membrane.  
 
Lammers et al. used the scintigraphic imaging method to investigate the influence of 
the incorporation of various functional groups into 131I-labeled HPMA copolymers on the 
whole-body distribution and tumor accumulation of the copolymers [75]. They prepared 
ten functionalized HPMA copolymers and evaluated the in vivo behaviors in AT1 tumor 
bearing rats. The authours found that the incorporation of carboxyl and hydrazide groups, 
as well as introduction of spacer, drug and peptide moieties reduced the long-circulating 
properties of the copolymers thereby lowering the accumulation in tumors and in all 
tissues except for kidney. But tumor-to-organ ratios were comparable to unmodified 
controls for the majority of the chemically modified copolymers. It was concluded that 








Figure 1.5: Evaluation of the tumor to organ ratio of HPMA copolymers with different 
functional groups at 168 h p.i. indicated that except for the pentapeptide PHSCN, other 














The administration route could also affect the tumor accumulation of radiolabeled 
HPMA copolymers. Lammers et al. compared the effect of intratumoral (i.t.) injection 
versus intravenous (i.v.) injection on the biodistribution of HPMA copolymers in prostate 
tumor bearing rats [76]. HPMA-MA-Tyr copolymers with different molecular weight were 
labeled with 131I in high efficiency. It was found the i.t. injected HPMA copolymers had 
significantly less blood radioactivity as compared to those from i.v. injection. The tumor 
to organ ratios from i.t. injection were 5 times higher for the 31 kDa copolymer and up to 
20 times higher for the 65 kDa copolymer compared to those from i.v. injection. Based 
on the findings, they suggested i.t. injection of polymer-based chemotherapy as an 
alternative to routine administration routes. 
 
Radioiodine has a number of disadvantages, which may limit its translational 
application for the HPMA copolymer based radiopharmaceuticals. 125I emits low-energy 
gamma rays with low tissue penetration that could limit its application in human. 131I has 
high gamma emission energy (364 keV) and ionizing radiation associated with its beta 
emission, so it’s not generally used for diagnostic imaging. 123I is more suitable than the 
aforementioned radionuclides for clinical imaging, but it is relatively expensive to 
produce [77]. Given the wide use of Technetium-99m in clinic for nuclear imaging and its 
ideal imaging energy, 99mTc-labeled HPMA copolymers were developed and evaluated in 
vivo. Ghandehari’s group prepared 99mTc-labeled HPMA copolymers of various charges 
and molecular weights at 7, 21 and 70 kDa and determined their biodistribution in non-
tumor bearing mice [77]. Neutral HPMA copolymers contained 95% HPMA and 5% MA-
GG-DPK while negatively charged HPMA copolymers contained 70% HPMA, 5% MA-
GG-DPK, 23% N-methacryloylglycylglyine (MA-GG-COOH) and 2% MA-Tyr. The 7 kDa 
negatively charged copolymer showed 8.1 ± 0.74% ID/g in the kidney at 24 h, while 
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higher renal activity was found for the 21 kDa and 70 kDa copolymer, which showed 
33.1 ± 1.6% and 23.3 ± 4.8% ID/g, respectively. At 24 h, the 70 kDa electronegative 
copolymer had little accumulation in the blood (1.5 ± 0.3% ID/g), spleen (1.4 ± 0.7% 
ID/g), and liver (2.2 ± 0.6% ID/g) while the other two showed < 1%ID/g in all tissues. For 
neutral copolymers, higher molecular weight showed longer circulation time and higher 
tissue retention, which is consistent with radioiodine labeled HPMA copolymers. At 24 h, 
the neutral 7 kDa copolymer had some hepatic (5.3 ± 1.7% ID/g) and splenic retention 
(5.9± 1.9% ID/g). The 21 kDa copolymer showed high renal (18.3 ± 6.9%ID/g) and 
splenic retention (10.3 ± 1.3% ID/g). The 70 kDa copolymer showed the highest blood 
activity (19.2 ± 4.2% ID/g) and retention in lung (12.8 ± 3.1% ID/g), spleen (14.9 ± 4.5% 
ID/g), and liver (25.3 ± 2.8% ID/g). Overall, all three negatively charged copolymer were 
more efficiently cleared from the body than the neutral copolymers and did not, with 
exception to the kidneys, exhibit substantial, long-term retention in any major tissues. 
 
More recently, HPMA copolymer labeled with different radiometals through 
coordination with DOTA or DTPA were evaluated in mice. Garrison’s group synthesized 
a 343 kDa HPMA-APMA copolymer and conjugated it with DOTA(tBu)3. The copolymer 
was successfully labeled with 177Lu after deprotection with TFA. The radiolabeled HPMA 
copolymer was mainly eliminated by the MPS and its high molecular weight resulted in 
high blood and tumor radioactivity after 72 h p.i. [66].  
 
Dr. Kopecek’s group recently developed a series of backbone degradable HPMA 
copolymers. A 109 kDa HPMA copolymer was first RAFT synthesized, and then was 
extended to a 335 kDa backbone degradable HPMA conjugate through a cathepsin B 
cleavable linker using “click chemistry” [78]. The copolymer was radiolabeled with 125I to 
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permit pharmacokinetic and imaging studies in mice. SPECT/CT imaging in mice 
bearing orthotopic ovarian tumor demonstrated biodegradability and elimination of the 
backbone degradable HPMA from the body. In the next study, they applied duallabeling 
to a 110 kDa backbone degradable HPMA copolymer to separately investigate the 
behavior of the carrier and payload [79]. The HPMA copolymer backbone was labeled 
with 125I and the 111In-DTPA complex was attached at the GFLG side-chain termini and 
served as the drug model. SPECT/CT imaging results demonstrated that payload (111In) 
had similar blood half-life and tissue uptake as polymeric carrier (125I), which indicated 
that the GFLG bond was stable in blood circulation. This “second generation” high-
molecular weight backbone-degradable HPMA copolymer showed five- (111In) to eight- 
(125I) times higher tumor accumulation as compared to the “first-generation” backbone 
non-degradable low molecular weight (< 50 kDa) conjugates.  
 
The in vivo behavior of 18F-labeled HPMA copolymer has also been investigated in 
mice, but mainly in the early time points. Different molecular weights of either HPMA 
homopolymer or HPMA-ran-LMA (LMA = lauryl methacrylate) copolymer was 
synthesized and labeled with [18F]FETos [80]. HPMA-ran-LMA copolymers could form 
aggregates in ~ 40nm size above their critical micelle concentration. The copolymer was 
less efficiently labeled as compared to the homopolymer, presumably due to the lower 
accessibility of phenolic groups in the interior of the polymer coils. MicroPET imaging 
was utilized over 2 h period of time after i.v. injection of the labeled polymers. The ex 
vivo biodistribution study was carried out at 2 h after i.v. injection and it was found that 
independently from the molecular weight, the HPMA-ran-LMA copolymer showed longer 
blood circulation, and the uptake of the larger Mw copolymer by the liver and spleen was 
much lower than that of the comparable homopolymer, which was also confirmed by the 
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PET imaging results. It was assumed that that the incorporation of the hydrophobic lauryl 
methacrylate block had significant impact on the biodistribution and helped avoid the 
uptake of the polymers by the MPS.   
 
The same group also studied the effect of PEGylation on the in vivo behavior of 18F 
labeled HPMA-b-LMA copolymer [81]. Different amounts of PEG 2000 were grafted to 
the polymer backbone from 0% to 11% while the ratio of polymerization with HPMA and 
LMA monomer was kept constant. The copolymer was labeled with 18F with a relatively 
low yield of less than 20%. Non-invasive PET imaging over 2h and quantification by ex 
vivo biodistribution measurements at 2 h and 4h p.i. were performed on mammary 
carcinoma bearing rats. The study showed that the lower PEG content copolymer had 
major kidney and MPS uptake with comparatively low blood retention as well as tumor 
accumulation while higher PEG content caused prolonged blood circulation times and 
led to a tumor accumulation constantly increasing with the increased amount of PEG.  
 
Active tumor-targeting HPMA copolymers 
Distinct from passive tumor targeting HPMA copolymers, active tumor targeting 
HPMA copolymers have been conjugated with different targeting ligands, including small 
molecules, peptides and antibodies with the aim of improving tumor-targeting efficacy. 
Many of these targeted HPMA copolymers have been radiolabeled and evaluated by 
nuclear imaging studies.  
 
The galactose receptor is highly expressed on liver hepatocytes [82]. Galactosamine, 
which was the first small molecule ligand conjugated to an HPMA copolymer, has good 
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affinity to the galactose receptor. As a consequence, HPMA-galactosamine conjugates 
have been investigated for liver-targeted drug delivery [83]. The galactose receptor-
targeted HPMA copolymer was labeled with a variety of radioiodines (123I, 125I, 131I) for 
biodistribution and gamma scintigraphy studies [69, 84]. Substantial hepatic 
accumulation of the galactosamine conjugated HPMA copolymer was seen as early as 
20 min p.i., which confirms the liver-targeting capability of galactosamine conjugated 
HPMA copolymers. 
 
Folate receptor is over-expressed on many different types of cancer cells including 
breast cancer, while its expression in healthy tissues and organs is limited [85]. The 
potential of folate receptor-targeted HPMA copolymers was evaluated in mammary 
tumor bearing rats [86]. HPMA copolymer of 10.5 and 52.5 kDa were functionalized with 
folate through copper catalyzed “click chemistry” and labeled with 18F as described in 
section 1.4.1. In vivo biodistribution and micro-PET imaging studies revealed a 1.5 to 2 
fold increase in tumor accumulation at the 2 and 4 h time-points for the folate-conjugated 
HPMA copolymer relative to the non-targeted HPMA copolymer control. The increased 
accumulation could be blocked by co-administration of native folic acid with 18F-labeled 
folate-HPMA copolymer. This work demonstrated the effectiveness of folate-conjugated 
HPMA copolymers for folate receptor positive tumor-targeting. 
 
Angiogenesis in tumor sites is critical for tumor growth and metastasis [87]. Targeting 
angiogenesis is an important area in tumor diagnosis and targeted therapy [88]. Tumor 
blood vessels highly express αvβ3 integrin receptors, which can be targeted by the RGD 
peptides. Numerous reports on the RGD peptides and analogues have demonstrated 
the in vivo efficacy of this integrin-targeted peptide [89]. A decade ago, RGD peptides 
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were firstly conjugated to HPMA copolymers in order to evaluate the potential of these 
integrin-targeted agents. 99mTc-labeled HPMA copolymer bearing a double cyclized RGD 
analogue (RGD4C) or a non-targeted control (RGE4C) was synthesized and evaluated 
in a DU-145 prostate tumor xenograft mouse model [70]. Based on this report, the 
HPMA-RGD4C conjugate had almost 4 times higher tumor accumulation (4.60 ± 1.80% 
ID/g) than the non-integrin-targeted HPMA copolymer (1.24 ± 0.15% ID/g) from the 24 h 
scintigraphic image results (Figure 1.6). The targeted copolymer had sustained tumor 
retention over a 72 h period with substantial clearance from non-target tissues. In 
addition, the authors also compared the biodistribution of 99mTc labeled HPMA-RGD4C 
conjugate with 99mTc labeled RGD4C peptide [90]. They found that the liver and spleen 
uptake at 24 h was higher for the radiolabeled peptide compared to polymer peptide 
conjugate, which might be due to reduced extravasation of the targeted polymeric 















Figure 1.6: A, scintigraphic image of 99mTc-labeled HPMA-RGD4C conjugate in a DU-
145 xenograft mouse model at 24 h p.i. B, scintigraphic image of 99mTc-labeled HPMA-
RGE4C conjugate in a DU-145 xenograft mouse model at 24 h p.i. C, biodistribution of 
three different 99mTc-labeled copolymers (white: HPMA-RGD4C, black: HPMA-RGE4C 
and grey: HPMA homopolymer) in a DU-145 xenograft mouse model at 24 h p.i. 
















RGD4C peptide is susceptible to degradation in vivo. To solve the stability issue 
associated with RGD4C, Ghandehari’s group attached a stable cyclic RGD analogue, 
RGDfK, to the HPMA copolymer, and compared it with the RGD4C-HPMA conjugate 
[91]. After labeling both with 111In, the in vivo efficacy of the αvβ3–targeted HPMA 
copolymers were evaluated in a LLC1 xenograft lung carcinoma mouse model. Both 
showed significant tumor accumulation after 24 h p.i. with peak accumulations at 4.9 ± 
0.9% and 5.0 ± 1.2% ID/g, respectively. There was no statistical difference in tumor and 
non-target tissues retention between the two peptide copolymer conjugates.  
 
Ghandehari’s group developed peptide conjugated HPMA copolymers for active 
targeting of HER2 positive pancreatic tumors [60]. The HPMA copolymer was 
conjugated with the HER2 targeted peptide (KCCYSL) by aminolysis and was 
radiolabeled with 111In using the DTPA chelator. Pancreatic tumors are characterized by 
the existence of dense stroma consisting of abundant hyaluronic acid, which prevents 
the diffusion of macromolecules. Their work demonstrated that the targeting efficacy of 
the HER2 targeted HPMA copolymer could be increased 2-3 fold after utilizing 
hyaluronidase prior to the injection of the radiolabeled copolymer. Hyaluronidase broke 
down the hyaluronic acid in the stroma thereby increasing the extravasation of HER2 
targeted HPMA copolymers into pancreatic tumors. 
 
Prostate tumors can over-express galectin-3 [92]. The G3-C12 peptide, with the 
sequence of ANTPCGPYTHDCPVKR, was discovered by phage display and has specific 
binding affinity galectin-3 [93]. Huang’s group developed the prostate carcinoma targeting 
HPMA copolymer conjugated with 3 mole% the G3-C12 peptide and labeled it with 131I 
[94]. Scintigraphic imaging was used to visualize the biodistribution of the peptide 
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modified copolymers and control copolymer (without peptide) in a PC-3 prostate tumor 
xenograft mouse model. It is important to note that both the targeted and the control 
HPMA have analogous molecular weights. At 2 h and 24 h p.i., the 131I-labeled G3-C12 
HPMA copolymer conjugate had significantly higher tumor accumulation (1.60 ± 0.08% 
ID/g and 1.04 ± 0.19% ID/g) as compared to the non-target HPMA copolymer (1.19 ± 0.04% 
ID/g and 0.36 ± 0.04% ID/g), implying the active tumor targeting effects of the G3-C12 
peptide in the HPMA copolymer paradigm. 
 
1.4.3 In Vivo application in human patients 
Based on many promising preclinical findings, in 1994, HPMA-GlyPheLeuGly-Dox 
(PK1) became the first applied passively tumor-targeted polymeric prodrug to enter 
clinical trials [95] and was given by i.v. administration to 36 patients with different types 
of tumors [96]. As part of the clinical investigation of PK1, planar scintigraphy imaging 
studies using 131I- and 123I-labeled PK1 was utilized to quantify the in vivo biodistribution 
and to visualize its tumor uptake. The tumor uptake of 131I-labeled PK1 allowed for clear 
visualization of the primary cancer in a number of patients. The scintigraphy study 
clearly showed the clearance of the 28 kDa radiolabeled HPMA copolymer from the 
body through renal filtration. 123I-labeled PK1 was found to localize into the metastatic 
lesions of some patients. For example, a large metastasis was observed in the left 
shoulder region of a breast cancer patient (Figure 1.7A) [97]. Further clinical 
investigations were carried out on PK2, an analogue to PK1, but functionalized with 
galactosamine to improve the liver targeting ability. 123I-labeled PK1 and PK2 were 
administered to some hepatocarcinoma patients and their in vivo behavior was 
compared [97]. Significant liver accumulation of PK2 was present even after 48 h p.i., 
while little accumulation was observed for PK1 at the same time point. However, the 
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integrated SPECT/CT images showed that the active targeting conjugate mainly 
accumulated in healthy liver tissues (17 ± 4% ID) instead of in hepatocarcinoma (3 ± 6% 
ID). This was explained by the relatively small size of liver tumors as compared to 
healthy livers and by the fact that hepatocarcinoma was not as well-perfused as healthy 
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Figure 1.7: A, Gamma scintigraphic imaging of 123I-labeled PK1 in a breast cancer 
patient with a metastatic lesion in the left shoulder region as indicated by the arrow; B, 
gamma scintigraphic imaging of 123I-labeled PK2 in four hepatocarcinoma patients. 





















1.4.4 Radiotherapy using HPMA copolymers 
The application of radiolabeled HPMA copolymers for tumor-targeted radiotherapy is 
relatively new and remains to be thoroughly explored. Mitra et al. prepared HPMA-
RGD4C conjugates and labeled them with Yttrium-90 (90Y) via the CHX-A’’-DTPA 
chelator side chain [64]. 90Y is a well-known therapeutic radioisotope due to its optimal 
beta emission (βmax 2.27 Mev) properties and the ability to form in vivo stable complexes 
with DTPA. They evaluated the radiotherapeutic efficacy of these 90Y-labeled HPMA-
RGD4C conjugates in a DU-145 tumor xenograft mouse model with a tumor size of 
around 0.3 cm3 in volume. Biodistribution studies showed that the tumor accumulation 
increased significantly (p<.01) over time from 1.05 ± 0.03 % ID/g at 1 h to 4.32 ± 0.32% 
ID/g at 72 h. At the end of the therapeutic study, they observed a 7% and a 63% 
average decrease in tumor volume for the single dose 100- and 250-μCi 90Y treatment 
groups, respectively, while the control tumors increased by 442% on average in volume 
(Figure 1.8). In addition, no acute toxicity was found in the liver and spleen samples from 
the treatment groups. The study showed that HPMA copolymers are effective carriers to 
deliver therapeutic doses of radioactivity to inhibit tumor growth. One recent study also 
showed that the combination treatment of 90Y-labeled HPMA copolymer and PEGylated 
gold nanorod-mediated hyperthermia could exhibit greater reduction in tumor growth as 






Figure 1.8: Tumor growth of DU-145 xenografts in SCID mice after different treatment:  
250 µCi 90Y-labeled HPMA-RGD4C conjugate (closed circle), 100 µCi 90Y-labeled HPMA 


























1.5 SUMMARY AND CURRENT PROPOSAL  
HPMA copolymers are very safe and biocompatible, and can effectively accumulate 
in tumor sites, which makes them a promising platform for the development of SPECT or 
PET tracers for pancreatic cancer imaging as well as a good carrier for targeted 
radiotherapy. However, one major challenge for the development of diagnostic and/or 
therapeutic HPMA copolymer based agents is their opsonization and sequestration by 
the MPS. In many cases, the sequestration of these polymers leads to substantial 
accumulation in the liver and spleen. From a diagnostic perspective, this MPS 
accumulation in non-target organs can hinder identification of resident or nearby 
metastatic lesions thereby decreasing the diagnostic efficiency. From the view of 
therapeutic applications, the non-target accumulation of the polymer drug conjugates 
can lead to significant toxicities which may be dose-limiting.    
 
Our laboratory is interested in developing synthetic approaches in which HPMA 
copolymers can be modified to significantly reduce the MPS accumulation or increase 
the tumor accumulation, thereby enhancing the diagnostic and/or radiotherapeutic 
efficacy of these agents. Hypotheses to be tested are: 1) the incorporation of metabolic 
active linkers into HPMA copolymers can lead to lower liver and spleen radioactivity 
retention; 2) the appropriate optimization of metabolic active linkers and the molecular 
weight of HPMA copolymers can result in a viable platform for pancreatic tumor imaging; 
3) the conjugation of certain targeting ligands (plectin-1 targeted peptide) to HPMA 





   Chapter 2  
177Lu-Labeled HPMA Copolymers Utilizing Cathepsin B and S 
Cleavable Linkers: Synthesis, Characterization and Preliminary 
In Vivo Investigation in a Pancreatic Cancer Model 
 
2.1 INTRODUCTION 
Over the last three decades, biomedical researchers have seen the dramatic 
emergence of polymeric micro- and nanoparticle drug delivery technologies for the 
treatment of human disease [99-101].  These drug delivery systems include an array of 
paradigms such as: liposomes, polymer micelles, dendrimers and polymer conjugates. 
The development of polymeric diagnostic and therapeutic drug delivery systems offer 
several advantages over traditional drug delivery including the ability to control both the 
rate and location of drug release. However, one of the main disadvantages of these 
micro- and nanoparticle based systems has been opsonization and uptake by 
macrophages (e.g. Kupffer cells) of the mononuclear phagocyte system (MPS) [101, 
102].   The hallmark of this MPS uptake is the significant accumulation of the drug 
delivery system in organs containing MPS cells, specifically the liver and spleen, which 
can lead to significant toxicity. The development of PEGylation strategies to create 
“stealth” micro- and nanoparticle systems has contributed to a decrease in MPS 
accumulation thereby increasing the longevity of the polymeric drug delivery system in 
the bloodstream [101].  Unfortunately, even with the development of PEGylated 
techniques, a substantial portion of these polymeric drug delivery systems are still being 
sequestered by MPS tissues. 
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N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers have been extensively 
investigated as a drug delivery vehicle for a variety of chemotherapeutics [100, 103].  
While most of the focus on HPMA polymer conjugates has centered on 
chemotherapeutics, there have been published reports by a variety of investigators 
regarding the development of diagnostic nuclear imaging and radiotherapeutic agents 
[67, 84, 96, 104-109].  To date, the majority of these radiolabeled HPMA copolymer 
conjugates have centered on radioisotopes of iodine (e.g. 131I and 123I). However, recent 
work by Line, Ghandehari and co-workers, has employed various radiometals (e.g. 99mTc, 
111In and 90Y) common to clinical nuclear medicine [104, 105, 107, 108, 110].  The bulk 
of the HPMA copolymer conjugates investigated has focused on copolymers that were 
below the renal excretion threshold (i.e. ~45 kDa) in order to reduce MPS accumulation. 
While HPMA copolymer conjugates with molecular weights higher than the renal 
excretion thresholds have demonstrated significantly enhanced tumor delivery, the 
corresponding substantial increase in MPS tissue retention has largely made this 
approach undesirable for diagnostics and therapeutic agent development [103].  
 
Cysteine cathepsins  are predominantly lysosomal proteases that have been found 
to have diverse functions, but are primarily attributed to protein catabolism [111]. The 
function of cathepsin B has mainly been associated with the turnover of both intracellular 
and extracellular (through endocytosis) proteins in the lysosomal compartment. Tissue 
expression of cysteine cathepsins has been shown to be variable largely depending on 
the function of the protease. In some cases such as cathepsin B, the protease is 
expressed ubiquitously in almost every tissue [100, 112].  However, the highest levels of 
cathepsin B activity have been found in the liver, spleen, thyroid and kidneys for both 
murine and humans [113, 114]. For humans the activity of these tissues are 3 -10 fold 
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higher than other non-target tissues.  Conversely, the expression of some cysteine 
cathepsins, for instance cathepsin S, is selectively expressed in only a small group of 
cells. Cathepsin S is thought to be an integral protease in the degradation of antigenic 
proteins as part of the Major Histocompatibility Complex Class II pathway in antigen 
presenting cells [112, 115].  As a consequence of the critical role of cathepsin S in 
human immune response, the expression of cathepsin S has been shown to reside 
primarily in immune cells [116, 117]. Cathepsin B and S are both highly expressed in 
tissues that are associated with MPS uptake and retention of drug delivery systems. 
 
Protease cleavable linkers are attractive for use in drug delivery due to the typically 
high serum stability and specificity of the substrate-linkers [118].  In polymer based drug 
delivery, Kopeček and others have demonstrated the utility of protease cleavable linkers, 
specifically cathepsin B cleavable linkers, to increase in vivo drug delivery to tumor 
tissues [100, 103].  However, this technique has also been exploited to decrease 
retention of radioimmunoconjugates in non-target tissues (e.g. liver) without significantly 
affecting tumor retention thereby increasing the therapeutic index of the agent [119].  
One of the research focuses of our laboratory has been the design of protease cleavable 
linkers for the development of diagnostic and radiotherapeutic drug delivery systems. 
The impetus for the development of linkers that are substrates for cathepsin B and S is 
the high level of expression of these proteases in MPS tissues. The goal of this research 
is to create metabolically active linkers (MALs) that will increase the efficacy of the 
diagnostic or radiotherapeutic drug delivery systems by reducing the MPS accumulation. 
Herein, we describe our initial efforts in the development of MALs using 177Lu-




2.2 MATERIALS AND METHODS 
2.2.1 Solid-Phase Peptide Synthesis 
The MAL1 and MAL2 peptides were synthesized on an H-Phe-2-ClTrt and H-Pro-2-
ClTrt SPPS resin, respectively, using a microwave peptide synthesizer. The resin 
(containing 0.25 mmole of peptide anchors) was deprotected using piperidine resulting in 
the formation of the primary amine. The carboxylic acids of the Fmoc protected amino 
acids (1 mmol) were activated using COMU and conjugated to the primary amines of the 
growing peptide on the resin. The process of deprotection, activation and conjugation 
was repeated until the desired peptide was synthesized. The selective cleavage of the 
peptide from the 2-chlorotrityl resin anchor was achieved by reaction with 1% TFA in 
dry DCM and subsequent filtration. The combined crude filtrates were dried by a rotary 
concentrator. Purification of the peptides was performed using a semi-preparative Proteo 
C12 column with a flow rate of 5.0 mL/min. HPLC solvents consisted of H2O containing 
0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B). For 
both peptides, the initial gradient of 70 % A: 30 % B linearly decreased to 60 % A: 40 % 
B over a 15 minute time period. At the end of the run time for all HPLC experiments, the 
column was flushed with the gradient 5 % A: 95 % B and re-equilibrated to the starting 
gradient. The yields after purification were 0.042 mmole, 16.9% (n = 1) for MAL1 and 
0.090 mmole, 37.5% (n = 1) for MAL2. Both peptides were determined to be ≥ 95% pure 
as characterized by LC/MS before in vitro or in vivo use. 
 
2.2.2 Cathepsin Cleavage Assay of MALs 
MAL1 and MAL2, 1.51 and 1.22 µmole, respectively, were each weighed and placed 
into a 1 mL centrifuge tube. Each peptide was dissolved in 100 μl of buffer solution 
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containing 100 mM sodium acetate, 1 mM EDTA and 5 mM DTT. Solutions of cathepsin 
B and S were prepared at a concentration of 25 ng/μL. The pH of the solution for 
dissolution of both the peptide and protease was adjusted to 5.0 and 6.0 for cathepsin B 
and S assays, correspondingly. In the appropriate tube, 2 and 50 μl of the cathepsin B 
and S, respectively, were added. The cleavage assay was allowed to proceed for 96 
hours at room temperature and was evaluated every 24 hours by LC/MS. Evaluation of 
the peptides was performed using an analytical Proteo C12 column with a flow rate of 1.5 
mL/min. HPLC solvents consisted of H2O containing 0.1% formic acid (solvent A) and 
acetonitrile containing 0.1% formic acid (solvent B). For both peptides, the initial gradient 
of 70 % A: 30 % B linearly decreased to 60 % A: 40 % B over a 15 minute time period. 
At the end of the run time for all HPLC experiments, the column was flushed with the 
gradient 5 % A: 95 % B and re-equilibrated to the starting gradient. Cleavage estimates 
were determined by integration of the peptides and metabolite peaks from the total ion 
chromatogram generated by the LC/MS Waters MassLynx software.  
 
2.2.3 Synthesis and Characterization of the HPMA Copolymer 
The HPMA copolymerization was accomplished using the reversible addition-
fragmentation chain transfer polymerization reaction with V-501 as the initiator and CTP 
as the chain transfer agent. The feed ratio of the polymerization consisted of 
98.75:0.85:0.40 mole% HPMA, APMA and APMA-FITC, respectively. The 
polymerization was run at a 1 M total monomer concentration in aqueous acetic buffer 
(pH = 5.2, 0.27 M acetic acid and 0.73 M sodium acetate) with a molar ratio of total 
monomer: chain transfer agent: initiator of 2340:3:1. Prior to proceeding with the 
polymerization reaction, the glass ampule and contents were purged with argon for 20 
min. Subsequently, the ampule was flame sealed and allowed to heat at 70 C in an oil 
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bath for 14 hours. After cooling the HPMA copolymer was evaporated to dryness, 
dissolved in methanol and purified by size exclusion chromatography using an LH-20 
packing material with methanol as the eluent. The conversion rate was 71% as 
determined by weight after purification. The weight average molecular weight and 
polymer dispersity of copolymers were determined by FPLC equipped with UV and RI 
detectors. The FPLC measurements were carried out on Superose 6 column (HR 10/30) 
with PBS (pH 7.3) as the eluent. The average molecular weights of the copolymers were 
estimated using HPMA homopolymer standards with narrow polydispersity indices. 
 
2.2.4 Quantification of the Amine Content in the HPMA Copolymers 
Quantitation of the primary amine content of the HPMA copolymer was assessed 
using a slightly modified ninhydrin assay reported by York and co-workers [120]. A 
ninhydrin solution was prepared by dissolving 5.61 mmole of ninhydrin in 25 mL ethylene 
glycol. A SnCl2 solution was made by dissolving 0.177 mmole of SnCl2.2H2O in 25 mL of 
0.2 M citrate buffer. A ninhydrin-SnCl2 solution, of the desired quantity, was prepared by 
mixing the two solutions together in a 1:1 volumetric ratio. For the purpose of the 
creation of a calibration curve, a solution of 3 mM glycine was dissolved in 10 mL DI H2O 
and seven standard solutions were prepared by aliquoting amounts from 7.5 – 45 μL of 
this glycine solution into separate tubes. A 3 mM HPMA copolymer solution was 
prepared in DI H2O. For the unmodified HPMA copolymers, MAC0, MAC1 and MAC2 the 
sample size used were 0.0171, 0.0176, 0.0173 and 0.010 µmole, respectively. For each 
HPMA copolymer solution, an aliquot of 7.5 μL was added to a sample tube. To both the 
standard and sample tubes, 200 μL of the ninhydrin-SnCl2 solution was added. The 
sample and standard solutions were heated to 100 oC for 2 h and then allowed to cool to 
room temperature. The volumes of all solutions were adjusted to 3 mL using DI H2O and 
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analyzed by UV spectroscopy at 570 nm. The amine content of the HPMA copolymers 
was determined based upon the calibration curve generated by the glycine standards. 
Amine content in the unmodified HPMA copolymers, MAC0, MAC1 and MAC2 was 
found to be 70.4, 11.5, 19.1 and 11.7 μmol/g of polymer (n = 1 for each copolymer), 
correspondingly. Conjugation efficiencies were calculated by determination of the 
difference in the amine content between the MAC and the unmodified HPMA copolymer. 
 
2.2.5 Synthesis of the MACs 
The HPMA copolymer (0.292 µmole) was dissolved in 500 μl of DMF. The amine 
content in 0.292 µmole of HPMA copolymer was 7.04 μmol (1 equiv). In a 10 mL round 
bottom flask, 20.3 (35.4 μmol, 5.0 equiv), 20.0 (16.2 μmol, 2.3 equiv) or 22.8 mg (16.2 
μmol, 2.3 equiv) of MAL0, MAL1 or MAL2 was dissolved in 500 μl of DMF. The solution 
was cooled to 0 C and NHS and DCC were added to the flask in the same equivalent 
amount as the MAL. The solution was stirred at 0 C for 3 h. At the end of that time, the 
HPMA copolymer was added and stirred for another 2 h at 0 C. Subsequently, the 
reaction was allowed to warm to room temperature and continued for an additional 18 
hours. The precipitate generated from the reaction was filtered off and the filtrate was 
evaporated to dryness. The residue was dissolved in methanol followed by size 
exclusion chromatography using an LH-20 packing material. Evaporation of the high 
molecular weight fraction afforded light yellow HPMA copolymer-peptide conjugates. 
Based on the determined conjugation efficiencies from the ninhydrin assays, the percent 
recovery (n =1) of MAC0 was 77.6 (0.233 µmole), MAC1: 45.3 (0.140 µmole) and MAC2:  




Deprotection of the orthogonal protecting groups was accomplished using standard 
peptide cleavage conditions. Briefly, to a 0.0875 µmole sample of the MAC0, MAC1 and 
MAC2 was added  4 mL of a cleavage cocktail at 0 C consisting of a 1:1:1:37 volumetric 
ratio of DODT, water, TIS and TFA. For the MAC2, the cleavage cocktail used was a 
1:1:1:0.75:46.25 volumetric ratios of DODT, water, TIS, thioanisole, and TFA. Initially, 
the solution was stirred for 15 min at 0 °C. Subsequently, the cleavage reaction was 
allowed to warm up to room temperature and was continued for an additional 3 h. At the 
end of that time, the solution was evaporated and the residue dissolved in methanol 
followed by size exclusion chromatography using LH-20 packing material with methanol 
as the eluent. The collected high molecular weight fractions were evaporated to dryness 
to afford the deprotected copolymer-peptide conjugates. Based on the determined 
conjugation efficiencies, the percent recoveries (n = 1) of MAC0, MAC1 and MAC2 were 
80.2 (0.0697 µmole), 100 (0.0863 µmole) and 93.4 % (0.0808 µmole), respectively.  
 
2.2.6 Radiolabeling of the HPMA Copolymers 
The radiolabeling of the MACs was accomplished by heating the copolymer at 90 C 
for 1 h in the presence of 74 MBq (2mCi) of 177LuCl3. After cooling the resulting 
177Lu-
radiolabeled MACs were purified by radio-SEC-HPLC. Isolation of the 177Lu-MACs was 
accomplished using an isocratic mobile phase consisting of PBS with 0.02 mM EDTA at 
pH 7.4. The linear flow rate was 0.80 mL/min. UV analysis was performed at a 
wavelength of 494 nm. After collection of the peak-purified 177Lu-radiolabeled MACs, 
0.113 mmole of L-ascorbic acid was added as a radiolysis inhibitor. The purified 177Lu-
radioconjugate was concentrated using an Amicon Ultra-4 Centrifugal Filter and washed 
with 5 mL of deionized water. The purified 177Lu-radiconjugates were diluted with sterile 
saline to 0.37 MBq (10 μCi) per 100 μL. The radiochemical purity of all radioconjugates 
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was re-evaluated before administration and found to be ≥ 95 % pure as determined by 
the radio-HPLC. 
 
2.2.7 Cathepsin Cleavage Assay of Radiolabeled Copolymers 
Briefly, 0.291 nmole of each purified 177Lu-radiolabeled MACs (90~120 µCi) was 
incubated in a buffer with the indicated cathepsin in Eppendorf tubes at 25 ºC. The 
buffer solution consisted of 50 mM sodium acetate, 1 mM EDTA and 5 mM DTT, and pH 
was adjusted 5.0 for cathepsin B and 6.0 for cathepsin S to maximize the enzyme 
activity. For the MAC0, the copolymer was incubated in the presence of either cathepsin 
B (5 ng/µl) or cathepsin S (10 ng/µl) in 400 µl of buffer solution. MAC1 and MAC2 were 
incubated with cathepsin B (5 ng/µl) and cathepsin S (10 ng/µl), respectively, in 400 µl 
buffer. After every 24 hours, a 100 µl aliquot of the copolymer solution was analyzed by 
radio-SEC-HPLC to determine the relative amount of cathepsin cleavage product. The 
analysis utilized an isocratic gradient with a mobile phase consisting of PBS with 0.02 
mM EDTA at pH 7.4. The radio-SEC-HPLC analysis was carried out utilizing a linear 
flow rate of 0.80 ml/min and a UV wavelength of 494 nm. 
 
2.2.8 Human Serum Stability of Radiolabeled Copolymers 
Briefly, 0.291 nmole of purified 177Lu-MAC0, 177Lu- MAC1 and 177Lu-MAC2 was 
incubated with 1 mL of human AB serum at 37 C. After 72 h, the stability was 
determined by centrifuge filtration using an Amicon Ultra Ultracel 10 kDa filter. A 100µl 
aliquot was loaded in the filter and diluted with 4 mL DI water, centrifuged and washed 
with an additional 4 mL DI water. The percent stability of 177Lu-radiolabeled copolymers 
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was calculated based on the radioactivity of the copolymers remaining in the 10 kDa 
filter and the total radioactivity added.  
 
2.2.9 Macrophage Differentiation and Cell Culture 
Human monocytes were harvested from normal donors in the UNMC Elutriation Core 
Facility. Upon receipt, monocytes were immediately plated into T75 tissue culture flasks 
at a concentration of 20 x106 cells in 20 mL of macrophage differentiation medium 
DMEM containing 10% FBS, 1% Penicillin/Streptomycin, 2 mM l-glutamine, 1% sodium-
pyruvate, 1% NEAA and 500 U rhM-CSF. Media was half-exchanged every 2 to 3 days 
for 7-10 days, at which time, visual confirmation of differentiation was made and media 
was changed to macrophage maintenance medium (differentiation medium without the 
rhM-CSF). Cells were maintained at 37 C at 5% CO2 in air. 
 
The HPAC cells were cultured in our laboratory, as per ATCC protocols, in a 1:1 
mixture of DMEM and Ham's F12 medium containing 14.3 mM sodium bicarbonate, 2.5 
mM L-glutamine, 15 mM HEPES and 0.5 mM sodium pyruvate supplemented with 0.350 
µM insulin, 0.0625 µM transferrin, 0.110 µM hydrocortisone, 1.562 nM epidermal growth 
factor and 5% FBS. Cells were incubated at 37 °C at 5% CO2 in air. 
 
2.2.10 Cathepsin B and S Activity Assays 
The cathepsin B and S activity in macrophage and HPAC cell lines was determined 
using a commercial cathepsin B and S activity assay kit. The method is simplified as 
follows: 2 million macrophage and HPAC cells each were subjected to 500 μl cell lysis 
buffer. After 10-min incubation on ice, the cell lysate was centrifuged at 3000 rpm for 5 
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min. For each individual assay, 50 μl of the supernatant was transferred to a 96-well 
plate to which 50 µl of reaction buffer and 2 µl of either cathepsin B or S substrate was 
added. For the control group, another 2 µl of cathepsin B or S inhibitor was added. The 
reaction was allowed to proceed at 37 C for one hour. Samples were read using a 
fluorometer with a 400-nm excitation filter and a 505-nm emission filter. Activities 
correlating with the specified cathepsin protease were determined by subtraction of the 
RFU measurements of the samples with and without inhibitor. Each individual assay was 
replicated 10 times. 
 
2.2.11 Internalization Study of MACs by Flow Cytometry 
Macrophage and HPAC cells were seeded in 6-well plates at a density of 5 × 105 
cells per well and incubated in media overnight (37 °C, 5% CO2). Cells were then 
incubated with three MACs (0.1 mg/mL) at 37 °C for the indicated time periods. After 
incubation, the media was removed. Cells were harvested and washed with PBS three 
times followed immediately by flow cytometry analysis. Each sample analysis involved 
the evaluation of 1.0 × 104 cells. The collected data was averaged and reported as the 
mean fluorescent intensity for each sample. 
 
2.2.12 Biodistribution Studies  
Biodistribution studies were carried out using SCID mice with HPAC xenografts. The 
inoculation media was prepared using a 1:1 volumetric ratio of suspended HPAC cells to 
Matrigel™ to obtain a final concentration of 2 × 106 HPAC cells per 100 μl. The mice 
received a 100 μl subcutaneous inoculation into each flank. Upon achieving sufficient 
tumor size, (10-20 mm in diameter) the mice were considered viable for biodistribution 
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studies. The mice (average weight, 25g) were injected with a 0.37 MBq (10 μCi) 
intravenous bolus of the purified 177Lu-MAC. The mice were sacrificed and their tissues 
excised at 24, 48 and 72 h time points post-injection. The excised tissues were weighed 
and the 177Lu activity measured in each tissue using a gamma counter. Aliquots of the 
injected dose were counted as a reference standard for the calculation of % ID/g values.   
 
2.2.13 Statistical Analysis 
Data is presented as mean ± SEM. Evaluation of significance between the three 
groups of data was accomplished using a non-parametric Kruskal Wallis test. If the 
overall p-value from the Kruskal Wallis test was < 0.05, pairwise comparisons were 
made between the three groups using a non-parametric Mann Whitney test. In all cases, 




2.3.1 Design and Synthesis of the Metabolically Active Linkers (MALs) 
The MALs used in synthesis of the metabolically active copolymers (MACs) are 
depicted in Figure 2.1. For MAL1 and MAL2, the peptide sequences are composed of 
three parts: the radiometal chelation system, the clearance sequence, and the metabolic 
sequence. Both MAL1 and MAL2 contain the same chelation system (DO3A) and 
clearance sequence (G-(D)S(tBu)-(D)S(tBu)), but  differ in the metabolic sequence. For 
MAL1 the metabolic sequence (G-G-G-F) is a known substrate for the cathepsin B 
protease whereas the metabolic sequence for MAL2 (P-M-G-L-P) is a known substrate 
for cathepsin S [121, 122]. In the studies described herein, MAL0 is simply the DO3A 
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chelation system and is the control for our experiments. The MAL0 contains no amino 
acids and would not be expected to undergo any proteolytic degradation. All of the MALs 
were prepared with intact orthogonal protecting groups in order to carry out subsequent 
conjugation reactions with the HPMA copolymer. The synthesis of MAL1 and MAL2 was 
accomplished using SPPS. Detachment of the protected MALs from the resin support 
was accomplished with dilute acid (1% TFA) using 2-chlorotrityl anchor chemistry. The 
crude MALs were isolated and peak purified (n = 1) yielding 16.9% for MAL1 and 37.5 % 
for MAL2 of isolated, purified material (based on a 0.25 mmol scale synthesis). The RP-
HPLC retention times and the mass spectrometric characterization of the MALs are 

















Table 2.1: MALs characterization 
MAL 
Peptide 
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2.3.2 In Vitro Metabolism of MALs 
In order to confirm that the MAL1 and MAL2 will undergo proteolytic cleavage, the un-
metalated, protected MALs were incubated in the presence of the appropriate cathepsin 
protease. LC/MS analyses (n = 1) of the metabolism of MAL1 and MAL2 by cathepsin B 
and S, correspondingly, are displayed in Figure 2.2. Under the gradient conditions 
employed, the MAL1 and MAL2 peptides exhibited retention times of 5.7 and 8.9 min, 
respectively. For MAL1 a significant metabolite peak was observed at a retention time of 
4.3 min. At 24 and 48 h post incubation, LC/MS analyses revealed that 56 and 78 %, 
respectively, of the original MAL1 peptide had been metabolized. Evaluation of the MAL1 
metabolite mass (1030.5 Da) corresponds to the site of proteolytic cleavage being 
between the first and second glycine residues from the C-terminus (GG┼GF). With 
respect to the MAL2 peptide, a metabolite was observed with a retention time of 7.0 min. 
Over the course of the study, the amount of MAL2 peptide metabolized increased from 11 
to 80 %. The mass of the metabolite corresponded with the cleavage site being located 
between the glycine and leucine residues (DO3A-G-(D)S-(D)S-P-M-G┼L-P). Overall, 
these studies demonstrate that both MAL1 and MAL2 are proteolytically active and that 
the rate of metabolism of MAL2 by cathepsin S was slower relative to the cathepsin B 
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Figure 2.2: Evaluation of cathepsin B and S cleavage of MAL1 and MAL2, 
correspondingly. A, Total ion chromatograms of the cleavage of MAL1 by cathepsin B at 
24 and 48 h post-incubation B, Total ion chromatograms of the cleavage of MAL2 by 
cathepsin S at 24, 48 and 72 h post-incubation C, Depicts the enzymatic cleavage sites 


























































































2.2.3 Design and Synthesis of the Metabolically Active Copolymers 
The scheme for the synthesis of the MACs is depicted in Figure 2.3. The HPMA 
copolymer consisted of HPMA, APMA and APMA-FITC monomers which were 
polymerized, using reversible addition-fragmentation chain transfer (RAFT) 
polymerization, with a feed composition of 98.75:0.85:0.40, respectively. Assessment of 
the synthesized HPMA copolymer by FPLC revealed a molecular weight of 343 kDa with 
a polydispersity of 1.6. Evaluation by quantitative ninhydrin analysis revealed that 121% 
of the APMA monomer was incorporated into the HPMA copolymer which yielded a total 


















Figure 2.3: Synthetic scheme for the synthesis of the 177Lu-MAC conjugates. For MAC0, 












Conjugation of the MALs to the HPMA copolymer was accomplished using standard 
coupling chemistry. The preparation of protected peptides allowed for chemo-selective 
coupling of the C-terminal carboxylic acid with the aliphatic amine of the HPMA 
copolymer. Once the MALs were conjugated to the HPMA copolymer, the HPMA 
copolymers were termed MAC0, MAC1 and MAC2 corresponding to the conjugated MAL. 
Deprotection of the peptide components of the MACs were carried out using a standard 
cleavage cocktail containing predominantly trifluoroacetic acid. The deprotection of the 
MACs was verified by evaluation of MAC0 before and after deprotection using NMR 
(supporting information). The signal for the t-butyl groups of the DO3A was eliminated 
after the deprotection reaction corresponding to the loss of the t-butyl groups. With this 
information in hand, the cleavage conditions used for MAC0 were determined to be 
sufficient for the deprotection of MAC1 and MAC2. After deprotection the coupling yield 
of the MACs were analyzed by quantitative ninhydrin analyses. Ninhydrin analysis gave 
an 83.6, 72.9 and 83.4 % coupling efficiency (n = 1) for MAC0, MAC1 and MAC2, 
respectively.   
 
2.3.4 Synthesis, Cathepsin Cleavage and Serum Stability of 177Lu-labeled-MACs  
The 177Lu-radiolabeled MACs were prepared using relatively mild conditions. 
Incubation of the MACs with 177LuCl3 for 1 h at 90 °C gave relatively moderate to good 
radiochemical yields of 60 - 85 % (n = 3). Radiolabeled yields were found to be 
dependent, to some extent, on the HPMA copolymer concentration. A more thorough 
investigation of the parameters that influence the radiolabeling efficiency of MACs is on-
going. The ability of the synthesized 177Lu-MACs to undergo Cathepsin B and S 
cleavage was investigated over a 72 h period, Figure 2.4. During the course of the 
investigation, the non-cleavable control (177Lu-MAC0) was found to be stable in the 
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presence of Cathepsin B and S with negligible cleavage as determined by radio-SEC-
HPLC. However, 177Lu-MAC1 and 177Lu-MAC2 demonstrated significant cleavage as 
shown by the generation of the low-molecular weight radiometabolite after 72 h of 
incubation. The percentage of the generated radiometabolite was 8 and 26 % (n = 1) for 
177Lu-MAC1 and 177Lu-MAC2, respectively. The stability of the 177Lu-labeled-MACs in 
human serum was investigated by incubation at 37 °C for a 72 h period. Over the course 



















Figure 2.4: Cathepsin B and S cleavage of 177Lu-MAC0, 177Lu-MAC1 and 177Lu-MAC2 as 







2.3.5 Cathepsin Activity and MAC Uptake in Macrophage and HPAC Cell Lines  
In the investigation of the in vitro properties of the MACs, differentiated human 
macrophage and HPAC cancer cell lines were used as in vitro models of the MPS and 
pancreatic cancer. The cathepsin B and S activity in both of these cell lines were 
investigated by fluorometric analysis, depicted in Figure 2.5. In a cell to cell comparison, 
the differentiated macrophage demonstrated substantially higher activities of both 
cathepsin proteases relative to the HPAC cell line. The protease activity in the 
macrophage was 70 and 10 fold higher for cathepsin B and S, respectively, relative to 
















Figure 2.5: Evaluation of cathepsin B and S activity between macrophage and HPAC cell 
















The cellular uptake of the MACs in differentiated macrophage and the HPAC cell line 
was investigated. Utilizing flow cytometry analysis, the relative uptake of the MACs in 
terms of mean fluorescence units is depicted in Figure 2.6. Over the 48 h incubation time, 
all of the MACs investigated demonstrated steady increase in macrophage uptake. In 
comparison, the HPAC cell line revealed little uptake of the MACs over the time period 



















Figure 2.6: Mean fluorescence of MAC0, MAC1 and MAC2 after 0 h, 24 h and 48 h 















2.3.6 Biodistribution Studies of 177Lu labeled MACs in HPAC Xenograft SCID Mice 
A preliminary investigation of the in vivo tumor targeting and clearance properties of 
the MACs was performed in a SCID mouse model bearing HPAC tumor xenografts. The 
results of the biodistribution studies of the three 177Lu-MACs at 24 and 72 h post-
injection are given in Table 2.2. At 24 h post-injection, the blood retention of the 177Lu-
MAC1 and 177Lu-MAC2 was, on average, lower than the control (177Lu-MAC0).  All of 
177Lu-MACs demonstrated a 2 fold decrease in blood retention by the 72 h p.i. time point. 
At 24 h post-injection, the liver accumulation of the 177Lu-MAC1 and 177Lu-MAC2 was 
3.44 ± 0.82 and 5.29 ± 0.98 %ID/g, correspondingly, which was lower than the 7.27 ± 
2.64 %ID/g of 177Lu-MAC0 (p = 0.34). The liver retention of the 177Lu-MAC0 increased to 
a final accumulation of 11.36 ± 1.65 %ID/g at 72 h post-injection. Conversely, the liver 
retention of the MACs that utilize cleavable peptides, 177Lu-MAC1 and 177Lu-MAC2, 
remain statistically the same with 3.61 ± 0.63 and 5.46 ± 0.44 %ID/g, respectively, at the 
72 h time-point. At the 24 h time-point, the spleen retention of 177Lu-MAC1 and 177Lu-
MAC2 were lower on average than the 177Lu-MAC0. However, by the 72 h time-point, the 
177Lu-MAC0 demonstrated a substantial increase in spleen retention of 21.46 ± 
4.41 %ID/g. In comparison, 177Lu-MAC1 and 177Lu-MAC2 exhibited a significantly lower 
retention of 5.63 ± 1.22 (p = 0.06) and 5.67 ± 0.75 %ID/g (p = 0.03), respectively, which 
corresponds to a substantial 4 fold reduction in spleen accumulation at the analogous 
time point. With regards to tumor retention, the control exhibited higher accumulation at 
all time-points investigated. At the 24h time point, the tumor uptake of 1.18 ± 0.25 and 
1.64 ± 0.18 %ID/g 177Lu-MAC1 and 177Lu-MAC2 was substantially lower than the 4.09 ± 
1.41 %ID/g of the 177Lu-MAC0 (p = 0.16). By 72 h post-injection, the 177Lu-MAC0 tumor 
accumulation increased by 61% to 6.58 ± 0.93. For 177Lu-MAC1 and 177Lu-MAC2, the 
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tumor retention increased to 2.33 ± 0.30 and 3.49 ± 0.28 %ID/g, representing an 






















Table 2.2: Biodistribution studies of 177Lu-MAC0, 177Lu-MAC1 and 177Lu-MAC2 at 24 and 
72 h post-injection in HPAC tumor-bearing SCID mice. Data is represented as %ID/g.    
 














Blood 28.50 ± 6.59 14.85 ± 1.23 17.76 ± 1.57 13.40 ± 1.71 8.54 ± 1.76 8.89 ± 0.65 
Bladder 9.09 ± 3.49 1.63 ± 0.94 3.11 ± 0.82 7.15 ± 2.61 2.18 ± 0.25 3.61 ± 0.34 
Small Int. 1.36 ± 0.42 0.85 ± 0.15 0.97 ± 0.12 1.25 ± 0.21 0.51 ± 0.09 0.67 ± 0.06 
Large Int. 1.48 ± 0.38 0.84 ± 0.09 1.31 ± 0.17 1.25 ± 0.21 0.54 ± 0.09 1.06 ± 0.15 
Stomach 1.02 ± 0.21 0.63 ± 0.07 0.80 ± 0.10 0.91 ± 0.14 0.37 ± 0.07 0.52 ± 0.04 
Pancreas 2.16 ± 0.66 0.93 ± 0.22 1.35 ± 0.25 2.95 ± 0.55 1.10 ± 0.20 1.10 ± 0.13 
Spleen 7.83 ± 3.32 5.09 ± 1.24 4.95 ± 0.49 21.46 ± 4.41 5.63 ± 1.22 5.67 ± 0.75 
Kidney 5.22 ± 1.57 2.50 ± 0.59 3.34 ± 0.44 4.20 ± 0.58 1.93 ± 0.38 2.51 ± 0.17 
Tumor 4.09 ± 1.41 1.18 ± 0.25 1.64 ± 0.18 6.58 ± 0.93 2.33 ± 0.30 3.49 ± 0.28 
Liver 7.27 ± 2.64 3.44 ± 0.82 5.29 ± 0.98 11.36 ± 1.65 3.61 ± 0.63 5.46 ± 0.44 
Lung 8.18 ± 2.60 3.81 ± 0.76 4.16 ± 0.37 5.56 ± 1.01 2.66 ± 0.46 3.56 ± 0.16 
Heart 6.13 ± 1.75 2.37 ± 0.50 2.72 ± 0.30 5.00 ± 0.75 1.85 ± 0.38 2.26 ± 0.22 
Brain 0.91 ± 0.23 0.30 ± 0.10 0.36 ± 0.04 0.57 ± 0.00 0.24 ± 0.05 0.27 ± 0.02 
Bone 1.71 ± 0.51 0.85 ± 0.09 1.20 ± 0.16 3.06 ± 0.46 0.68 ± 0.12 1.02 ± 0.11 
Muscle 1.36 ± 0.42 0.71 ± 0.13 0.75 ± 0.08 2.38 ± 0.55 1.37 ± 0.39 1.46 ± 0.15 
       














For cancer diagnostics and therapeutics based on biopolymers such as HPMA 
copolymers, it is well known that increases in the molecular weight of the carrier typically 
results in an improvement in the enhanced permeability and retention (EPR) effect [103, 
123, 124]. As a result of the increase in the EPR effect of the carrier, the drug delivery 
system will typically demonstrate an increased localization and retention in cancerous 
tissues. Conversely, an increase in the molecular weight of a biopolymer by and large 
causes a substantial increase in the MPS accumulation, particularly if the molecular 
weight of the carrier is above the renal excretion threshold. The MPS accumulation of 
HPMA copolymers, and other nanomedicine platforms, is a major hurdle in the 
development of more efficacious biopolymer systems and the translation of these 
systems to the clinic [125, 126].  
 
Our approach to this challenge is to develop MALs that preferentially hydrolyze in 
MPS cells in order to reduce the retention, and thus radiotoxicity, in non-target tissues. 
In our design peptide substrates of cathepsin B and S were chosen due to the high level 
of expression of these proteases in MPS tissues. As depicted in Figure 3, the MAL 
design is composed of three components: radiometal chelation system, metabolic 
sequence and clearance sequence. The DO3A chelation system was chosen because it 
has been shown to stabilize a variety of radiometals, including 177Lu, in preclinical and 
clinical investigations [127, 128].  The metabolic sequences are composed of known 
peptide substrates for the cathepsin B and S enzymes [121, 122].  It is expected that 
alterations of the metabolic sequence can be used to influence the rate of enzymatic 
cleavage and thus affect clearance of the radiometabolites from the tissues. While the 
chosen amino acid sequences have demonstrated selectivity for the corresponding 
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protease relative to other lysosomal proteases, it is important to keep in mind that other 
proteases may contribute to the metabolism of these sequences in vivo. In order to 
better control the pharmacokinetics of the radiometabolite after cleavage, D-amino acids 
were employed in the design of the clearance sequence, G-D(S)-D(S), to prevent, or at 
least significantly reduce, metabolism. By preventing metabolism the pharmacokinetic 
properties of the generated radiometabolite can be better controlled to influence diffusion 
and thus biological clearance [129].      
 
The MALs were prepared with intact orthogonal protecting groups using standard 
SPPS techniques. Synthesis of the protected MALs was necessary for later 
chemoselective conjugation to the HPMA copolymers. Both MAL1 and MAL2, protecting 
groups intact, underwent incubation in the presence of the appropriate cathepsin 
protease. Over the course of the metabolism study, both of the MALs demonstrated 
conversion into a single metabolite. Both of these cleavage sites are in accordance with 
previous literature reports [121, 130]. From these initial investigations, the enzyme 
kinetics for cathepsin B for MAL1 appears to be significantly faster as compared to 
cathepsin S for MAL2.   
 
Synthesis of the HPMA copolymer backbone was accomplished using the RAFT 
polymerization technique. The synthesized HPMA copolymer (Mw = 343 kDa, PDI = 1.6) 
is well above the renal threshold of 45 kDa. Conjugation of the MALs to the terminal 
amine of the APMA copolymer constituent was accomplished in fairly high yield as 
determine by ninhydrin assay. In order to ensure chemo-selectivity, MALs were prepared 
with intact orthogonal protection groups. The protecting groups prevented functional 
groups other than the desired C-terminal carboxylic acid from conjugating to the primary 
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amine on the HPMA copolymer. Deprotection of the MACs was accomplished, as 
confirmed by NMR, in 3 hours using a standard SPPS cleavage cocktail. Radiolabeling 
of the MACs with 177Lu was achieved in good yield using standard radiolabeling 
conditions. Incubation of 177Lu-MAC1 and 177Lu-MAC2 in the presence of Cathepsin B 
and S, respectively, demonstrated, as expected, that a low-molecular weight 
radiometabolite is generated. Exposure of 177Lu-MAC0 (non-cleavable control) to either 
of the investigated cathepsin did not show any signs of radiometabolite generation. This 
data shows that the generation of the radiometabolite is a proteolytic process. In 
additional, this data confirms that the MAL can still be cleaved despite being attached to 
the HPMA copolymer support. Serum stability studies of the 177Lu-MACs revealed 
essentially no degradation (> 98% intact) suggesting that the 177Lu-MACs would not 
susceptible to extracellular blood proteases in vivo.  
 
In our investigations of the in vitro properties of the MACs, we modeled the 
phagocytic cells of the MPS and pancreatic cancer cells utilizing differentiated human 
macrophage and the HPAC pancreatic cancer cell line, correspondingly. Evaluation of 
the cathepsin B and S activity of these cell lines revealed that both cathepsin B and S 
activity is substantially higher, 70 and 10 fold respectively, in the macrophages relative 
to the HPAC cell line. Additionally, analysis of the internalization rate of the MACs in 
these two cell lines demonstrated that macrophages undergo steady uptake of the 
MACs over the course of the study, while relatively little uptake was exhibited by the 
HPAC cancer cell line. These data imply that the in vivo uptake and metabolism of the 
MACs should be strongly favored in MPS cells relative to the pancreatic cancer cells. 
Given this, we would expect enhanced clearance from tissues containing MPS 
components (i.e., liver and spleen) in vivo.        
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Our initial investigation into the in vivo characteristics of the 177Lu-MACs was 
undertaken in an HPAC xenograft mouse model. All of the 177Lu-MACs investigated 
demonstrated extended blood circulation due to the molecular weight of the HPMA 
copolymer being substantially higher than the renal excretion threshold [131]. 
Interestingly, the blood retention of 177Lu-MAC1 and 177Lu-MAC2 demonstrate similar 
longevity in the blood pool and is approximately half of the value of the 177Lu-MAC0 at all 
reported time points. The reduced blood retention of the 177Lu-MAC1 and 177Lu-MAC2 
relative to the control (177Lu-MAC0) strongly suggest that the HPMA copolymers with 
MALs underwent proteolytic cleavage in the blood. However, the in vitro serum stability 
studies of the 177Lu-MAC1 and 177Lu-MAC2 revealed no significant proteolysis. These 
data imply that the cleavage of the 177Lu-MAC1 and 177Lu-MAC2 is likely due to the 
uptake and metabolism by cellular blood components. While long-term blood circulation 
of the 177Lu-MACs leads to better tumor targeting, the substantial blood retention of the 
177Lu-MACs is detrimental to practical application of these agents for diagnostic and 
radiotherapeutic approaches. Utilizing these initial results, our future designs of the 
177Lu-MACs will seek to provide faster blood clearance to better balance the 
circulation/tumor targeting time and the clearance rates needed for clinical applications.    
 
The significant blood retention of the 177Lu-MACs overall led to high baseline 
radioactivity values observed in all analyzed tissues. When evaluating the biodistribution 
data, it is important to keep in mind the contribution to the tissue radioactivity given by 
blood residing in the tissue. It is undoubtedly true that the high blood activity of the 177Lu-
MACs is contributing, to some extent, to the various tissues values, particularly those 
tissues that normally contain large blood volumes (e.g., liver and kidney). However, as 
we move from the 24 to the 72 h time-point we observe substantial decreases (~2 fold) 
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in blood retention and, at the same time, a significant increase in both liver, spleen and 
tumor retention. The increase in the liver, spleen and tumor retention, while during the 
same period blood activity reduces, leads us to the conclusion that increases observed 
in the biodistribution time-points is mostly attributable to the tissue uptake and not 
background blood activities. 
 
The MPS uptake of nanomedicine platforms is typified by significant accumulation of 
the delivery system in the liver and spleen. The liver accumulation of the 177Lu-MAC0 
demonstrated an increase from 7.27 ± 2.64 to 11.36 ± 1.65 %ID/g over the time course 
of the experiment. In comparison 177Lu-MAC1 and 177Lu-MAC2 demonstrated lower 
average accumulation in the liver at every time-point investigated. 177Lu-MAC1 and 
177Lu-MAC1 demonstrated a 24 h post-injection liver retention of 3.44 ± 0.82 and 5.29 ± 
0.98 %ID/g, but demonstrated nearly identical values at 72 h post-injection. At 72 h post-
injection, 177Lu-MAC1 and 177Lu-MAC1 gave liver retention values that were 3.1 and 2.1 
times lower than the control (p=0.024,both). With regard to spleen retention, the average 
spleen retention of 177Lu-MAC0 increased from 7.61 ± 1.37 to 21.46 ± 4.41 %ID/g over 
the time-points investigated. For the 177Lu-MAC1 and 177Lu-MAC2, the HPMA 
copolymers demonstrated substantially lower spleen accumulation compared to control. 
This was particularly evident at the 72 h time-point with spleen values 3.8 and 3.7 times 
lower (5.63 ± 1.22 and 5.67 ± 0.75 %ID/g) for 177Lu-MAC1 (p = 0.03) and 177Lu-MAC2 (p 
= 0.06), respectively. The substantial reduction in liver and spleen retention observed in 
these studies show that the MAL design is capable of enhancing clearance from the 




HPAC tumor accumulation of the 177Lu-MACs was achieved through passive 
targeting due to the EPR effect. Relative to 177Lu-MAC1 and 177Lu-MAC2, 177Lu-MAC0 
demonstrated superior tumor retention at all of the time points studied, with the highest 
value being 6.58 ± 0.93 %ID/g at 72 h p.i. At 72 h post-injection, 177Lu-MAC1 and 177Lu-
MAC2 gave tumor activities of 2.33 ± 0.30%ID/g (p =0.024) and 3.49 ± 0.28 %ID/g (p 
=0.06), correspondingly, which were significantly lower than control. It is not clear why 
the tumor retention of the values of 177Lu-MAC1 and 177Lu-MAC2 are substantially lower 
than those of 177Lu-MAC0. Possibly, the reduced blood retention of the 177Lu-MAC1 and 
177Lu-MAC2 or potential metabolism and clearance in the HPAC tumor could contribute 
to lower overall tumor retention. Unfortunately, the current biodistribution study does not 
unambiguously demonstrate the in vivo specificity and mechanism of the MACs. Future 
studies looking into the in vitro and in vivo metabolism of the 177Lu-MACs are planned 
and will hopefully shed more light with regard to the in vivo tumor-targeting and retention 
properties of these agents.  
 
2.5 CONCLUSION 
In utilizing the MAL design, we seek to take advantage of the relative differences in 
cathepsin B and S expression as well as the lymphatic and vasculature structure of 
pancreatic cancer and non-target tissues leading to a decrease in non-target retention of 
various nanomedicine systems. Herein, we have reported the synthesis and purification 
of two MALs that are known substrates of cathepsin B and S. These MALs were shown 
to be metabolized by cathepsin B and S into single metabolites. The MALs were 
conjugated to the HPMA copolymer and radiolabeled with 177Lu. The synthesized 177Lu-
MAC1 and 177Lu-MAC2 demonstrated a substantial decrease in long-term liver and 
spleen retention relative to the control (177Lu-MAC0). However, compared to the control, 
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the MALs in 177Lu-MAC1 and 177Lu-MAC2 exhibited higher clearance from HPAC tumors. 
Our future work will focus on the optimization of the circulation time to achieve faster 
blood clearance of the MAC design to better suit clinical application. Additionally, further 
studies into the in vitro and in vivo behavior of the 177Lu-MACs are planned to elucidate 
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-
related deaths in the United States with a 5-year survival rate of only 6% and a median 
survival of approximately 6 months [132]. The poor prognosis for pancreatic cancer 
patients is mainly due to the asymptomatic nature of the early disease state with 
symptoms typically presenting only in advanced stages, where effective treatment 
options are severely limited [133, 134]. For the small portion of the pancreatic cancer 
population (< 10%) diagnosed with localized disease, surgical resection has been shown 
to be an effective treatment and is the current standard of care. Pre-operative staging is 
crucial in determining whether a patient is a viable candidate for surgical resection [24]. 
Inaccurate identification of patients with un-resectable tumors leads to unnecessary 
surgeries that can result in significant increases in patient morbidity and mortality [24]. 
To date, accurate staging of pancreatic cancer represents a major challenge in patient 
treatment.  
 
Several noninvasive imaging techniques are currently used for the diagnosis and 
staging of pancreatic cancer. These modalities include contrast-enhanced computed 
tomography (CT), abdominal ultrasound (US), magnetic resonance imaging (MRI) and 
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MR cholangiopancreatography (MRCP) [24]. While these techniques have superb 
anatomical resolution, these imaging modalities do not have the sensitivity and 
specificity associated with nuclear imaging instrumentation, namely Single Photon 
Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) 
[135, 136]. Recently, the fusion of nuclear imaging with the CT modality has resulted in 
hybrid imaging systems, SPECT/CT and PET/CT, which have been demonstrated to 
more accurately detect and stage a variety of cancers [136]. Unfortunately, the potential 
of these hybrid imaging systems for improving pancreatic cancer staging has not been 
fully realized due to the lack of an effective radiotracer to target the disease [24].        
 
The development of polymer-based diagnostics and therapeutics for human disease 
has been an area of intense research and has yielded several drugs that have 
progressed to the clinic [137]. N-(2-hydroxypropyl)-methacrylamide (HPMA) copolymer 
is a polymeric platform that has been extensively investigated for a variety of biomedical 
applications including the development of SPECT and PET tracers [64, 70, 77, 90, 91, 
138-143]. HPMA copolymers are capable of targeting solid tumors either passively, 
through the enhanced permeability and retention (EPR) effect, and/or actively by 
inclusion of targeting vectors into the polymeric construct [40, 70, 77, 144]. However, 
one major challenge for the development of diagnostic and/or therapeutic HPMA based 
drugs, as well as other polymer and nanomedicine systems, is opsonization and 
sequestration by the mononuclear phagocyte system (MPS) [126, 145]. In many cases, 
the sequestration of these polymeric drugs leads to substantial accumulation in the liver 
and spleen. From a diagnostic perspective, this MPS accumulation in non-target organs 
can hinder identification of resident or nearby metastatic lesions thereby decreasing the 
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diagnostic effectiveness. For therapeutic applications, the non-target accumulation of 
these polymeric drugs can lead to significant toxicities which may be dose-limiting.   
  
Our laboratory is interested in developing synthetic approaches in which HPMA 
copolymers can be modified to significantly reduce the MPS accumulation thereby 
enhancing the diagnostic and/or radiotherapeutic efficacy of the agent. Recently, we 
have described the development of cathepsin S susceptible linkers (CSLs) [146], which 
degrade in the presence of cathepsin S, a lysosomal protease that is selectively and 
highly expressed in MPS tissues [117, 147, 148]. From our initial investigation, we found 
that CSLs significantly reduced long-term retention of 177Lu-labeled HPMA copolymers in 
tissues associated with the MPS (i.e., liver and spleen). However, the high molecular 
weight HPMA copolymer (343 kDa) utilized in the study gave blood circulation times that 
were not ideal for diagnostic or therapeutic use. Herein, we report our continued 
investigation of the CSL design by evaluating the structure-activity impact of linking 
groups of varying size on the in vitro and in vivo efficacy of HPMA copolymer based 
radiopharmaceuticals. In conjunction with these studies, we utilize a lower molecular 
weight HPMA (109 kDa) copolymer with a blood circulation time that is more suitable for 
diagnostic and/or radiotherapeutic applications.   
 
3.2 MATERIALS AND METHODS 
3.2.1 Synthesis and Characterization of the HPMA Copolymer 
The HPMA copolymerization was accomplished using the reversible addition-
fragmentation chain transfer (RAFT) polymerization reaction with V-501 as the initiator 
and CTP as the chain transfer agent. The feed ratio of the polymerization consisted of 
98.75:0.85:0.40 mole% HPMA, APMA and APMA-FITC, respectively. Polymerization 
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was run at a 1 M total monomer concentration in 1 M acetate buffer (pH = 5.2) with a 
molar ratio of total monomer: chain transfer agent: initiator of 1200:3:1. Prior to 
proceeding with the polymerization reaction, the glass ampoule and contents were 
purged with argon for 20 min. Subsequently, the ampoule was flame sealed and allowed 
to heat at 70 ºC in an oil bath for 14 h. After cooling the HPMA copolymer was 
evaporated to dryness, dissolved in methanol and purified by size exclusion 
chromatography using an LH-20 packing material with methanol as the eluent. The 
conversion rate was 42.3 % as determined by mass measurement after purification. The 
weight average molecular weight and polydispersity of the copolymers were determined 
by FPLC equipped with UV and RI detectors.  The average molecular weights of the 
copolymers were estimated using HPMA copolymer standards with narrow 
polydispersity indices. Quantification of the primary amine content of the HPMA 
copolymer was assessed using a ninhydrin assay [146].  
 
3.2.2 Solid Phase Peptide Synthesis 
For the synthesis of the CSLs with linking groups (CSL2 and CSL3), the resin was 
manually pre-loaded.  Briefly, to a fritted reaction vessel, 2-ClTrl-Cl resin (3 g, 3.60 
mmol), 1 equiv of the linker group (Fmoc-5-Ava-OH or Fmoc-NH-(PEG)2-COOH) and 4 
equiv of DIEA in dry DMF (30 mL) was added. The reaction mixture was stirred for 2 h, 
filtered and washed sequentially with: (1) 3 X 100 mL of a solution consisting 
DCM/MeOH/DIEA (17:2:1); (2) 3 X 100 mL of DCM (3) 2 X 100 mL of DMF and (4) 2 X 
100 mL of DCM. The resin was dried in vacuum over KOH. For estimating residue 
loading, the Fmoc group from a small sample of the resin was cleaved with 2% DBU in 
DMF and the concentration of liberated dibenzofulvene was measured by UV 
spectroscopy (304 nm). Using known standards of Fmoc-Gly-OH as a reference, the 
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residue loading was estimated from the equation: mmole/g = (Abssample-Absref) *16.4/mg 
of resin [149]. Estimation of the level of residue attachment indicated substitution of 0.60 
and 0.65 mmol/g for the Fmoc-5-Ava-trityl and Fmoc-NH-(PEG)2-trityl resin, respectively.  
 
The CSLs were synthesized using automated solid phase peptide synthesis. Briefly, 
the resin (containing 0.25 mmole of peptide anchors) was deprotected using piperidine 
resulting in the formation of the primary amine. The carboxylic acids of the Fmoc 
protected amino acids (1 mmol) were activated using COMU and conjugated to the 
primary amines of the growing peptide on the resin. The process of deprotection, 
activation and conjugation was repeated until the desired peptide was synthesized. The 
selective cleavage of the peptide from the 2-chlorotrityl resin anchor was achieved 
by reaction with 1% TFA in dry DCM and subsequent filtration. The combined crude 
filtrates were dried by a rotary concentrator.  Purification of the peptides was performed 
using a semi-preparative Proteo C12 column with a flow rate of 5.0 mL/min. HPLC 
solvents consisted of H2O containing 0.1% formic acid (solvent A) and acetonitrile 
containing 0.1% formic acid (solvent B). For all peptides, the initial gradient of 70% A: 30% 
B linearly decreased to 60% A: 40% B over a 15 min time period. At the end of the run 
time for all HPLC experiments, the column was flushed with the gradient 5% A: 95% B 
and re-equilibrated to the starting gradient. The yields after purification were 0.1326 g 
(37.5%) for CSL1; 0.166 g (44%) for CSL2 and 0.109 g (27.1%) for CSL3.  The peptides 
were confirmed to be ≥ 95% purity as characterized by LC/MS before in vitro/ in vivo use. 
 
3.2.3 Synthesis of Cathepsin S Cleavable Copolymers (CSCs) 
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The CSCs were prepared by condensation of the HPMA copolymer and the CSLs as 
previously described. Briefly, in a 10 mL round bottom flask, 16.5 (28.9 μmol, 5.0 equiv), 
16.5 (11.6 μmol, 2.0 equiv), 17.4 (11.6 μmol, 2.0 equiv) or 18.6 mg (11.6 μmol, 2.0 equiv) 
of CSL0, CSL1, CSL2 or CSL3 was dissolved in 600 μL of DMF. The solution was 
cooled to 0 °C and 2.4 equivalents of NHS and DCC, relative to the CSL, were added to 
the flask. The solution was stirred at 0 °C for 3 h. At the end of that time, the HPMA 
copolymer was added and stirred for another 2 h at 0 °C. Subsequently, the reaction 
was allowed to warm to room temperature and continued overnight. The precipitate 
generated from the reaction was filtered off and the filtrate was evaporated to dryness. 
The residue was dissolved in methanol, isolated by size exclusion chromatography using 
an LH-20 packing material and evaporated to dryness. The attached protected peptides 
of the resulting CSCs were deprotected using standard peptide cleavage conditions. In 
the case of CSC0, the copolymer was added to 4 mL of a cleavage cocktail consisting of 
a 1:1:1:37 volumetric ratio of DODT, water, TIS and TFA. This solution was kept at 0 °C 
and stirred for 2 h. For CSC1-3, the cleavage cocktail contained a 1:1:1:0.75:46.25 
volumetric ratio of DODT, water, TIS, thioanisole, and TFA.  After deprotection, the 
mixture was evaporated to dryness and the polymers were finally purified by size 
exclusion chromatography using an LH-20 packing material and methanol as the eluent. 
The conjugation yield for CSC0 was determined by the ninhydrin assay. For CSC1-3, the 
conjugation yield was determined using amino acid analysis conducted by the UNMC 
Protein Structure Core Facility.  
 
3.2.4 Radiolabeling of the CSCs 
The radiolabeling of the CSCs was accomplished by heating 200 μg of the CSC at 
90 C for 1 h in the presence of 37 MBq (~1mCi) of 177LuCl3. After cooling, the resulting 
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177Lu-radiolabeled CSC was purified by radio-SEC-HPLC. Purification of the 177Lu-CSCs 
was accomplished using a Biosep-SEC-S2000 column with an isocratic mobile phase 
consisting of PBS with 0.02 M EDTA at pH 7.2. The linear flow rate was 0.80 mL/min. 
UV analysis was performed at a wavelength of 494 nm. After collection of the peak-
purified 177Lu-CSC, approximately 10 mg of L-ascorbic acid was added to inhibit 
radiolysis. The purified 177Lu-CSC was concentrated using an Amicon Ultra-4 centrifugal 
filter (10 kDa) and washed with 2 X 4 mL of deionized water. The radiochemical purity of 
all radio-conjugates was re-evaluated prior to in vitro/ in vivo use and found to be ≥ 95 % 
pure as determined by the radio-HPLC. 
 
3.2.5 Cathepsin Cleavage Assay of Radiolabeled Copolymers 
Human cathepsin S (20 ng/µL) in 100 µL of buffer solution (50 mM sodium acetate, 1 
mM EDTA and 10 mM DTT, pH 6.0) was incubated with 100 μg of each purified 177Lu-
CSC0-3 at 25 ºC. After 12 h, a 50 µL aliquot of each copolymer solution was analyzed 
by radio-SEC-HPLC to determine the relative amount of cathepsin S cleavage product. 
The analysis utilized an isocratic gradient at a linear flow rate of 0.80 mL/min with a 
mobile phase consisting of PBS with 0.02 M EDTA at pH 7.2. The UV analysis of the 
HPLC eluent was carried out at a wavelength of 494 nm. 
 
3.2.6 Human Serum Stability of Radiolabeled Copolymers 
Briefly, 10 μg of purified 177Lu-CSC was incubated with 1 mL of human AB serum at 
37 C. After 144 h, the stability was determined by centrifuge filtration using an Amicon 
Ultra-4 10 kDa filter. A 100µL aliquot was loaded in the filter and diluted to 4 mL using DI 
water.  The loaded sample was centrifuged and washed with 4 mL of DI water. The 
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percent of intact 177Lu-CSC was calculated by dividing the remaining radioactivity in the 
10 kDa filter to the total radioactivity added.  
 
3.2.7 Cell Culture 
The HPAC cells were cultured in our laboratory, as per ATCC protocols, in 
DMEM/Ham's F12 medium containing 5% FBS, 1.562 nM EGF, 14.3 mM sodium 
bicarbonate, 2.5 mM L-glutamine, 15 mM HEPES and 0.5 mM sodium pyruvate 
supplemented with 0.350 µM insulin, 0.0625 µM transferrin and 0.110 µM hydrocortisone. 
Cells were incubated at 37 °C with 5% CO2 in air. 
 
Human monocytes were provided by the UNMC Elutriation Core Facility. Monocytes 
were plated into T75 tissue culture flasks at a concentration of 20 x106 cells in 20 mL of 
macrophage differentiation medium: DMEM containing 10% FBS, 1% NEAA, 500 U rhM-
CSF, 1% Penicillin/Streptomycin, 2 mM l-glutamine and 1% sodium-pyruvate. Media was 
half-exchanged every 2 to 3 days for 7-10 days, at which time, visual confirmation of 
differentiation led to media replacement with the macrophage maintenance medium 
(differentiation media without the rhM-CSF). Cells were maintained in a 37 C humidified 
atmosphere with 5% CO2. 
 
3.2.8 Confocal Microscopy 
Macrophage cells and HPAC cells were seeded onto 4-well chambered coverglass 
units with 1 × 104 and 5 × 104 cells, respectively. FITC-labeled polymer conjugates were 
diluted in blank media to 100 μg/mL concentration. The cells were then incubated with 
the polymer for 24 h in a 37 C humidified atmosphere with 5% CO2. Half an hour before 
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the end of this incubation, LysoTracker Red DND-99 and Hoechst 33342 were added in the 
media to stain the lysosomal compartment and the nuclei. Following incubation, the media 
was aspirated, and the cells were washed with PBS to remove free polymers that were 
not internalized prior to confocal imaging.  
 
3.2.9 Immunoblot Analysis 
Whole cell HPAC and differentiated macrophage lysate as well as mice HPAC tumor 
homogenate were prepared using RIPA buffer and a cocktail of proteases inhibitors. The 
lysates and homogenate were centrifuged at 13,000 RPM at 4 ºC for 20 min. The 
supernatants containing 50 μg total proteins were mixed with sample buffer and then 
separated by 10% SDS-PAGE, followed by transfer to PVDF membrane. After blocking 
in 5% nonfat milk, 0.1% Tween-20, and Tris-buffered saline at room temperature for 1 h, 
membranes were probed with primary antibodies in blocking solution for 1 h at room 
temperature, followed by extensive washing in TBS.  Rabbit anti-goat and goat anti-
mouse secondary antibodies were used for the detection of immunoreactive proteins by 
chemiluminescence. 
 
3.2.10 Biodistribution Studies 
Biodistribution studies were carried out using age-matched normal CF-1 and HPAC 
tumor bearing SCID mice. For biodistribution studies involving HPAC xenograft mice, the 
mice were inoculated in each flank with 100 μL of a 1:1 ratio of suspended HPAC cells 
and Matrigel™ to obtain a final concentration of 5 x 106 HPAC cells per 100 μL. Upon 
achieving sufficient tumor size, (10-15 mm in diameter) the mice were considered viable 
for biodistribution studies. The CF-1 mice and HPAC xenograft mice were injected with a 
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0.37 MBq (10 μCi) intravenous bolus of the purified 177Lu-CSCs. The mice were 
sacrificed and their tissues excised at 4, 24, 72 and 144 h time points post-injection (p.i.). 
The blood and excised tissues were weighed, the 177Lu radioactivity measured using a 
gamma counter, and the percentage injected dose (%ID) and the percentage injected 
dose per gram (%ID/g) calculated for each tissue.  
 
3.2.11 SPECT/CT Imaging Studies 
Xenograft mice were intravenously injected with 400~600 μCi of CSCs in 100 μL 
saline and then anesthetized with 5% isoflurane delivered in 0.5 mL/min oxygen.  Image 
acquisition with a 5-pinhole (1.0 mm/pinhole) collimator was acquired at 4, 24, 72 and 
144 h time-points p.i. Five hundred and twelve CT projections for each image were 
acquired and reconstructed using Triumph X-O 4.1 at a matrix size of 512×512×512 with 
a 0.15-mm voxel dimension. Sixty four SPECT projections for each image were acquired 
using a Triumph SPECT with a 20% window at 208 keV for 177Lu and reconstructed 
using Triumph SPECT Reconstruction Application 1.0.8.0 at a matrix size of 64×64×64 
with a 1.14 mm voxel dimension.  Co-registration of anatomical CT images and 
functional SPECT was performed using 3D image visualization and analysis software 
VIVID based on Amira 4.1. A median filter was applied to all SPECT images.  
 
3.2.12 Statistics 
Statistical analyses were done using a two-tailed unpaired Student's t-test (2 groups) 
or one way ANOVA (> 2 groups) with Bonferroni post-tests, a p < 0.05 indicating 




3.3 RESULTS AND DISCUSSION 
3.3.1 Design and Synthesis of Cathepsin S Cleavable Linkers (CSLs) 
Herein, we report the evaluation of a series of CSLs incorporated into a 177Lu-labeled 
HMPA copolymer construct. The objective of our approach is to utilize the CSLs to 
enhance the diagnostic/therapeutic potential of HPMA copolymer based drugs by 
improving the clearance properties of these agents from MPS associated tissues, in 
particular the liver and spleen. The CSLs, depicted in Figure 3.1, are composed of four 
components: 1) the DOTA moiety that is responsible for chelation of the diagnostic/ 
therapeutic radiometal; 2) the P-M-G-L-P substrate (Y) which cleaves in the presence of 
cathepsin S [146, 150]; 3) a clearance sequence (X), in this case G-(D)S-D(S), that can 
be modified to influence the clearance rate of the resulting radiometabolite; and finally 4) 
the linker group (Z) that is used to optimize the distance of the cathepsin S substrate 
from the polymer backbone. The distance of the cathepsin S substrate from the HPMA 
copolymer backbone is expected to be a factor, due to steric inhibition, that influences 
the cleavage rate of the cathepsin S substrate. In this study we investigate the impact of 
linking groups of various lengths (0, 6 and 13 atoms) on the in vitro cleavage rate and in 






























As shown in Figure 3.1, we chose to investigate CSL1-3 containing a null, a six atom 
hydrocarbon (5-Ava) and a 13 atom polyethylene glycol (PEG) linking group, 
respectively. In the case of CSL3, a PEG linker was chosen in place of a 13 atom 
hydrocarbon chain in order to reduce the potential for hydrophobic, intramolecular 
associations that would have likely limited separation of the cathepsin S substrate and 
the HPMA copolymer backbone [151, 152]. The control for our study, CSL0, is simply 
the DOTA chelation system absent of any peptide components. The CSL1-3 were 
synthesized with intact orthogonal protection using automated solid-phase peptide 
synthesis. The synthesis of the CSLs with orthogonal protection results in the generation 
of a single carboxylic acid functionality at the C-terminus which will later be used for 
conjugation to the HPMA copolymer. Purification of the crude synthetic peptides by 
HPLC gave yields of 37.5, 44.0 and 27.1 for CSL1-3, respectively. The HPLC and mass 
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3.3.2 Synthesis and Characterization of Cathepsin S Cleavable Copolymers (CSCs) 
The scheme for synthesis of the CSCs is depicted in Figure 3.2. The HPMA 
copolymer consisting of HPMA, APMA and APMA-FITC monomers were prepared by 
RAFT polymerization. The estimated molecular weight of the synthesized HPMA 
copolymer was 109 kDa with a polydispersity of 1.3 as determined by FPLC analysis. 
Ninhydrin assay revealed a total amine concentration of 57.2 µmol/g (n=1), which 
corresponds, based on the feed content, to 97% incorporation of the APMA monomer. 
On average, this yields approximately six APMA moieties per polymer backbone. 
Conjugation of CSLs to HPMA copolymers was accomplished using EDC/NHS 
amidation chemistry. The orthogonal protection of the CSLs allowed for the chemo-
selective conjugation of the C-terminal carboxylic acid to the APMA moiety on the HPMA 
copolymer. Conjugation of the DOTA chelation system to the HPMA copolymer (CSC0) 
gave a DOTA content of 31.3 µmol/g polymer (n=1), corresponding to a 54% conjugation 
yield, as evaluated by ninhydrin assay. Amino acid analysis of the conjugation of CSL1-3 
to the HPMA copolymer gave a peptide content of 15.0, 13.4 and 12.7 µmol/g polymer 
(n=3), which corresponds to 26.0, 23.4 and 22.2 % for CSC1-3, respectively. The 
orthogonal protecting groups were removed with a cleavage cocktail (92.5% TFA) to 
give the deprotected CSCs. Size exclusion chromatography was used to purify the 




Figure 3.2: Schemes for the synthesis of the 177Lu-CSC conjugates. For CSC0, CSC1, 
CSC2 and CSC3, X = Y = Z = null; X = GSS, Y = PMGLP; X = GSS, Y = PMGLP Z = 5-















3.3.3 Synthesis of 177Lu-labeled CSCs 
The 177Lu-labeled CSCs were prepared by heating 177LuCl3 in the presence of CSCs 
at 90°C for 1 h. The radiochemical yields for CSC0-4, as determined by radio-SEC-
HPLC, were on average (n=3) 77%, 90%, 43% and 81%, respectively. Correspondingly, 
the achievable specific activities were 142.45, 166.50, 79.55 and 149.85 MBq/mg. 
 
3.3.4 Serum Stability and Cleavage Studies of 177Lu-Labeled CSCs 
The stability of the 177Lu-CSCs in human serum was investigated over the course of 
144 h at 37°C. At the end of this incubation period, 98% of the 177Lu-CSCs remained 
intact thus suggesting that the 177Lu-CSCs would be stable to serum proteases in vivo 
while in circulation. It is important to note that this stability study does not reflect potential 
uptake and metabolism by cellular components of the blood (e.g., circulating monocytes), 
which likely impacts the stability of the 177Lu-CSCs in circulation. The in vitro 
susceptibility of the 177Lu-CSCs to cathepsin S cleavage was investigated by incubating 
the radiolabeled copolymers at 37°C for 12 h in the presence of cathepsin S. Analysis of 
aliquots of the reaction medium by radio-SEC-HPLC, Figure 3.3, revealed that 177Lu-
CSC1-3 underwent proteolytic cleavage when challenged with cathepsin S. The non-
cleavable control CSC0, not shown, was found to be stable in the presence of cathepsin 
S over 72 h. All of the intact 177Lu-CSCs demonstrated a retention time of approximately 
10.5 min on the SEC column. Upon cleavage, the generated radiometabolite resulted in 
a substantially higher retention time of 12.4 min, which corresponds to the expected 
reduction in molecular weight. We have previously demonstrated that the cleavage site 
for the CSLs are between the glycine and leucine residues (P-M-G┼L-P) of the substrate 
sequence [146]. Over the 12 h incubation period, the 177Lu-CSC1-3 demonstrated an 




















As stated previously, the proximity of the metabolic sequence to the HPMA 
copolymer backbone is expected to influence the cleavage rate of the CSCs. Our basis 
for the introduction of linking groups of various lengths (Z) into the CSLs was to 
investigate the structure-activity relationship, with respect to cathepsin S activity, of the 
CSLs when integrated into the HPMA copolymers. From the above data, some insight 
can be gleaned regarding the structure-activity relationship of the HPMA copolymer 
incorporated CSLs. The inclusion of the smaller linking group, 5-Ava, into the CSL 
(177Lu-CSC2) gave no statistically significant increase in cleavage relative to the null 
analog (177Lu-CSC1). In the case of 177Lu-CSC3, the introduction of the longer PEG 
linking group gave much higher rates of cathepsin S cleavage. These data suggest that 
the length of the linking group is capable of influencing the cathepsin S cleavage activity 
likely through a reduction of steric hindrance.  
 
3.3.5 Cathepsin S Expression in HPACs and Macrophages  
It is well known that the MPS is primarily responsible for the non-target accumulation 
of nanomedicine platforms, particularly in the liver and spleen [153]. The MPS is 
composed of phagocytic cells (e.g., macrophages and monocytes) that sequester drug 
delivery systems which typically results in loss of diagnostic/therapeutic effectiveness 
and potential toxicity. These phagocytic cells are also known as antigen presenting cells 
(APCs) due to their function in adaptive immunity where these cells process pathogenic 
material and present antigen fragments on the cellular surface. Cathepsin S is a 
predominantly lysosomal proteolytic enzyme that has been shown to be highly regulated, 
relative to other cathepsins (e.g., cathepsin B), and predominately expressed in APCs 
[154]. The substantial expression of cathepsin S in APCs is thought to be due to its 
unique role in the catabolism of pathogenic proteins [155-157]. Our design seeks to take 
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advantage of the cathepsin S expression/activity in APCs to preferentially enhance 
clearance from non-target tissues [134, 146].  
 
In this study, we utilize the HPAC human pancreatic cancer cell line as our in vitro 
and in vivo model of pancreatic cancer. Human monocytes have been differentiated to 
macrophages to serve as our model of tissue-resident macrophages. In order to 
determine cathepsin S expression, immunoblotting was performed on both cell types. As 
shown in Figure 3.4, cathepsin S is highly expressed in differentiated macrophages with 
negligible detectable expression in the HPAC cells. Overall, this corresponds well with 
our previous observations that the cathepsin S protease activity is much higher (tenfold) 
in differentiated macrophages versus the HPAC cell line [146]. Evaluation of the 
cathepsin S expression in HPAC tumor homogenates revealed increased levels of 
cathepsin S relative to cultured cells. This relative increase in expression may be a 
consequence of the dissimilarity of the in vivo tumor microenvironment versus the in vitro 
cultured milieu. However, it seems likely that the escalation in cathepsin S signal may, at 
least partially, be attributable to tumor-associated macrophages (TAM), which exist in 








Figure 3.4: Western Blot analysis of cathepsin S expressions in cultured HPACs 
(HPAC1), differentiated macrophages, and HPACs from corresponding in vivo tumor-




















The intracellular trafficking of FITC-labeled copolymers in both the differentiated 
macrophages and the HPAC cell line was investigated using confocal microscopy, 
Figure 3.5. In these studies, the CSC0 was utilized as our model HPMA copolymer. 
Lysotracker® Red and Hoechst fluorescent markers were used to delineate the lysosome 
and nucleus compartments, respectively. After 24 h incubation with CSC0, the 
differentiated macrophages (Figure 3.5A) demonstrated substantially higher levels of 
cellular accumulation relative to the HPAC cell line (Figure 3.5B). This is in accordance 
with our previously reported flow cytometric studies working with a higher molecular 
weight HPMA copolymer [146]. As can be seen in the overlay, the CSC0 accumulation in 
the macrophages is co-localized with the Lysotracker® Red marker.  The accumulation of 
HPMA copolymers in lysosomal compartments is in agreement with previous literature 
reports [159, 160]. By accumulating in the macrophage lysosomes, the CSCs are co-
localized with the highest sub-cellular concentrations of cathepsin S. The selective 
uptake of the CSCs in macrophages and the accumulation of the copolymer in the 
lysosomal compartments are expected to substantially and selectively increase the CSC 
cleavage kinetics in macrophages and other APC cell types. The proteolytic degradation 
of the CSCs will result in the formation of low molecular weight radiometabolites which 
are anticipated to clear more rapidly from the APC cells residing in non-target tissues 




Figure 3.5: After 24 h incubation, FITC-labeled HPMA copolymer showed intense 




























3.3.6 Biodistribution Studies of 177Lu-CSCs 
The biodistribution properties of the 177Lu-CSCs were investigated at 4, 24, 72 and 
144 h post-administration in both a normal CF-1 (Table 3.2) and HPAC xenograft mouse 
models. With exception of the blood clearance rate (elaborated on below), the 177Lu-
CSCs demonstrated similar biodistribution trends in both animal models. The data 
obtained from the biodistribution studies of the 177Lu-CSCs in a HPAC xenograft mouse 
model are given in Table 3.3. The calculated tumor-to-non-target ratios for selective 
tissues are given in Table 3.4. At the 4 h p.i. time point, the 177Lu-CSCs revealed 
excretion values that ranged from 23.82 ± 3.23 - 34.57 ± 2.41 %ID. Those HPMA 
copolymers with the cathepsin S cleavable linkers (177Lu-CSC1-3) demonstrated 
significantly higher levels of radioactivity excretion relative to the non-cleavable control 
(177Lu-CSC0) by the 24 h time point (p < 0.05). At the 144 h time point, 83.29 ± 1.24 - 
87.93 ± 1.49 %ID of the 177Lu-CSC1-3 had been eliminated from the body in comparison 
to only 55.65 ± 2.26 %ID of 177Lu-CSC0 (p < 0.0001). The overall elimination of 
radioactivity from the mouse corresponded well to the blood retention profiles of the 
177Lu-CSCs. At 4 h p.i., all four 177Lu-CSCs demonstrated blood retention profiles that 
were statistically identical. By the 24 h time-point, 177Lu-CSC1 and 177Lu-CSC2 
demonstrated significantly lower blood retention (p < 0.05) relative to the control. The 
blood retention of 177Lu-CSC1-3 at 72 and 144 h post-administration were all 
substantially lower (p < 0.001), 2.2 - 2.9 and 3.0 - 4.4 fold lower, respectively, in 
comparison to 177Lu-CSC0. Comparison of the blood clearance profile of the 177Lu-CSCs 
in both the CF-1 and HPAC xenograft model revealed that the CF-1 model demonstrated 
a relative two-fold lower retention for all 177Lu-CSCs at all time points investigated. This 
suggests that the alterations made to the SCID model (i.e., absence of functional T and 
B lymphocytes) may be impacting the blood clearance of the 177Lu-CSCs. However, 
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when the blood clearance profiles are taken into account, the overall trends of the 177Lu-
CSCs, with respect to uptake, retention and clearance, in solid tissues remain consistent 
























Table 3.2: Biodistribution of 177Lu-labeled CSCs in CF-1 mice. N=5 at each time-point. 




















 4 h p.i. 24h p.i. 
blood 13.61 ± 2.35 12.03 ± 1.58 13.85 ± 3.13 13.72 ± 2.82 6.17 ± 1.20 3.82 ± 0.65 2.77 ± 0.49 4.57 ± 0.56 
heart 3.40 ± 1.01 3.54 ± 0.50 5.57 ± 1.18 4.33 ± 1.14 2.10 ± 0.22 1.65 ± 0.16 1.50 ± 0.62 1.97 ± 0.12 
lung 4.47 ± 1.39 3.84 ± 0.50 3.93 ± 0.77 3.97 ± 0.92 2.08 ± 0.28 1.90 ± 0.25 1.07 ± 0.19 1.89 ± 0.35 
liver 2.92 ± 0.55 2.47 ± 0.15 2.73 ± 0.37 3.16 ± 0.66 2.56 ± 0.31 1.79 ± 0.29 1.74 ± 0.25 2.15 ± 0.19 
pancreas 1.74 ± 0.33 1.96 ± 0.59 2.72 ± 1.29 2.39 ± 0.34 1.08 ± 0.10 1.10 ± 0.08 1.26 ± 0.43 1.26 ± 0.20 
stomach 1.62± 1.06 1.33 ± 0.33 1.05 ± 0.23 1.46 ± 0.66 0.66 ± 0.11 0.97 ± 0.19 0.53 ± 0.21 0.49 ± 0.07 
spleen 2.55 ± 0.43 2.11 ± 0.29 1.66 ± 0.29 2.65 ± 0.71 2.33 ± 0.26 1.26 ± 0.19 1.14 ± 0.21 1.92 ± 0.65 
small int. 2.26 ± 0.53 2.01 ± 0.42 2.46 ± 0.44 2.61 ± 0.65 1.22 ± 0.25 1.21 ± 0.32 0.80 ± 0.10 1.29 ± 0.07 
large int. 3.30 ± 1.34 3.11 ± 0.48 1.94 ± 0.26 2.62 ± 1.17 1.46 ± 0.45 1.43 ± 0.35 0.99 ± 0.07 1.04 ± 0.19 
kidney 3.77 ± 0.87 3.88 ± 0.97 3.68 ± 0.42 3.67 ± 0.93 2.06 ± 0.33 1.93 ± 0.12 1.59 ± 0.39 2.03 ± 0.11 
muscle 0.79 ± 0.23 0.76 ± 0.15 1.14 ± 0.37 0.98 ± 0.38 0.56 ± 0.06 0.62 ± 0.11 1.17 ± 0.49 0.63 ± 0.11 
bone 1.22 ± 0.29 1.09 ± 0.06 1.97 ± 0.68 1.37 ± 0.44 0.68 ± 0.09 0.73 ± 0.08 0.89 ± 0.25 0.71 ± 0.07 
brain 0.40 ± 0.14 0.35 ± 0.08 0.47 ± 0.17 0.59 ± 0.05 0.18 ± 0.03 0.19 ± 0.02 0.12 ± 0.04 0.21 ± 0.05 
Excretion 21.56 ± 11.0 28.36 ± 3.31 37.02 ± 6.24 23.12 ± 5.59 56.15 ± 15.65 55.37 ± 2.89 59.03 ± 5.28 53.78 ± 1.90 
 72 h p.i. 144 h p.i. 
blood 3.42 ± 0.78 1.18 ± 0.16 0.47 ± 0.09 1.13 ± 0.19 1.40 ± 0.30 0.38 ± 0.10 0.07 ± 0.04 0.26 ± 0.05 
heart 1.80 ± 0.17 1.00 ± 0.08 0.80 ± 0.19 0.97 ± 0.20 1.65 ± 0.37 0.55 ± 0.04 0.42 ± 0.07 0.61 ± 0.08 
lung 1.75 ± 0.36 0.78 ± 0.20 0.50 ± 0.10 0.79 ± 0.19 1.20 ± 0.18 0.25 ± 0.06 0.20 ± 0.06 0.33 ± 0.05 
liver 3.49 ± 0.75 1.82 ± 0.36 0.91 ± 0.10 1.46 ± 0.08 3.45 ± 0.38 0.82 ± 0.06 0.54 ± 0.03 1.06 ± 0.08 
pancreas 1.44 ± 0.47 0.82 ± 0.23 0.78 ± 0.34 0.73 ± 0.12 1.35 ± 0.53 0.53 ± 0.09 0.37 ± 0.11 0.45 ± 0.08 
stomach 0.58 ± 0.16 0.46 ± 0.14 0.26 ± 0.07 0.36 ± 0.13 0.41 ± 0.17 0.11 ± 0.03 0.08 ± 0.03 0.15 ± 0.05 
spleen 4.31 ± 1.47 1.85 ± 0.71 0.78 ± 0.28 1.45 ± 0.09 6.70 ± 3.46 0.82 ± 0.34 0.67 ± 0.41 1.05 ± 0.12 
small int. 0.85 ± 0.19 0.54 ± 0.10 0.32 ± 0.06 0.47 ± 0.08 0.50 ± 0.07 0.23 ± 0.03 0.18 ± 0.03 0.22 ± 0.05 
large int. 1.42 ± 0.27 1.22 ± 0.37 0.54 ± 0.04 0.64 ± 0.20 0.91 ± 0.14 0.35 ± 0.03 0.19 ± 0.02 0.32 ± 0.09 
kidney 1.76 ± 0.31 1.04 ± 0.17 0.77 ± 0.14 1.01 ± 0.15 1.17 ± 0.24 0.49 ± 0.08 0.42 ± 0.04 0.61 ± 0.21 
muscle 0.59 ± 0.08 0.42 ± 0.10 0.49 ± 0.13 0.44 ± 0.10 0.57 ± 0.15 0.19 ± 0.03 0.27 ± 0.07 0.22 ± 0.02 
bone 1.03 ± 0.21 0.49 ± 0.13 0.54 ± 0.08 0.58 ± 0.18 0.72 ± 0.37 0.37 ± 0.11 0.26 ± 0.05 0.32 ± 0.12 
brain 0.18 ± 0.03 0.06 ± 0.02 0.03 ± 0.01 0.07 ± 0.04 0.11 ± 0.02 0.03 ± 0.02 0.01 ± 0.01 0.02 ± 0.01 











Table 3.3: Biodistribution of 177Lu-labeled CSCs in HPAC tumor bearing mice. N=5 at                                                          






























 4 h p.i. 24 h p.i. 
Blood 21.02 ± 6.09 17.62 ± 2.87 16.42 ± 2.87 20.47 ± 2.19 11.34 ± 2.24 5.80 ± 0.62 6.87 ± 1.15 9.22 ± 1.78 
Heart 6.33 ± 2.04 5.05 ± 0.97 4.64 ± 1.30 5.12 ± 1.81 3.77 ± 0.35 2.44 ± 0.19 2.65 ± 1.10 3.00 ± 0.82 
Lung 6.68 ± 1.09 5.32 ± 1.26 5.73 ± 1.48 6.44 ± 2.22 3.87 ± 1.18 2.83 ± 0.40 2.78 ± 0.58 4.02 ± 0.87 
Liver 4.97 ± 0.74 4.20 ± 0.64 4.27 ± 0.38 5.13 ± 0.64 4.74 ± 0.65 3.33 ± 0.05 4.21 ± 0.32 4.88 ± 0.90 
Pancreas 2.92 ± 0.57 2.48 ± 0.12 2.50 ± 0.66 2.98 ± 0.76 3.09 ± 1.07 2.05 ± 0.76 1.96 ± 0.47 1.65 ± 0.57 
Stomach 1.04 ± 0.29 1.15 ± 0.27 1.00 ± 0.27 1.15 ± 0.28 0.93 ± 0.35 0.76 ± 0.18 0.72 ± 0.29 0.73 ± 0.27 
Spleen 3.35 ± 0.56 2.88 ± 0.83 4.04 ± 1.56 3.55 ± 0.61 7.79 ± 1.47 3.24 ± 1.29 4.53 ± 2.21 4.93 ± 0.66 
Small Int. 1.96 ± 0.34 2.06 ± 0.74 
0.748.2 
1.56 ± 0.29 1.66 ± 0.52 1.03 ± 0.13 0.68 ± 0.11 0.69 ± 0.13 0.96 ± 0.22 
Large Int. 1.88 ± 0.20 3.84 ± 3.42 2.33 ± 0.59 1.93 ± 0.43 1.25 ± 0.37 1.24 ± 0.16 1.50 ± 0.26 1.67 ± 0.33 
Kidney 5.28 ± 1.25 5.08 ± 1.06 3.81 ± 0.76 4.63 ± 0.88 3.01 ± 1.01 2.38 ± 0.44 2.58 ± 0.20 3.03 ± 0.72 
Muscle 1.21 ± 0.24 1.22 ± 0.24 1.58 ± 0.95 1.22 ± 0.31 1.89 ± 1.14 1.26 ± 0.70 1.07 ± 0.31 1.37 ± 0.42 
Bone 1.52 ± 0.21 1.68 ± 0.21 1.65 ± 0.37 1.59 ± 0.21 1.42 ± 0.34 1.39 ± 0.19 1.14 ± 0.20 1.17 ± 0.21 
Brain 0.68 ± 0.09 0.70 ± 0.10 0.48 ± 0.08 0.56 ± 0.10 0.46 ± 0.08 0.29 ± 0.10 0.28 ± 0.04 0.25 ± 0.04 
Tumors 3.67 ± 0.72 3.29 ± 0.64 2.57 ± 0.39 3.04 ± 1.01 3.66 ± 0.62 3.70 ± 0.52 2.71 ± 0.34 3.98 ± 2.16 
Excretion 23.82 ± 3.23 25.40 ± 3.08 34.57 ± 2.41 25.85 ± 4.68 40.22 ± 4.70 56.54 ± 1.75 56.44 ± 4.30 48.90 ± 1.10 
 72 h p.i. 144 h p.i. 
Blood 5.15 ± 0.86 1.85 ± 0.35 1.75 ± 0.47 2.36 ± 0.47 2.35 ± 0.43 0.53 ± 0.19 0.68 ± 0.25 0.78 ± 0.30 
Heart 3.60 ± 1.06 2.05 ± 0.43 1.22 ± 0.16 1.49 ± 0.39 2.79 ± 1.38 1.24 ± 0.36 0.88 ± 0.20 1.06 ± 0.34 
Lung 3.24 ± 0.43 1.33 ± 0.20 1.21 ± 0.36 1.44 ± 0.22 1.89 ± 0.33 0.74 ± 0.22 0.50 ± 0.26 0.81 ± 0.19 
Liver 5.29 ± 1.17 2.46 ± 0.30 2.83 ± 0.56   2.96 ± 0.47 5.13 ± 0.64 1.40 ± 0.33 1. 16 ± 0.19 1.48 ± 0.34 
Pancreas 3.10 ± 1.70 1.02 ± 0.43 0.92 ± 0.13 0.84 ± 0.30 1.71 ± 0.56 0.75 ± 0.62 0. 41 ± 0.21 0.88 ± 0.25 
Stomach 0.82 ± 0.33 0.52 ± 0.23 0.32 ± 0.07 0.29 ± 0.10 0.48 ± 0.24 0.17 ± 0.06 0.14 ± 0.07 0.24 ± 0.04 
Spleen 8.22 ± 2.63 2.72 ± 0.72 3.00 ± 1.78 2.70 ± 0.69 8.27 ± 1.91 3.25 ± 0.86 3. 43 ± 1.46 3.68 ± 1.18 
Small Int. 0.59 ± 0.15 0.57 ± 0.12 0.45 ± 0.05 0.62 ± 0.15 0.55 ± 0.19 0.12 ± 0.04 0.18 ± 0.07 0.29 ± 0.04 
Large 
Int. 
1.15 ± 0.12 0.58 ± 0.09 0.63 ± 0.11 0.90 ± 0.53 0.92 ± 0.30 0.29 ± 0.04 0.31 ± 0.10 0.33 ± 0.15 
Kidney 2.40 ± 0.70 1.45 ± 0.30 1.45 ± 0.36 1.44 ± 0.18 1.95 ± 0.36 0.83 ± 0.20 0.91 ± 0.18 1.03 ± 0.07 
Muscle 1.57 ± 0.59 0.85 ± 0.48 0.81 ± 0.32 1.10 ± 0.29 1.21 ± 0.39 0.41 ± 0.21 0.46 ± 0.24 0.64 ± 0.16 
Bone 1.88 ± 0.82 1.45 ± 0.68 0.49 ± 0.21 0.78 ± 0.14 1.30 ± 0.42 0.48 ± 0.27 0.48 ± 0.33 0.83 ± 0.24 
Brain 0.30 ± 0.04 0.32 ± 0.35 0.07 ± 0.05 0.08 ± 0.02 0.20 ± 0.07 0.06 ± 0.04 0.07 ± 0.09 0.09 ± 0.09 
Tumors 5.00 ± 1.40 3.28 ± 0.74 2.38 ± 0.59 2.81 ± 0.52 3.21 ± 0.68 2.61 ± 0.93 1.49 ± 0.31 1.68 ± 0.43 
Excretion 51.84 ± 2.65 72.12 ± 1.28 75.70 ± 1.35 68.96 ± 3.13 55.65 ± 2.26 83.29 ± 1.24 87.93 ± 1.49 84.10 ±0.82 
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Table 3.4: Tumor to non-target organ ratios of 177Lu- labeled CSCs in HPAC tumor 


































 4 h p.i. 24 h p.i. 
Blood 0.19 ± 0.10 0.19 ± 0.02 0.16 ± 0.03 0.15 ± 0.06 0.33 ± 0.05 0.65 ± 0.12 0.41 ± 0.09 0.44 ± 0.17 
Liver 0.74 ± 0.12 0.79 ± 0.08 0.60 ± 0.06 0.61 ± 0.22 0.79 ± 0.18 1.11 ± 0.16 0.65 ± 0.08 0.81 ± 0.31 
Spleen 1.13 ± 0.35 1.23 ± 0.42 0.73 ± 0.32 0.86 ± 0.22 0.49 ± 0.12 1.26 ± 0.44 0.70 ± 0.32 0.80 ± 0.32 
Kidney 0.72 ± 0.19 0.68 ± 0.19 0.69 ± 0.14 0.66 ± 0.17 1.32 ± 0.43 1.59 ± 0.28 1.06 ± 0.16 1.39 ± 0.84 
 72 h p.i. 144 h p.i. 
Blood 0.98 ± 0.17 1.83 ± 0.39 1.46 ± 0.53 1.25 ± 0.41 1.41 ± 0.45 5.49 ± 2.32 2.47 ± 1.09 2.36 ± 0.87 
Liver 0.96 ± 0.18 1.35 ± 0.26 0.84 ± 0.15 0.96 ± 0.12 0.63 ± 0.13 1.92 ± 0.68 1.31 ± 0.28 1.14 ± 0.17 
Spleen 0.66 ± 0.22 1.28 ± 0.38 0.90 ± 0.28 1.08 ± 0.26 0.40 ± 0.08 0.82 ± 0.27 0.47 ± 0.11 0.48 ± 0.15 
Kidney 2.14 ± 0.39 2.34 ± 0.55 1.67 ± 0.32 1.97 ± 0.36 1.69 ± 0.45 3.31 ± 1.65 1.67 ± 0.32 1.63 ± 0.35 
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As with most nanomedicine platforms, the 177Lu-CSCs exhibited liver and spleen 
retention as a result of MPS driven sequestration [161]. The liver and spleen uptake of 
the non-cleavable control, 177Lu-CSC0, plateaued by 24 h post-injection with retention  
values of 4.74 ± 0.65 and 7.79 ± 1.47 %ID/g, respectively. The retention of 177Lu-CSC0 
associated radioactivity in the liver and spleen remained essentially constant throughout 
the remaining time points investigated. As a result of the incorporation of the CSLs, the 
177Lu-CSC1-3 demonstrated substantially lower levels of long-term retention in 
comparison to the control. Significant differences (p < 0.05) in the spleen retention of the 
177Lu-CSC1-3 versus the 177Lu-CSC0 were observed by 24 h post-administration. By 72 
h p.i., both spleen and liver retentions of the 177Lu-CSC1-3 were considerably lower (p < 
0.01) than control. At our terminal time-point, the liver and spleen retentions of the 177Lu-
CSC1-3 were 3.5 - 4.4 and 2.2 - 2.5 fold lower, correspondingly, than the 177Lu-CSC0.    
 
The increased excretion and lower blood, liver and spleen retention profiles of 177Lu-
CSC1-3 are undoubtedly linked to the incorporation of the cathepsin S cleavable linker 
into the HPMA copolymer. The lower liver and spleen retention is likely due primarily to 
the processing of 177Lu-CSC1-3 by tissue-resident macrophages (e.g., Kupffer cells of 
the liver) thus resulting in low-molecular weight radiometabolites that are more readily 
cleared [145, 161]. With respect to blood retention, the 177Lu-CSC1-3 are being cleared 
from circulation significantly faster than the non-cleavable control. The inclusion of the 
CSLs into the HPMA copolymers is possibly leading to a markedly higher opsonization 
and sequestration by the MPS. Such responses have been observed with 
functionalization of other drug delivery systems, but this seems unlikely given the limited 
functionalization (< 1 mole%) of the HPMA copolymers used in these experiments [161]. 
Alternatively, and to us more likely, is the possibility that the 177Lu-CSCs are being 
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internalized and processed by cellular components of the blood. The human serum 
studies that were performed suggest that the 177Lu-CSCs are stable in the presence of 
extracellular serum proteases. However, many drug delivery platforms are known to be 
taken up by circulating blood monocytes, an APC known to express cathepsin S [162-
164]. If this is the case, the 177Lu-CSCs would be expected to be taken up and 
processed by phagocytic cells in the blood, presumably circulating monocytes. 
Metabolism of the CSLs by these APCs would lead to the generation of radiometabolites 
which would likely favor clearance from the processing cell as well as the circulation 
relative to the non-cleavable 177Lu-CSC0. 
 
The 177Lu-CSCs exhibited substantial accumulation in the HPAC xenograft tumors 
through the EPR effect [124, 165]. 177Lu-CSC0 demonstrated the highest tumor retention 
with a peak accumulation of 5.00 ± 1.40 %ID/g at 72 h post-administration. For the 177Lu-
CSC1-3, maximal tumor retention for each copolymer was observed by the 24 h time 
point with values of 3.70 ± 0.52, 2.71 ± 0.34 and 3.98 ± 2.16 %ID/g, respectively. By the 
144 h time-point, the tumor retention of 177Lu-CSC1 (2.61 ± 0.93 %ID/g) was statistically 
identical to the non-cleavable control (3.21 ± 0.68 %ID/g), but was higher than 177Lu-
CSC2 (p < 0.05) and 177Lu-CSC3 (p<0.05) (1.49 ± 0.31 and 1.68 ± 0.43 %ID/g, 
correspondingly). 
  
The tumor to non-target ratios for selected tissues at 4, 24, 72 and 144 h p.i. are 
given in Table 3.3. For 177Lu-CSC1, the HPAC tumor retention and non-target clearance 
properties yielded superior tumor-to-non-target ratios by 24 h p.i. relative to the other 
177Lu-CSCs, including the control. The superiority of 177Lu-CSC1, relative to the other 
copolymers, improved longitudinally with maximal divergence in tumor to non-target 
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ratios being observed at the 144 h time-point. At this time-point, the tumor-to-liver, 
spleen and kidney ratios of 177Lu-CSC1 are on average 3.0 (p<0.01), 2.1 (p<0.05) and 
2.0 (p=0.067) higher, respectively, than the control.  
 
Evaluation of the biodistribution data for the CSL containing HPMA copolymers 
reveals some interesting trends with regard to the structure-activity profiles of the 177Lu-
CSC1-3 in HPAC tumor and non-target tissues. As described earlier, in vitro assays 
revealed that the addition of the PEG linker (177Lu-CSC3), the longest (13 atoms) linker, 
significantly enhanced the cathepsin S cleavage rate relative to 177Lu-CSC1 or 177Lu-
CSC2. Given this, one would anticipate that 177Lu-CSC3 would have exhibited the fastest 
clearance rates from MPS associated non-target tissues. However, in vivo biodistribution 
studies revealed that the 177Lu-CSC1, null (0 atom) linker, exhibited overall the fastest 
clearance of radioactivity from the blood, liver and spleen among the CSL containing 
HPMA copolymers. In fact, at 24 h p.i., the clearance of 177Lu-CSC1 from MPS 
associated non-target tissues is statistically better (p < 0.05) than 177Lu-CSC3. Though, 
by 72 h and beyond, the clearance of radioactivity in the blood, liver and spleen is 
statistically identical for all three copolymers. Interestingly, this trend is somewhat 
reversed with regard to HPAC tumor retention. At 144 h p.i., 177Lu-CSC1 exhibits 
substantially higher tumor retention relative to both 177Lu-CSC2 and 177Lu-CSC3. At this 
point, the factors driving these observations remain unclear. Likely, the clearance 
kinetics of the 177Lu-CSCs relies primarily on a combination of the cleavage kinetics and 
the vascular and lymphatic efficiencies of the tissue. The inequalities between the non-
target, normal tissues and the HPAC tumors with regard to the abundance of cathepsin 
S expressing APCs and the vasculature and lymphatic systems are likely the driving 
influences behind these observations. Currently, we are pursuing studies that will 
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hopefully yield a better understanding of the in vivo cathepsin S cleavage kinetics and 
clearance mechanisms of the 177Lu-CSCs.  
 
3.3.7 Small Animal SPECT/CT Imaging Studies 
For the development of nuclear imaging agents based on nanomedicine platforms, 
the clinical success of antibody based agents (e.g., ProstaScint® and OncoScint®) can 
serve as an example, due to the similar pharmacokinetic profiles of the two systems [166, 
167]. Similar to many nanomedicine platforms, monoclonal antibodies are large 
macromolecules that typically don’t achieve optimal tumor-to-non-target ratios until days 
after injection. As a consequence, image acquisitions for clinical imaging agents based 
on monoclonal antibodies are typically obtained between 2 and 5 days post-injection 
[166, 168]. For the investigated 177Lu-CSCs, the biodistribution studies suggest that this 
same time frame would be suitable, if not optimal, for diagnostic imaging. 
 
In order to better evaluate the imaging potential of the 177Lu-CSCs, micro-SPECT/CT 
studies were performed for 177Lu–CSC0, 177Lu–CSC1 and 177Lu–CSC3 in mice bearing 
bilateral flank HPAC xenografts. 177Lu –CSC2 was not chosen for μSPECT/CT analysis 
due to the similarity in its biodistribution profile with 177Lu –CSC3. Whole body images, 
depicted in Figure 3.6, were collected at 4, 24 and 72 h post-administration. At 4 h p.i., 
visual inspection of the normalized images revealed substantial accumulation in the 
abdominal cavity as well as the bladder for all three copolymers. The bladder activity at 
such an early time-point suggests that the clearance of activity is likely from the 
copolymer fraction that is below the renal excretion threshold [131]. Visualization of the 
flank HPAC tumors was limited at 4 h p.i., but became clearly evident by the 24 h time- 
107 
 
point. At 24 h p.i., decreases in the abdominal activity, which includes the liver, were 
noted for the three copolymers. By the 72 h time-point, all of the investigated 177Lu–
CSCs demonstrated considerable uptake/retention in the HPAC tumors. In addition, 
177Lu–CSC1 and 177Lu–CSC3 demonstrated superior abdominal clearance relative to the 
non-cleavable control (177Lu-CSC0). Overall, the SPECT/CT images agree well with the 
data obtained from the biodistribution study. The substantial retention of 177Lu–CSC1 in 
the HPAC tumors coupled with the enhanced clearance of activity from the abdominal 
region suggest that the CSL1 is the most promising linker to move forward with in the 
























































In summary, our laboratory is pursuing the development of CSLs that cleave in the 
presences of cathepsin S, to reduce the non-target accumulation of diagnostic/ 
radiotherapeutic HPMA copolymers in MPS tissues. To this end, we have evaluated a 
series of CSLs incorporated into a 177Lu-labeled HMPA copolymer construct with the 
purpose of understanding the structure activity relationship with regard to the length of 
the linking groups. In vitro cleavage assays revealed that the longest linking group (13 
atoms) demonstrated the highest cathepsin S cleavage kinetics. Additionally, confocal 
microscopy confirmed the selective uptake of HPMA copolymers in differentiated 
macrophages and trafficking to the lysosomal cellular compartments. Contrary to in vitro 
observations, in vivo biodistribution studies revealed that the linking group length in the 
CSL design did not substantially impact the non-target clearance. However, in the case 
of HPAC tumor retention, the CSC1 demonstrated significantly higher levels of retention 
relative to the other CSCs. This gave CSC1 superior tumor-to-non-target ratios as 
confirmed by longitudinal SPECT/CT imaging studies. Taken together, our results 
suggest that the dissimilarities in the metabolism and clearance kinetics of the CSL 
incorporated HPMA copolymers are tissue specific. Our future work will focus on gaining 
an understanding of the tissue-specific underpinnings influencing CSL metabolism and 
clearance. Lastly, these results demonstrate that the CSLs can substantially improve the 
non-target clearance of HPMA copolymers, and likely other nanomedicine platforms, 








Comparison of 177Lu-Labeled Plectin-1 Targeted Peptide (PTP) 
and PTP-HPMA conjugates for Pancreatic Tumor Targeting 
 
4.1 INTRODUCTION 
World-wide, radiotherapy (e.g., external beam, brachytherapy and targeted 
radionuclide radiotherapy) plays a primary role in the standard of care for many cancer 
types [169-171]. While the majority of today’s clinical radiotherapy centers around 
external beam, systemic radiotherapy using radionuclide containing carriers that 
selectively target tumors, through active or passive mechanisms, offer significant 
advantages and clinical potential [169, 172, 173]. Given that the metastatic spread of 
cancer, and not the primary tumor, is the main cause of most cancer related deaths; 
perhaps the greatest advantage of targeted radionuclide therapy (TRT) is the potential to 
systemically target and eliminate small metastatic lesions that are unobserved clinically 
due to their size and/or location. Based on this potential, the development of TRT has 
been an active field of research with reports of radionuclide carriers that range from low 
molecular weight compounds (e.g., small molecules and peptides) to large 
macromolecule platforms (e.g., antibodies and nanomedicines) [174-178]. 
 
Plectin-1 (Plec1) is a large protein (500kDa) that plays a crucial role in the 
cytoskeleton in mammalian cells [179]. It is able to bind and crosslink microtubules, actin 
microfilaments, and intermediate filaments in the cytoplasm. In addition, Plec1 serves as 
an anchor point between the cytoskeleton and the organelles, nucleus and intracellular 
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membrane. In normal cells, Plec1 is localized within the cell and as a consequence 
cannot be targeted using traditional cell-surface targeting approaches. However, for 
pancreatic ductal adenocarcinoma (PDAC), Plec1 becomes over-expressed on the 
extracellular surface of the cell thus making it a potential molecular target [37, 180]. 
Based on a report by Kelly and co-workers, Plec1 is expressed on the extracellular 
surface of 100% of PDAC samples (n=42), 60% of late-stage, pre-invasive pancreatic 
intraepithelial neoplasia (PanIN) III samples (n = 15) and 4% of PanIN II samples (n = 26) 
[180]. Furthermore, normal pancreas (n = 4), chronic pancreatitis (n = 15) and PanIN I (n 
= 14) samples were negative for Plec1 extracellular surface expression. Given these 
studies, it appears Plec1 over-expression and extracellular surface localization begins 
during the pre-invasive PanIN III stage and further increases as the disease progresses 
into the invasive stage. As a consequence, Plec1 appears to be a potentially valuable 
molecular target for both diagnostic and therapeutic applications for PDAC. 
 
Recently, a seven amino acid peptide (KTLLPTP) that exhibits submicromolar 
binding affinity to Plec1 has been reported [37]. As a result of the attractive properties of 
Plec1, we are interested in developing Plec1-targeted platforms, based on the above 
peptide targeting vector, for PDAC TRT. Currently, we develop radiopharmaceuticals for 
oncologic purposes that range in size from small receptor-targeted peptides to 
nanomedicine platforms [181, 182]. It is well known that the size and molecular weight of 
targeted radiopharmaceuticals plays a significant role in their in vitro and in vivo 
biological performance/profile [129, 183]. As our first investigation into the development 
of Plec1-targeted agents, we were interested in comparing and contrasting the biological 
profiles of two starkly different Plec1-targeted carriers, specifically one based on a small 
peptide and one utilizing an N-(2-hydroxypropyl)methacrylamide (HPMA) polymeric 
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system. To that end, we have synthesized and characterized the two Plec1-targeted 
agents outlined above. Herein, we describe the in vitro and in vivo properties of these 
agents using the HPAC human pancreatic cancer cell line.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Peptide Synthesis 
The plectin-1 targeted peptide (PTP) analogue 1 (KTLLPTPGGG-NH2 or PTP-NH2) 
was synthesized on the rink amide resin using an automated solid phase peptide 
synthesizer. The resin (0.1 mmole of peptide anchors) was deprotected using 20% 
piperidine in DMF resulting in the formation of the primary amine. The carboxylic acids of 
the Fmoc protected amino acids (1 mmol) were activated using COMU and conjugated 
to the primary amines of the growing peptide on the resin. The resulting peptide was 
orthogonally deprotected and cleaved from the resin by shaking in a cleavage cocktail 
consisting of TIS: H2O: DODT: TFA = 2: 2: 2: 94 for 2 h. The cleaved peptide was 
subsequently precipitated and washed with ice cold methyl-tert-butyl ether (40 ml×3). 
Crude peptide was purified using the semi-preparative C12 column with a flow rate of 
5.0 mL/min. All HPLC experiments used solvents consisting of H2O containing 0.1% 
formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B). The 
initial gradient of 90% A: 10% B linearly decreased to 70% A: 30% B in 15 minutes. At 
the end of the run time for all HPLC experiments, the column was flushed with gradient 5% 
A: 95% B and re-equilibrated to the starting gradient. 
 
The PTP analogue 2 (DO3A-PTP) was conjugated with a DOTA at the N terminal 
position, and was synthesized on rink amide resin using the peptide synthesizer. The 
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resin (0.1 mmole) was deprotected using 20% piperidine in DMF resulting in the 
formation of the primary amine. The carboxylic acids of the Fmoc protected amino acids 
(1 mmol) were activated by COMU and conjugated to the primary amines of the growing 
peptide on the resin. DOTA(tBu)3 was added to the N terminus at the final step during 
the peptide synthesis. The resulting DOTA peptide conjugate was deprotected and 
cleaved from the resin by stirring in a cleavage cocktail consisting of TIS: H2O: DODT: 
TFA = 2: 2: 2: 94 for 2 hours. The cleaved conjugate was precipitated and washed with 
ice cold methyl-tert-butyl ether (40 ml×3). Crude conjugate was purified using the semi-
preparative C12 column with a flow rate of 5.0 mL/min. The initial gradient of 90% A: 10% 
B linearly decreased to 85% A: 15% B in 15 minutes.  
 
PTP analogues 3 and 4 were synthesized in orthogonally protected forms on the 2-
chlorotrityl-Gly-resin using an automated solid phase peptide synthesizer. The resin (0.1 
mmole of peptide anchors) was deprotected with 20% piperidine resulting in the 
formation of the primary amine. The carboxylic acids of the Fmoc protected amino acids 
(1 mmol) were activated using COMU and conjugated to the primary amines of the 
growing peptide on the resin. All the protected groups and N terminal Fmoc group were 
kept intact in the synthesized peptides. The selective cleavage of the protected peptides 
from the 2-chlorotrityl resin anchor was achieved by reaction with 1% TFA in dry DCM 
and subsequent filtration. The cleaved peptides were subsequently precipitated and 
washed thrice using ice cold methyl-tert-butyl ether (40 ml×3). Purification of the 
peptides was performed using the semi-preparative C12 column with a flow rate of 5.0 
mL/min. For peptide 3, the initial gradient of 30% A: 70% B linearly decreased to 5% A: 
95% B in 15 minutes. For peptide 4, 40% A: 60% B was linearly decreased to 10 % A: 
90 % B in 15 minutes.  
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The ethylenediamine-DOTA(t-Bu)3 was prepared by first reacting DOTA(t-Bu)3 (1 
mmole) with DCC (1.3 mmole) and NHS (1.3 mmole) overnight in 1/1(v/v) ethyl acetate 
/dioxane solution. The mixture was then washed with 5% sodium bicarbonate, followed 
by water and brine. The organic layer was dried over MgSO4. The filtrate was 
concentrated in vacuo, followed by addition of N-Boc ethylenediamine (1.2 mmole). The 
mixture was stirred overnight. The N-Boc ethylenediamine-DOTA(t-Bu)3 product was 
peak purified on HPLC using the C12 column with a flow rate of 5.0 mL/min. The initial 
gradient of 70% A: 30% B linearly decreased to 60% A: 40% B over 15 minutes. The 
purified N-Boc-ethylenediamine-DOTA(t-Bu)3 0.52 gram (0.74 mmole) was dissolved in 3 
mL of tBuOAc, and 44 μL of 18 M H2SO4 (1.5 equiv) was added to the solution. The 
mixture was stirred overnight. The solution was then neutralized with saturated sodium 
bicarbonate and extracted with ethyl acetate (20 mL×3). The organic layer was dried 
with MgSO4. The solution was evaporated to dryness and yielded light yellow oil as the 
desired compound. The yield was 66.5% with MS found: 615.4 ([M+H]+).  
 
The L and D forms of PTP with the C terminal conjugated with a DOTA chelator 
(peptide 5 or PTP-DO3A and peptide 6 or D-PTP-DO3A) were prepared by reacting the 
protected peptides 3 and 4 with ethylenediamine-DOTA(t-Bu)3. In general, 3 mg of 
purified peptide 3 or 4 (2.2 μmole) was reacted with 1.4 mg of ethylenediamine-DOTA(t-
Bu)3 in the presence of 2 equiv of EDC and DIPEA in DMF overnight. The crude product 
was dried in vacuo and treated with a cleavage cocktail consisting of TIS: H2O: DODT: 
TFA = 2: 2: 2: 94 for 2 h. The cleaved peptides were precipitated and washed thrice 
using ice cold methyl-tert-butyl ether (40 mL×3) and then dried in vacuo. After that, 20% 
piperidine in DMF was used to remove the N-terminal Fmoc group. DMF was removed in 
vacuo after 20 min deprotection. The final peptides were peak purified by LC-MS on the 
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C12 column with a flow rate of 5.0 mL/min. The initial gradient of 95% A: 5% B linearly 
decreased to 70% A: 30% B in 15 minutes.  
 
To prepare the PTP analogues used for “click chemistry”, an Fmoc-D-Lysine-OH 
containing 5-hexynoic acid at the ԑ-amine site was synthesized first. To the 5-hexynoic 
acid (5 mmole) dissolved in DCM was added NHS (6 mmole), EDC.HCl (6 mmole) and 
triethylamine (6 mmole). The reaction was allowed to proceed at room temperature 
overnight. The crude product was washed with H2O and extracted with DCM. The 
organic layer was dried in vacuo and the crude product was separated by flash 
chromatography (ethyl acetate/hexane = 1/3). The purified product (2 mmole) was 
dissolved in DMF, and reacted with Fmoc-D-Lysine-OH.HCl (2 mmole) and triethylamine 
(2.5 mmole). The mixture was stirred at room temperature overnight. After reaction, the 
mixture was dried in vacuo and subjected to flash chromatography (MeOH/DCM = 1/9) 
and the 5-hexynoyl-Fmoc-D-Lysine-OH was obtained in light yellow oil with a 41.6% 
yield. 1H NMR (DMSO): δ 1.35~1.39 (m, 2H, CH2CH2C=CH), 1.36~1.39 (m, 2H, 
CH2CH2CH2CH2), 1.64~1.67 (m, 4H, CH2CH2CH2CH2NH), 2.13~2.15 (t, 4H, CH2CH2CH2 
C=CH), 2.75 (s, 1H, CH2CH2 C=CH),  3.03 (m, 2H, CH2CH2CH2NH), 3.90 (m, 1H, 
CHCH2OCO), 4.2 (d, 3H, CH2OCO and NHCH(CH2)COOH), 7.2~7.6 (m, 8H, benzene), 
7.8 (s, 2H, CONH). 13C NMR (DMSO): δ 17.6, 23.2, 24.5, 28.9, 30.6, 34.3, 38.4, 46.8, 
53.9, 65.8, 71.6, 84.2, 120.2, 127.2, 127.8, 129.6, 140.9, 144.0, 156.3, 171.4, 174.1.    
 
The L and D forms of PTP analogues 7 and 8 were synthesized on a Sieber Amide 
resin using a solid phase peptide synthesizer. The resin (0.1 mmole of peptide anchors) 
was deprotected using 20% piperidine resulting in the formation of the primary amine. 
The carboxylic acids of the Fmoc protected amino acids (1 mmol) were activated using 
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COMU and conjugated to the primary amines of the growing peptide on the resin. The N 
terminal Fmoc group was also kept intact in the synthesized peptides. The selective 
cleavage of the protected peptides from the Sieber Amide resin was achieved by 
reaction with 1% TFA in dry DCM and subsequent filtration. The cleaved peptides were 
subsequently precipitated in ice cold water (40 ml). Purification of the peptides was 
performed using the C12 column with a flow rate of 5.0 mL/min. For both peptides, the 
initial gradient of 40% A: 60% B linearly decreased to 10% A: 90% B over a 15 minute 
time period. 
 
The iFluor-647-labeled PTP was prepared through “click chemistry”. The PTP 
analogue 9 was synthesized on a rink amide resin using a solid phase peptide 
synthesizer. The resin (0.05 mmole of peptide anchors) was deprotected using 20% 
piperidine resulting in the formation of the primary amine. The carboxylic acids of the 
Fmoc protected amino acids (0.5 mmol) were activated using COMU and then 
conjugated to the primary amines of the growing peptide on the resin. The resulting 
peptide was orthogonally deprotected and cleaved from the resin by shaking in a 
cleavage cocktail consisting of TIS: H2O: DODT: TFA = 2: 2: 2: 94 for 2 h. The cleaved 
peptides were subsequently precipitated and washed thrice using ice cold methyl-tert-
butyl ether (40 ml×3). Purification of the peptide was performed using the C12 column 
with a flow rate of 5.0 mL/min. The initial gradient of 90% A: 10% B linearly decreased to 
80% A: 20% B over a 15 minute time period.  
 
For the preparation of peptide 10, 1 mg of purified peptide 9 (0.86 μmole) was first 
dissolved with 1 mg of iFluro-647 (0.92 μmole) in MeOH. After that, 0.2 μmole TBTA 
dissolved in 30 μL DMSO was added to a solution of 0.1 μmole CuSO4 in 100 μL 
117 
 
MeOH/H2O (v/v, 1/1). Next, 0.5 μmole of L-ascorbic acid dissolved in 100 μL MeOH/H2O 
(v/v, 1/1) was slowly added to CuSO4/ TBTA mixture to produce the Cu(I) ion as the 
catalyst. The catalyst solution was then mixed with peptide 9 and iFluro-647 solution in 
an ampoule. The ampoule was flame sealed and stirred for 48 h. The iFluro-647-labeled 
plectin-1 targeted peptide 10 was finally peak purified by LC-MS on the C12 column with 
a flow rate of 5.0 mL/min. The initial gradient of 90% A: 10% B linearly decreased to 60% 
A: 40% B over 15 minutes.  
 
4.2.2 Radiolabeling of the Peptides 
Each 25 µg sample of peptides 2, 5 and 6 were dissolved in ammonium acetate 
buffer (0.5 M, 100 μL, pH 5.5). 177LuCl3 (1 mCi) was added to the vial containing the 
conjugate, and the solution was heated for 60 min at 90 °C and allowed to cool to room 
temperature. To facilitate the separation of radiolabeled peptides from unlabeled 
peptides on the column, 2-3 mg CuSO4 were added and incubated for 5 min at 90 °C to 
increase the hydrophobicity of unlabeled conjugates. The resulting radio-conjugate was 
peak purified using RP-HPLC on a C12 250 × 4.6 mm column and was concentrated 
using a C18 extraction disk followed by elution with 300 μL ethanol/sterile saline solution 
(v/v, 3:2) to deliver the radio-conjugate in high purity. The radiolabeled peptides were 
purified by RP-HPLC with 95% H2O: 5% acetonitrile linearly decreasing to 70% H2O: 30% 
acetonitrile in 15 minutes. 
 
4.2.3 Cell Culture 
The HPAC cells were cultured at 37 °C at 5% CO2 in air, as per ATCC protocols, in 
DMEM/ Ham's F12 medium containing 5% FBS, 1.562 nM EGF, 14.3 mM sodium 
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bicarbonate, 2.5 mM L-glutamine, 15 mM HEPES and 0.5 mM sodium pyruvate 
supplemented with 0.35 µM insulin, 0.0625 µM transferrin and 0.11 µM hydrocortisone. 
 
4.2.4 Internalization and Efflux of Radiolabeled Peptides 
Internalization studies were performed using HPAC cells in 12 well plates. HPAC 
cells (~1×105) were seeded in each well in DMEM/Ham's F12 media and incubated 
overnight. The next day, about 100,000 cpm of 177Lu-labeled peptides was added to 
each well, and cells were incubated for up to 3 h at 37°C. During the incubation, at time-
points 15, 45, 90 and 180 min, cells were washed three times with media to remove the 
free radiolabeled peptide. Surface-bound radioactivity was removed by washing the cells 
twice with an ice cold acid wash (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8). The 
amount of non-acid washable radioactivity in each well was measured after lysing the 
cells with 10% NaOH solution.   
 
For efflux studies, HPAC cells (~1×105) were incubated in 12 well plates overnight. 
On the day of the experiment, HPAC cells were first incubated for 2 h at 37°C in the 
presence of ~100,000 cpm of the 177Lu labeled peptide to reach the plateau amount of 
cell associated radioactivity. Upon completion of the incubation, cells were washed three 
times with medium to remove the unbound peptide. Then, fresh medium was put in each 
well as the reservoir for efflux. After 0, 1, 2 and 4 h, the medium for each time point was 
harvested for quantitative analysis of ligand efflux. Surface-bound radioactivity was 
removed by washing the cells twice with an ice cold acid wash (50 mM glycine-HCl/0.1 
M NaCl buffer, pH 2.8). The cells were then lysed using a 10 % NaOH solution, and the 
remaining cell associated radioactivity was quantified. The radioactivity in the effluxed 
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and cell associated fractions was determined by a gamma counter. The effluxed fraction 
is expressed as a percentage of the total amount of radioactivity, which is the sum of the 
effluxed and the remaining fraction in the cell. 
 
4.2.5 In vitro Competitive Binding Study of PTP Analogues 
For in vitro binding studies, the half maximal inhibitory concentration (IC50) for the 
PTP-NH2 conjugate was determined on the HPAC cell line. In these studies, 
177Lu-PTP-
DO3A served as the control and PTP-NH2 as the cold ligand for comparing the relative 
effectiveness of the conjugates. Briefly, HPAC cells (~5×104) were seeded in each well 
of a 24-well plate and allowed to adhere overnight. The cells were then incubated at 
37 °C for 1 h in the presence of radiolabeled 177Lu-PTP-DO3A (~100,000 cpm) and 
various concentrations (10-9~10-4 M) of the PTP-NH2. At the end of the incubation, the 
media was removed and cells were washed with cold PBS three times. The cell-
associated radioactivity was measured by a gamma counter and the IC50 value was 
determined by nonlinear regression using the one-binding site model of GraphPad Prism 
5 (U.S.). The IC50 values for peptide 2 and 6 were determined using the same protocol.  
 
4.2.6 Confocal Microscopy 
HPAC cells were seeded onto 4-well chambered coverglass units with 5 × 104 cells. 
The iFluor-647 labeled peptide 10 was dissolved in blank media to 5 μM concentration. 
The cells were then incubated with the peptide for 4 h in a 37 ºC humidified atmosphere 
with 5% CO2. Half an hour before ending the incubation, LysoTracker Red DND-99 and 
Hoechst 33342 were added in the media to stain the lysosomal compartment and the 
nuclei respectively. Following incubation, the media was aspirated, and the cells were 
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washed with PBS to remove free peptides that were not associated with cells prior to 
microscopic imaging. 
 
4.2.7 Biodistribution of the Radiolabeled PTP Analogue 
Biodistribution studies were carried out using age-matched HPAC tumor bearing 
SCID mice. The animals were inoculated in each flank with 100 μL of a 1:1 ratio of 
suspended HPAC cells and Matrigel™ to obtain a final concentration of 5 x 106 HPAC 
cells per 100 μL. Upon achieving sufficient tumor size (10-15 mm in diameter), the mice 
were used for biodistribution studies. The HPAC xenograft mice were injected with a 10 
μCi (0.37 MBq) intravenous bolus of the purified 177Lu-PTP-DO3A. The mice were 
sacrificed and the tissues excised at 1 and 4 h time-points p.i. The blood and excised 
tissues were weighed, the 177Lu radioactivity was measured using a gamma counter, and 
the percentage injected dose per gram (%ID/g) was calculated for each tissue.  
 
4.2.8 Metabolic Stability in Human Serum 
The stability of peptide 5, PTP-DO3A and 177Lu-PTP-DO3A in human serum was 
determined. Briefly, 10 µg of PTP-DO3A or 200 µCi (7.4 MBq) of 177Lu-PTP-DO3A was 
added to 100 µL of human serum and incubated at 37 °C for 15 minutes. After the 
incubation, 100 µL of an ethanol/ acetonitrile (v/v, 1:1) was added to the serum and the 
whole mixture was vortexed to help precipitate the serum proteins. The resulting mixture 
was centrifuged at 12000 x g for 10 min. The supernatant was collected and purged with 
N2 gas for 20 minutes to remove the ethanol and acetonitrile. The resulting sample was 
dissolved in 100 µL water and injected into LC/MS or radio-HPLC for analysis. The 
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gradient used was 95% H2O: 5% acetonitrile linearly decreasing to 70% H2O: 30% 
acetonitrile in 15 minutes. 
 
4.2.9 Synthesis and Characterization of “Click” Reactive HPMA Copolymer 
The “click” reactive monomer: N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl) 
methacrylamide (AzMA) was synthesized. First, 1 gram of methacrylic acid (11.63 
mmole) was reacted with 1.38 gram of NHS (12 mmole) and 2.3 gram of EDC.HCl (12 
mmole) in DCM overnight, the resulting mixture was washed with water, and extracted 
with ethyl acetate. The organic layer was dried in vacuo. The dried product was 
monitored over 90% pure on LC-MS so directly used without purification. The dried 
product (1 gram) was dissolved in DMF followed by addition of 1.2 gram of 11-Azido-3, 6, 
9-trioxaundecan-1-amine (5.5 mmole) and triethylamine (11 mmole). The mixture was 
stirred overnight, then washed with water, and extracted with DCM twice. The organic 
layer was dried and subjected to silica gel flash chromatography (ethyl acetate/DCM = 
9/1) and yielded 0.6 gram of pure monomer-AzMA (40% yield). 1H NMR (CDCl3): δ 1.90 
(s, 3H, CH2=CCH3), 3.32 (t, 2H, CONHCH2CH2), 3.45 (t, 2H, CH2CH2-N3), 3.50~3.70 (t, 
12H, CH2OCH2), 5.67 and 5.28 (s, 2H, CH2=CCH3). 
13C NMR (CDCl3): δ 18.7, 39.5, 
50.8, 70.2, 70.2, 70.2, 70.6, 70.6, 70.7, 119.9, 139.9, 168.8.   
 
The HPMA copolymerization was accomplished using the reversible addition-
fragmentation chain transfer polymerization reaction with AIBN as the initiator and CTP 
as the chain transfer agent. The feed ratio of the polymerization consisted of 78: 19. 6: 
2.2: 0.20 mole% HPMA, AzMA, APMA and APMA-FITC, respectively. The 
polymerization was run at a 1 M total monomer concentration in a dioxane: H2O (v/v, 2/1) 
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mixture with a molar ratio of total monomer: chain transfer agent: initiator of 100: 1: 1. 
Prior to proceeding with the polymerization reaction, the glass ampoule and contents 
were purged with nitrogen for 20 minutes. Subsequently, the ampoule was flame sealed 
and allowed to heat at 50 ºC in an oil bath for 48 h. After cooling, the HPMA copolymer 
was evaporated to dryness, dissolved in methanol and purified by size exclusion 
chromatography (SEC) using an LH-20 packing material with methanol as the eluent. 
The conversion rate was 81% as determined by weight after purification. The weight 
average molecular weight and polymer dispersity of copolymers were determined by the 
TDA 305 equipped with UV, RI and static light scattering detectors. The static light 
scattering was calibrated with a PolyCALTM PEO-24K standard. The SEC was carried 
out on an Asahipak GF-510 HQ column with 40% acetonitrile in PBS as the eluent. The 
average molecular weights of the copolymers were estimated by OmniSEC 5.1 software. 
 
4.2.10 Synthesis and Characterization of PTP-HPMA Conjugates 
The L and D form of PTP analogues - peptide 7 and 8 and were conjugated to HPMA 
copolymer by copper catalyzed “click chemistry”. Briefly, 100 μmole TBTA dissolved in 
30 μL DMSO was first added to 54 μmole CuSO4 in 100 μL (v/v, 1/1) MeOH/H2O. Then 
250 μmole L-ascorbic acid in 100 μL of (v/v, 1/1) MeOH/H2O was slowly added to 
CuSO4/TBTA mixture to produce the Cu(I) ion as the catalyst. Next, 2 μmole “click” 
reactive HPMA copolymer dissolved in 100 μL MeOH was mixed with 54 μmole of 
peptide 7 or 8 (1.2 mole equivalent of azide group in the copolymer) in an ampoule. The 
reduced Cu+ solution was added slowly to the HPMA and peptide mixture. The ampoule 
was flame sealed and stirred at 40 ºC over 48 h. After reaction, the mixture was 
subjected a LH-20 size exclusion chromatography for purification. The polymer peptide 
conjugates were collected and dialyzed against EtOH/H2O (v/v, 3/1) for 48 h. The 
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dialyzed products were dried and reacted with DCC activated DOTA(tBu)3 (2 equiv) in 
DMF. The final HPMA conjugates were precipitated in cold ether to remove free DOTA. 
The conjugation efficiency was determined by ninhydrin assay as reported. The 
conjugates were then deprotected with 20% piperidine in DMF and precipitated in cold 
ether again. The conjugates were finally treated with a peptide cleavage cocktail. The 
final polymer peptide conjugates were precipitated again in cold ether and lyophilized for 
storage.          
 
4.2.11 Internalization Study of PTP-HPMA Conjugates by Flow Cytometry  
HPAC cells were seeded in 12-well plates at a density of 1 × 105 cells per well and 
incubated in media overnight (37 °C, 5% CO2). Cells were then incubated with two 
different peptide polymer conjugates (0.2 mg/mL) at 37 °C for the indicated time periods. 
After incubation, the media was removed. Cells were washed with PBS three times, then 
harvested and fixed followed by flow cytometry analysis. Each sample analysis involved 
an evaluation of ~1.0 × 104 cells. The collected data was averaged and reported as the 
mean fluorescent intensity for each sample. 
 
4.2.12 Radiolabeling and in vitro Evaluation of 177Lu Labeled PTP-HPMA Conjugates 
The radiolabeling of the conjugates was accomplished by heating the peptide 
polymer conjugate (200 μg) dissolved in water at 90 ºC for 1 h in the presence of 14.8 
MBq (400 μCi) of 177LuCl3. After cooling, the 
177Lu-labeled HPMA conjugates were 
purified by size exclusion chromatography using an LH-20 packing material in methanol. 
All the purified 177Lu-labeled HPMA conjugates were concentrated using an Amicon 
Ultra-4 Centrifugal Filter and washed twice with 5 mL of de-ionized water. For 
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internalization study, HPAC cells were seeded in 12-well plates at a density of 1 × 105 
cells per well overnight (37 °C, 5% CO2). Cells were then incubated with different 177Lu-
labeled HPMA conjugates (~ 100,000 cpm in each well) at 37 °C for 6 and 24 h. After 
incubation, the media was removed. Cells were washed with PBS three times, and then 
lysed with 10% NaOH solution. The internalized amount of radioactivity was measured 
by the gamma counter. For competitive binding study, HPAC cells (~5×104) were seeded 
in each of 24-well plate overnight and incubated at 37 °C for 1 hour in the presence of 
177Lu-PTP-DOTA (~100,000 cpm, 100 µl), with or without 200 µg HPMA-PTP conjugate. 
At the end of the incubation, the incubation media was removed and cells were washed 
with media. The cell-associated radioactivity was measured by a gamma counter. 
 
4.3 RESULTS 
4.3.1 Design and Synthesis of PTP Analogues 
A series of plectin-1 targeted peptide (PTP) analogues were synthesized by solid 
phase peptide synthesis and characterized by LC/MS. The peptide sequences and mass 
spectrometric analysis were summarized in Table 4.1. The plectin-1 targeted peptide 
sequence was initially identified by phase display and consisted of a seven amino acid 
sequence - KTLLPTP. It has been shown that the C terminal of this peptide could be 
modified with other compounds without causing the loss of binding affinity to Plec1. In 
order to investigate whether the N terminal of this peptide is essential for plectin-1 
binding, we prepared a PTP analogue with modification at the N terminal. Peptide 2 or 
DO3A-PTP was synthesized with the N terminal conjugated with a DOTA molecule by 
adding DOTA in the last step during solid phase peptide synthesis. A GGG linker was 
inserted between the targeting sequence and the DOTA (Figure 4.1). In order to prepare 
a C terminal DOTA modified peptide, orthogonally protected peptide 3, consisting of ten 
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amino acids: KTLLPTPGGG, was synthesized on the 2-chlorotrityl-Gly resin. Peptide 4 
had the same peptide sequence and molecular structure with peptide 3 and was 
prepared following the same strategy with 3 except that all the amino acids used in 4 
were the corresponding D forms other than glycine. By evaluating the binding affinity of 
D-PTP towards plectin-1, we can determine whether the cell-association/binding of the 
PTP is target-specific or due to any contribution from non-specific binding.  
 
The ethylenediamine(EDA)-DOTA(t-Bu)3 was synthesized and used to modify the C 
terminal of peptide 3 and 4 with a DOTA molecule. N-Boc-ethylenediamine was firstly 
reacted with DCC activated DOTA(tBu)3, followed by treatment with dilute H2SO4 in 
tBuOAc solution in order to selectively remove the N-Boc protecting groups. The EDA-
DOTA(t-Bu)3 was then conjugated to the C terminal carboxylic acid of peptide 3 and 4 
via EDC and NHS coupling. The crude products were not purified but directly subjected 
to TFA and piperidine treatment to remove the protecting groups. The final desired 
peptide 5 (PTP-DO3A) and 6 (D-PTP-DO3A) were purified by LC/MS based on the 
presumed molecular weight in a relatively poor yield. The poor yield might be due to our 
one-pot conjugation and deprotection method. We might achieve a better yield if we had 









Table 4.1: MS characterization of plectin-1 targeted peptide analogues. All the D form 
amino acids were abbreviated in lower case letters. (a, the exact molecular formula of 











time / min 
Yield 
(%) 
1 KTLLPTPGGG-NH2 C42H74N12O12 939.33 8.03 34.1 
2 DO3A-GGGKTLLPTPG-NH2 C60H103N17O20 1382.39 13.77 43.4 
3 Fmoc-KTLLPTPGGG-OH C70H107N11O17 1374.61 6.88 31.5 
4 Fmoc-ktllptpGGG-OH C70H107N11O17 1374.61 9.67 30.5 
5 KTLLPTPGGG-EDA-DO3A C60H105N17O19 1368.72 9.37 13.3 
6 ktllptpGGG-EDA-DO3A C60H105N17O19 1368.61 9.31 15.1 
7 Fmoc-KTLLPTPGGG-p(4-F)- 
k(5-hexynoate) 
C91H134FN15O19 1761.78 10.77 30.7 
8 Fmoc-ktllptpGGG-p(4-F)-k(5-
hexynoate) 
C91H134FN15O19 1761.82 10.21 32.1 











 Figure 4.1: Structure of DO3A-PTP conjugate and synthesis for PTP-DO3A conjugate. 
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We next prepared an amino acid derivative that can be used in peptide synthesis to 
introduce the alkyne functional group into PTP analogues. Those PTP analogues 
bearing alkyne groups can be conjugated to azide functionalized compounds through 
“click chemistry”. The ɛ-amine of Fmoc-D-lysine was conjugated with a 5-hexnoic acid 
within two steps (Figure 4.2). The resulting product: 5-hexynoate-Fmoc-D-lysine was 
then used for the synthesis of peptides 7-10. Peptides 7 and 8 were synthesized in 
orthogonally protected form on the Sieber Amide resin. An amino acid derivative 4-19F D-
phenylalanine was inserted between the GGG linker and the 5-hexynoate-D-lysine and 
functionalized as a “tag”. Thereby, the amount of peptide conjugated to the copolymer 
could be easily determined by 19F NMR. Except for glycine, 4-19F D-phenylalanine and 5-
hexynoate-D-lysine, all the other amino acids in peptide 7 was in L forms while all the 
other amino acids in peptide 8 was in D forms. Peptide 8 was used in the following 
section to prepare a polymer peptide conjugate as a control. Peptide 9 was a PTP 
analogue with a GGG linker after the targeting sequence, followed by the 5-hexynoate-
D-lysine at the C terminal position. Peptide 9 was used to conjugate with a near infrared 














The fluorophore labeled PTP analogue 10 was synthesized by copper (I) catalyzed 
“click chemistry” and was used to investigate the cellular localization of PTP on 
pancreatic tumor cells. The Cu(I) ion was in-situ generated after reducing CuSO4 with 
ascorbic acid. TBTA could protect Cu(I) from oxidation and disproportionation, while 
enhance its catalytic activity. The fluorophore we used is iFluor-647, which has an azide 
functional group in it with similar excitation/emission spectra as Cy 5.5 but the exact 
molecular structure was unknown. However, the molecular weight was known to be 
1079.1. The desired peptide peak was identified in LC/MS based on the calculated 
molecular weight and peptide 10 was purified by RP-HPLC. The “click” reaction yield 
was about 30%, which should be increased by optimizing the reaction conditions. Even 
though we didn’t characterize the excitation/emission property of the collected peptide, 
the conjugate showed a deep blue color in solution, which confirmed the successful 
conjugation of the fluorophore to the peptide.  
 
4.3.2 Competitive Binding, Internalization, Efflux Studies of 177Lu PTP Analogues 
The binding affinity, internalization and efflux of plectin-1 targeted peptide analogues 
were investigated on HPAC cell lines. All the peptides were successfully labeled with 
177Lu at > 90% efficiency. The non-radiolabeled peptides were labeled with Cu(II) by 
adding excess amount of CuSO4.5H2O (2 mg) to the labeling mixture, which results in 
better separation from the 177Lu labeled peptide in HPLC. The synthesized cold ligand, 
KTLLPTPGGG-NH2(PTP-NH2) could compete with 
177Lu-PTP-DO3A towards plectin-1 
binding on HPAC, with a IC50 at 1.6 ± 0.2 µM (Figure 4.3 A), which is very close to the 
reported tetrametric PTP analogue [14]. The 177Lu-labeled PTP-DO3A exhibited very 
efficient targeting ability in vitro, with a initial 24.49 ± 3.94% of cell associated 
radioactivity in 15 min, and increased to 46.77 ± 1.36% after 3 h incubation. The acid 
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washable portion was very low, but increased from 1.64 ± 0.53% at 15 min to 3.72 ± 
0.37% at 3 h (Figure 4.3 B). Neither the DO3A-PTP nor the D-PTP-DO3A showed any 
significant binding toward plectin-1, with IC50 > 200 µM. Neither exhibited any uptake to 
pancreatic cancer cells, which implys that N terminal of KTLLPTP is more essential for 
plectin-1 binding and cell-association/binding of the PTP is target-specific but not due to 
any contribution from non-specific binding. In our experiments, we also found that 177Lu-
PTP-DO3A did not exhibit any binding toward plectin-1 when we performed  the 
competitive binding assay at 4 ºC, the reason is still unknown. The IC50 value was 
obtained at 37 ºC instead of 4 ºC. The efflux study was initiated after 1 h incubation of 
177Lu-PTP-DO3A with HPACs. The 1 h incubation time was chosen because based on 
the internalization study, the uptake level reached the plateau as soon as in 45 min. The 
effluxed amount of cell associated activity increased from 8.47 ± 0.50% at 1 h to 29.63 ± 
















Figure 4.3: Competitive binding, internalization/efflux studies of 177Lu-labeled PTP 
analogues in HPAC cells. A, the N terminal modified analogue DO3A-PTP showed more 
than 100 times lower binding ability towards plectin-1 as compared to the C-terminal 
modified analogue PTP-DO3A. B and C, the 177Lu-PTP-DO3A exhibited the highest 
uptake and sustained efflux in the study period.    








4.3.3 Confocal Microscopy Study of iFluor-647 labeled PTP analogue  
The cellular localization of plectin-1 targeted peptide on HPAC human pancreatic 
cancer cell was determined using the iFluor-647-labeled peptide with confocal 
microscopy. Single and triple cell staining studies were performed. In the triple staining 
study, the lysosome compartments were labeled with the Lysotracker (red) and the 
nuclei were stained with Hoeschst 33342 (blue). After 4 h incubation, the majority of the 
peptide was found on the HPAC cell membrane (Figure 4 A, red and 4 B, pink) instead 
of inside the lysosome compartment (Figure 4 B, red). Even though the internalization 
study showed that most cell-associated radioactivity was acid non-washable, the 
peptides were not internalized after 3~4 h.    
 
 














Figure 4.4: Cell trafficking of iFluor-647-labeled PTP in HPAC cells under confocal 
microscopy. A, overlay of bright field image and near infrared image of the localization of 
iFluor-647-labeled PTP in HPAC; B, iFluor-647-labeled PTP staining (pink), lysosome 
















4.3.4 Biodistribution Study of 177Lu-labeled PTP Analogue 
The in vivo targeting efficacy for pancreatic tumor was evaluated in an HPAC 
xenograft mice model by intravenous injection of 177Lu-PTP-DO3A. The radioactivity was 
eliminated quickly, mainly throughout the renal system. At 1 h p.i., even though the 
absolute value was low, tumor sites still had the second highest radioactivity level 
(ID%/g of tumor vs spleen, p = 0.70) among all tissues (Table 4.2 and Figure 4.5). The 
tumor to muscle ratio was 3.45 ± 1.66. At 4 h p.i., the radioactivity was absent in all 

















Table 4.2: Biodistribution (ID%/g) of 177Lu-PTP-DO3A in HPAC xenograft mice at 1 and 4 
h p.i. N=3 at each time-point.  
 
Tissue 1 hour 4 hour 
blood 0.46 ± 0.05 0.09 ± 0.10 
heart 0.26 ± 0.08 0.04 ± 0.06 
lung 0.38 ± 0.04 0.05 ± 0.06 
liver 0.37 ± 0.18 0.19 ± 0.05 
pancreas 0.16 ± 0.06 0.05 ± 0.06 
stomach 0.08 ± 0.01 0.01 ± 0.02 
spleen 0.89 ± 0.67 0.06 ± 0.07 
small int. 0.47 ± 0.36 0.04 ± 0.01 
large int. 0.31 ± 0.14 0.20 ± 0.01 
kidney 4.33 ± 1.59 2.50 ± 0.30 
tumor 0.72 ± 0.28 0.08 ± 0.03 
muscle 0.32 ± 0.33 0.01 ± 0.01 
bone 0.28 ± 0.40 0.06 ± 0.08 
















Figure 4.5: Biodistribution (ID%/g) of 177Lu-PTP-DO3A in HPAC xenograft mice at 1 and 
4 h p.i. N=3 at each time-point. Tumor sites had the second highest accumulation at 1 h 
but were quickly decreased at 4 h.   
 





























4.3.5 Metabolic Stability of Plectin-1 Targeted Peptide 
The low tumor uptake in vivo was considered due to the instability of the 177Lu-PTP-
DO3A in the blood. In vitro serum stability study was performed to investigate the 
stability and metabolite of the radiolabeled and non-radiolabeled plectin-1 targeted 
peptides. The 177Lu-PTP-DO3A was degraded very fast in serum, generating one major 
metabolite and two other metabolites after 15 min incubation with human serum (Figure 
4.6 A&B). The LC-MS analysis was used to investigate the metabolites of non labeled 
PTP-DO3A in human serum. We found that the major metabolite was the product from 
the N-terminal D-lysine residual cleavage (peak 4, calculated 620.84 / found 620.81). 
Two other metabolites were identified where cleavage sites were between the 3L--4L 
residual (peak 1, calculated 513.77 / found 513.75) and 2T--3L residual (peak 2, 












Figure 4.6: Metabolism of plectin-1 targeted peptide in human serum. A, Radio-HPLC 
signal of 177Lu-PTP-DO3A before incubation; B, radio-HPLC signal of the degradants of 
177Lu-PTP-DO3A after 15 min incubation; C, total ion chromatography of PTP-DO3A 












4.3.6 Synthesis and Characterization of PTP-HPMA Conjugates 
Click reaction has shown improved conjugation efficiency as compared to many 
other bio-conjugation methods. In order to prepare the “click” reactive HPMA copolymer, 
we first developed a monomer bearing the azide functional group. The monomer AzMA 
was synthesized by reacting methacrylic acid with the 11-Azido-3, 6, 9-trioxaundecan-1-
amine (Figure 4.7). The PEG3 linker between the azide group and the HPMA backbone 
was considered to help increase the conjugation efficiency by decreasing the steric 
hindrance. HPMA copolymers containing APMA and AzMA were prepared by RAFT 
polymerization using CTP as the chain transfer agent and AIBN as initiator. Dioxane and 
water mixture (v/v, 2/1) was used to solubilize all the monomer content. The copolymer 
had a molecular weight 25,610 Da and the PDI 1.2 based on the static light scattering 
measurement. The mole content of HPMA, APMA and AzMA unit in the copolymer was 
determined by 1H NMR (Figure 4.8). The copolymer had 14.5 mole% and AzMA 1.2 
mole% APMA, which corresponded to 132 molecules of HPMA unit, 23 molecules of 
AzMA unit and 2 molecule of APMA on average in each copolymer backbone. The PTP 
analogues 7 and 8 were successfully conjugated to the HPMA copolymer by “click 
chemistry”, as confirmed by the 19F NMR. Initially we tried to use D-propargylglycine, 
which was commercially available, to introduce the alkyne group into the peptide but the 
resulting peptide did not conjugate well with the polymer, possibly due to steric 
restriction. We switched to the 5-hexynoate-D-lysine as it had longer distance between 
the alkyne group and the amino acid back bone, which should help increase the 
conjugation efficiency. We also optimized the “click chemistry” reaction conditions to 
increase the conjugation efficiency. The amount of CuSO4 we used was one molar 
equivalent to the alkyne group. This is a much larger quantity as compared to amounts 
other researchers reported (normally between 0.01 to 0.1 mole equivalent). The amount 
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of peptide conjugated to the HPMA copolymer was determined by quantitative 19F NMR. 
Known amounts of the 4-fluoro-3-nitrobenzotrifluoride were added as the internal 
standard. The peptide content was calculated out based on the 19F NMR integral area 
ratio between the -CF3 peak (0 ppm) from the internal standard and the –PhF peak 
(56.7 ppm) from the D-phenylalanine residual (4-F). We obtained a high conjugation 
yield with 10.4 mole% peptide 7 and  8.9 mole% peptide 8 conjugated to the HPMA 
copolymer, corresponding to 71.1% and 60.8% conjugation efficiency. The average 
number of peptides in the copolymer was about 16 for peptide 7 and 14 for peptide 8. 
The conjugated peptides in the copolymer were subsequently deprotected by piperidine 
and then TFA cocktail, after conjugation with DOTA(tBu)3. Ninhydrin assays showed that 





Figure 4.7: Synthesis of HPMA-AzMA-APMA copolymer and plectin-1 targeted peptide 
conjugated HPMA copolymers (PTP-HPMA) and the control (D-PTP-HPMA).  
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Figure 4.8: 1H NMR spectra of “click” reactive HPMA-AzMA-APMA copolymer in D2O 















4.3.7 Internalization Study of PTP-HPMA conjugates 
The efficacy of the plectin-1 targeted peptide conjugated HPMA copolymer (PTP-
HPMA) and the corresponding control conjugate (D-PTP-HPMA) for pancreatic tumor 
targeting was evaluated by flow cytometry (Figure 4.9). At 200 μg/ml concentration, the 
D-PTP-HPMA conjugate didn’t show any uptake from 6 to 24 h.  At 6 h, there wasn’t any 
uptake difference between the PTP-HPMA conjugate and the D-PTP-HPMA conjugate. 
The PTP-HPMA conjugate had a significantly higher uptake than the D-PTP-HPMA 
conjugate at 24 h. However, such increase didn’t seem to be mediated by plectin-1, as 











Figure 4.9: Analysis of FITC-labeled peptide-HPMA conjugate cell uptake at 6 and 24 h. 
A and B, uptake of D-PTP-HPMA conjugate at 6 and 24 h; C and D, uptake of PTP-
HPMA conjugate at 6 and 24 h; E and F, uptake of PTP-HPMA conjugate after co-












The internalization of PTP-HPMA conjugate in pancreatic tumor cells was also 
investigated using radiolabeled conjugates. Both conjugates could be labeled with 177Lu 
easily with efficiency > 80%. But the 177Lu-labeled, PTP-HPMA copolymer had very 
minimal amounts of cell uptake, even though slightly higher than the 177Lu-labeled, D-
PTP-HPMA copolymer at 6 h, but their cellular uptake was not significantly different at 
24 h (Figure 10). An excess amount of free PTP-NH2 again did not affect the overall 
internalization of 177Lu-PTP-HPMA at 6 or 24 h. Overall, the 177Lu-labeled, PTP-HPMA 














    
Figure 4.10: Internalization of 177Lu-PTP-HPMA conjugates in HPAC cells at 6 and 24 h. 
The uptake of 177Lu-PTP-HPMA conjugate was slightly higher at 6 h but not significantly 

















The interaction between PTP-HPMA conjugate and the plectin-1 was also examined 
by competitive binding study. However, even with 200 µg/ml of PTP-HPMA conjugate 
present in the media, the uptake of 177Lu-PTP-DO3A wasn’t decreased. This, in another 
aspect, showed the conjugate didn’t exhibit any plectin-1 binding capability.    
 
4.4 DISCUSSION 
There is an urgent need to develop better diagnostic agents for pancreatic cancer 
detection and staging [184, 185]. Recent reports by Kelly and colleagues identify plectin-
1 as a potential biomarker for PDAC [14]. Plectin-1 is a cytoskeleton protein that is 
ubiquitously expressed in cells, but is normally constrained to the intracellular 
compartment. However, in the case of PDAC, plectin-1 becomes aberrantly expressed 
on the extracellular surface. Plectin-1 appears to be a potentially valuable molecular 
target for diagnostic applications for PDAC. Herein, we prepared two different plectin-1 
targeted carriers, the small peptide and the peptide HPMA conjugates and radiolabeled 
these carriers with 177Lu. We evaluated the in vitro and in vivo properties of these 
carriers using the HPAC human pancreatic cancer cell line.  
 
Based on existing knowledge, the C-terminus of the PTP can be modified without 
substantial loss in binding affinity to plectin-1. However, based on our results from 
incorporating a N-terminal DOTA (peptide 2), the N-terminus was found to be more 
sensitive to modification, greater than a 100 fold decrease in binding affinity relative to 
C-terminally modified PTP-DO3A (peptide 5), thus suggesting that the N-terminal amino 
acids are crucial for activity. In addition to modification of the termini of the peptide, we 
investigated the D-form analogue of the PTP (D-PTP-DO3A, Peptide 6) to determine 
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what role the physiochemical properties of the targeting vector plays in cell-association 
activity. The D-form of the PTP (177Lu-D-PTP-DO3A) demonstrated negligible cell-
association toward the HPAC cells and lacked the ability to competitively inhibit the 
binding of the L-form of the PTP to plectin-1. These studies suggests that the cell-
association/binding of the PTP is target-specific and not due to any contribution from 
non-specific binding.  
 
Using a fluorescently labeled PTP analogue (Peptide 10), the cell trafficking of the 
PTP was investigated in the HPAC cell line. At the 4 h time-point, it was found that the 
PTP localizes on the cell membrane with little evidence of internalization, which is 
consistent with reported findings. This data was important for the subsequent 
interpretation of the internalization and efflux data of the PTP. The C-terminal modified 
PTP (177Lu-PTP-DO3A) exhibited a high percentage of cell associated radioactivity in as 
little as 15 min and plateaued after 45 min. Attempts to distinguish internalized 
radioactivity from surface-bound, using was acid buffer washes, initially led us to believe 
that the radio-conjugate was being internalized. However, based on the confocal studies, 
it seems that the standard acid buffer wash is unable to remove radiolabeled PTP from 
the cell surface. We are currently working on developing more rigorous surface removal 
buffers to adequately distinguish surface-bound from internalized radioactivity. One 
alternative explanation for this observation is the possibility that the fluorescently labeled 
peptide (peptide 10) has markedly different internalization properties relative to 177Lu-
PTP-DO3A. However, this seems unlikely since distance of the chelator/fluorophore 
from the pharmacophore is quite large, relative to other receptor-targeted peptides, and 
would not be expected to generate such a contrasting phenomenon in terms of 
internalization profiles.     
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Encouraged by the in vitro results, we investigated 177Lu-PTP-DO3A in an HPAC 
xenograft mouse model. At the 1 h time-point, the radio-conjugate cleared rapidly from 
the blood and other non-target tissues and was excreted from the mice largely by the 
renal system. Due to this excretion profile, the kidneys were found to have the highest 
radioactivity retention with 4.33 ± 1.59 %ID/g and 2.50 ± 0.30 %ID/g at the 1 and 4 h 
post-injection time-points, respectively. While the HPAC tumors sites had the second 
highest uptake among all tissues, the tumor uptake was only 0.72 ± 0.28 ID/g at 1 h and 
had essentially cleared all remaining activity by the 4 h time-point. These results are 
disappointing, particularly in light of reports by Kelly and co-workers in which they 
describe the successful application of a tetrameric PTP which demonstrated good in vivo 
targeting [14]. Based on their reports, it seems likely that the tetrameric PTP radio-
conjugate allows for better in vivo targeting and/or metabolic stability (due to sterics) 
relative to the monomeric 177Lu-PTP-DO3A. Based on the strong in vitro performance of 
the 177Lu-PTP-DO3A, it seems likely that the poor in vivo performance is due, at least 
partially, to the metabolic instability of the PTP. It is well known that peptides with a free 
N-terminus can be susceptible to certain proteases called aminopeptidases [186], which 
are also known to exist in the blood and on the surface of the tumor vasculature [187]. 
The rapid in vivo metabolism of 177Lu-PTP-DO3A would explain both the poor initial 
uptake at 1 h and rapid clearance by the 4 h time-point.  
 
To further examine the metabolic stability of 177Lu-PTP-DO3A, an in vitro serum 
stability study was conducted using both radiolabeled and un-metallated peptides. Using 
radio-HPLC and LC-MS, it was found that PTP was easily degraded in serum leading to 
one major and two minor metabolites. The major metabolite corresponded to the loss of 
the first lysine residue, while the other two minor metabolites corresponded to cleavages 
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at the subsequent amino acids 2T-3L and 3L-4L. The sequential nature of these 
degradations is consistent with what would be expected from an aminopeptidase [188]. 
However, to further confirm this, a protease inhibition study should be performed in the 
future. Given this and the in vivo biodistribution data, it is clear that alterations to the 
PTP are needed to increase the in vivo metabolic stability of future PTP radio-conjugates.        
 
The peptide-polymer conjugate is a promising targeting platform for targeted 
diagnostic and therapeutic agent development due to the potential of the multi-valency 
effect [189]. We prepared “click” reactive HPMA copolymers bearing azide groups on the 
side chains and conjugated it with an alkyne group functionalized PTP (peptide 7). The 
“click” chemistry resulted in incorporation efficiencies of greater than 60%. It has been 
shown that the incorporation of receptor-targeted peptides of just 10 mole% into HPMA 
copolymers has led to substantial increases in multivalent binding [190], however, the 
resulting PTP-HPMA conjugate demonstrated substantially lower than expected binding 
towards pancreatic tumors, as established by flow cytometry and the competitive binding 
studies. This is particularly evident, when one compares the cell-associated activity of 
the 177Lu-PTP-HPMA conjugate to the 177Lu-PTP-DO3A peptide from the internalization 
and efflux studies. The reason why the plectin-1 binding for the PTP- HPMA conjugate is 
so poor remains unknown. One possible explanation is that the steric hindrance between 
the peptide and the polymer backbone is impeding plectin-1 binding. In such a case, a 
possible solution might be the insertion of a longer PEG chain between the PTP and the 






 In this study, we found that the PTP analogue with DOTA conjugated to the C 
terminal (PTP-DO3A) had significantly higher binding affinity and cellular uptake as 
compared to the N terminal DOTA conjugated PTP (DO3A-PTP). The PTP-DO3A was 
un-stable in vivo, leading to decreased targeting efficacy to pancreatic tumor in a 
xenograft mouse model. PTP can be efficiently conjugated to HPMA copolymer by “click 
chemistry”, but the resulting PTP-HPMA conjugate lost the binding affinity towards 
plectin-1, possibly due to steric hindrance. The 177Lu-labeled PTP-HPMA exhibited much 

















Chapter 5  
Summary 
Pancreatic tumor remains difficult to diagnose at the early stages and all clinically 
available biomarkers and diagnostic tools fail to detect early stage PDAC or suffer from 
low specificity and sensitivity [14]. SPECT/CT imaging can provide information about the 
anatomical structures as well as the functional, metabolic or molecular status of specific 
tissues or organs and holds great potential for PDAC diagnosis because of its high 
sensitivity and spatial resolution [191]. However, the application of SPECT/CT in PDAC 
diagnostic imaging is hampered by the lack of an effective clinical radiotracer. There is 
an urgent need for the development of more effective SPECT/CT probes for the 
diagnosis of pancreatic tumors. 
 
The advancement of nanomedicine has offered new opportunities for the 
development of novel probes for the effective targeting of cancer [192]. Nanomedicine 
has many advantages such as the increased circulation time and targeted drug delivery 
[193]. Nanomaterials can passively target tumor sites due to the EPR effect [40]. Those 
nanomaterials can be multifunctional and modified to carry diagnostic probes and/or 
therapeutic drugs with the targeting ligands at the same time [194]. Many nanomedicine 
platforms have been evaluated for pancreatic cancer diagnosis [195]. One of the 
platforms we are interested in is HPMA copolymers. HPMA copolymers are non-toxic 
and non-immunogenic and many of HPMA-drug conjugates have been evaluated in 
clinical trials without causing any major side effects [62]. HPMA copolymers can 
effectively accumulate in the tumor sites through the EPR effect. HPMA copolymers can 
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be multifunctional and modified to introduce diagnostic probes such as radioisotopes or 
fluorescent dyes, or carry therapeutic drugs and targeting ligands. Radiolabeled HPMA 
copolymers have been successfully applied to for tumor imaging with the imaging 
modality SPECT/CT. However, a major problem associated the radiolabeled HPMA 
copolymers, as well as other nanomedicine platforms, is their opsonization and 
sequestration by the mononuclear phagocyte system [196]. As a result of MPS uptake, 
these polymeric drugs tend to accumulate in the liver and spleen. This MPS 
accumulation in non-target organs can hinder identification of resident or nearby 
metastatic malignant lesions thereby decreasing the diagnostic efficacy of polymer 
based diagnostic agents. With regard to therapeutic applications, the non-target 
accumulation of these polymeric drugs can lead to significant toxicities which may be 
dose-limiting [181].  
 
We are interested in developing new approaches in which radiolabeled HPMA 
copolymers can be synthetically modified to significantly reduce the MPS accumulation 
and/or to increase the tumor accumulation, thereby enhancing the diagnostic and/or 
radiotherapeutic efficacy of the agents. In chapter 2, we incorporated metabolic active 
linkers (MAL) into radiolabeled HPMA copolymers in order to reduce the MPS 
radioactivity accumulation. Those linkers are peptide substrates for cathepsin B and S, 
which have higher levels of expression in MPS tissues as compared to tumor tissues. 
We confirmed the in vitro cleavage of these linkers and conjugated them to a 343 kDa 
HPMA copolymer prepared by RAFT polymerization. We further investigated the cellular 
uptake of those conjugates; all the conjugates were easily taken up by differentiated 
macrophages while little uptake was observed in human pancreatic tumor cells. All the 
polymer conjugates were labeled efficiently with 177Lu. The in vitro serum stability studies 
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of all the radiolabeled conjugates revealed no significant proteolysis. However, we found 
that after treatment with cathepsins, small molecule radio-metabolites were generated 
from radiolabeled HPMA bearing MAL. The small molecular weight and hydrophilic 
radio-metabolite were considered to be favorably cleared away from the MPS tissues 
after in vivo accumulation. In a pancreatic tumor xenograft mice model, the synthesized 
cathepsin B and S cleavable HPMA copolymers: 177Lu-MAC1 and 177Lu-MAC2 
demonstrated a substantial decrease in long-term liver and spleen retention relative to 
the non-cleavable HPMA copolymer control (177Lu-MAC0). The significant reduction in 
liver and spleen retention observed in these studies prove that the MAL design is 
capable of enhancing radioactivity clearance from the MPS tissues.  
 
The promising results from the previous study prompted us to further develop a 
better HPMA copolymer based diagnostic agent used for SPECT/CT imaging. In 
chapter 3, an HPMA copolymer with molecular weight 109 kDa and PDI 1.3 was 
prepared by RAFT and conjugated to three different cathepsin S cleavable linkers in 
order to evaluate the structure-activity relationship with regard to the length of the linking 
groups on the in vitro and in vivo efficacy of radiolabeled cathepsin S cleavable HPMA. 
The 109 kDa allowed efficient tumor targeting due to the molecular weight being above 
the renal clearance threshold (~45 kDa), but also demonstrated relatively fast clearance 
from the blood to achieve satisfying tumor to blood ratio. In vitro cleavage assays 
showed that the longest linking group (13 atoms) possessed the highest cathepsin S 
cleavage kinetics. In addition, confocal microscopy confirmed the selective uptake of 
HPMA conjugates in differentiated macrophages and trafficking to the lysosomal cellular 
compartments. Contrary to in vitro observations, in vivo biodistribution studies in 
pancreatic tumor bearing mice revealed that the linking group length in the cathepsin S 
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cleavable linker design did not substantially impact the non-target clearance of 
radiolabeled cathepsin S cleavable HPMA. However, in the case of HPAC tumor 
retention, the one with the shortest length linker - CSC1 demonstrated significantly 
higher levels of retention relative to the other cathepsin S cleavable HPMA copolymers. 
This gave CSC1 superior tumor-to-non-target ratios as confirmed by longitudinal 
SPECT/CT imaging studies. Our results demonstrated that the introduction of cathepsin 
S cleavable linkers can substantially improve the non-target radioactivity clearance of 
HPMA copolymer based radiopharmaceuticals, and likely many other nanomedicine 
platforms, leading to an enhancement in the tumor-to-non-target ratios and ultimately 
clinical translation. 
 
Many peptide ligands have been conjugated to polymers and have successfully 
increased the in vitro and/or in vivo targeting ability of polymers [197]. Pancreatic tumors 
can highly express many biomarker proteins[44] and these biomarkers can become 
potential targets to increase the tumor targeting efficacy of HPMA copolymers. The 
plectin-1 protein is a recently discovered biomarker that is aberrantly expressed on the 
extracellular surface of PDAC [14]. The peptide sequence KTLLPTP, discovered by 
phage display,[37] was found to have submicromolar affinity for plectin-1. In chapter 4, 
to further improve the pancreatic tumor targeting ability of HPMA copolymer and solve 
the problem associated with the low tumor uptake of plectin-1 targeted peptide (PTP) in 
vivo, we prepared a 177Lu-labeled PTP-HPMA conjugate and evaluated its targeting 
efficacy. We found even though up to 10 mole% PTP could be successfully conjugated 
with HPMA copolymers through “click chemistry”, the PTP-HPMA conjugate did not 
display any multivalent effects but rather lost the binding affinity towards plectin-1. The 
177Lu-labeled HPMA-PTP exhibited very little uptake in pancreatic cancer cells while the 
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177Lu-labeled PTP showed very efficient uptake in vitro. Incorporation of the PTP into the 
HPMA copolymer diminished the activity of the peptide. One possible explanation is that 
steric hindrance, between the targeting peptide and the polymer backbone, inhibits 
plectin-1 binding. A possible solution can be inserting longer PEG chains between the 
targeting peptide and the HPMA copolymer.     
 
Future Studies 
Even though the above studies proved the great potential of 177Lu radiolabeled 
cathepsin S cleavable HPMA for pancreatic tumor imaging, the agent can be improved 
to achieve better efficacy.  
 
1) The efficacy of 177Lu-labeled cathepsin S cleavable HPMA for pancreatic tumor 
imaging should be determined in a transgenic mice model. In chapter 2 and 3, we 
evaluated the cathepsin S cleavable HPMA in a subcutaneous xenograft mouse model 
and had encouraging results. The xenograft mouse model provides a relevant and 
convenient model for the initial evaluation of many investigational drugs. However, it is 
well-known that there are many great differences between the xenograft mouse model 
and the transgenic mouse model. The transgenic mouse model can offer many 
advantages in our future study: (1) the mice are immuno-competent such that the tumor 
microenvironment can be mirrored as much as possible in a murine model; (2) specific 
genetic abnormalities present in human tumors can be reproduced, in an inducible 
manner, at specific ages in the tissue-type of origin; (3) the stages of tumor progression 
can be studied over time; (4) several therapeutic approaches can be explored at various 
stages of tumor development [198]. The model we will use is the LSL-KrasG12D; p53R172H; 
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Pdx-1-Cre (KPC) mouse model. The KPC model is well validated as a clinically relevant 
model of the morphology, metastatic spread, and chemotherapeutic response of 
pancreatic cancer. For example, treatment of the KPC model with gemcitabine gave only 
a 10-15% response rate, correlating well with the clinical disease profile. The evaluation 
of our agents in a transgenic mouse model will help to better measure the potential 
towards clinical translation. 
 
2) Other biomarkers and targeting ligands can be exploited for pancreatic tumor 
targeting. In this thesis, we have successfully explored the feasibility of incorporating 
targeted peptide ligands (PTP) into HPMA copolymers even though the final conjugate 
did not exhibit significant binding affinity. The failure may be due to the steric hindrance 
problem. We’d like to investigate whether adding longer spacers between the peptide 
ligand and polymer backbone can increase the interaction. Pancreatic tumors also 
express many other receptors such as EGFR and uPAR, which can become potential 
targets [199, 200]. Peptide ligands with high affinity to those receptors have been 
reported previously and can be conjugated to HPMA copolymers using similar strategies. 
However, those peptide polymer conjugates should be designed carefully and 
investigated in detail using various in vitro and in vivo studies to determine their 
structure-activity relationships.   
 
3) Radiotherapeutic efficacy study can be carried out to prove another advantage of 
177Lu labeled cathepsin S cleavable HPMA. 177Lu is also an effective beta emitter, which 
enables the application of 177Lu-labeled cathepsin S cleavable HPMA for tumor targeted 
radiotherapy. The cathepsin S cleavable HPMA can lead to lower liver and spleen 
radioactivity accumulation, which should help increase the therapeutic index. This 
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means we can deliver a higher dose of radioactivity to the tumor site without causing any 
greater damage to other non-target tissues. The maximum tolerated doses for the 177Lu 
radiolabeled cathepsin S cleavable HPMA copolymers is expected to be higher than the 
non-cleavable control copolymer and can be easily determined in a mouse model.    
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